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Abstract 
β-2-himachalen-6-ol (HC) is a major sesquiterpene that was isolated from the 
Lebanese Daucus carota ssp. carota and was shown to possess potent anticancer activity 
against various cancer cell lines. The aim of the present study was to explore the in vitro 
and in vivo anticancer activities of HC and to investigate the possible mechanisms of 
action involved. 
Lebanese Daucus carota spp. carota plant oil was extracted from dried mature 
umbels with methanol/acetone (1/1) and HC was purified using silica gel column 
chromatography to 92% purity as confirmed by GC-MS and NMR.  
The in vitro effect of HC on cell viability was tested against a panel of colon 
cancer cell lines (Caco-2, HT-29, SK-Co, LoVo, SW-1116 and T-84), a normal colon cell 
line CCD-33Co, the HaCaT-ras II-4 epidermal squamous carcinoma and the 4T1 breast 
cancer cell lines. HC displayed potent cytotoxic activity as measured by the WST-1 cell 
proliferation assay against all cancer cell lines with an IC50 ranging between 8-14.5µg/ml 
and an IC90 between 19-36µg/ml. No significant cytotoxic effect was observed on the 
normal colon cell line at the concentrations used.  
Upon treatment with HC, flow cytometry and western blot analyses showed 
similar results for both the SW1116 and HaCaT-ras II-4 cell lines, with an observed 
accumulation of cells in the sub-G1 apoptotic phase and decreased cell population in S 
and G2/M phases indicating cell cycle arrest at sub-G1phase. A decrease in the p-Erk, p-
Akt, anti-apoptotic protein (Bcl-2) and an increase in pro-apoptotic proteins (p53, Bax, 
p21, cleaved Caspase-3 and PARP) was also observed. 
The in vivo anticancer effect of HC was investigated using DMH-induced colon, 
DMBA/TPA-induced skin carcinogenesis and 4T1 breast metastatic murine models of 
cancer. HC proved to be effective in reducing cancer incidence and size in all the 
experiments with a relatively low hepato-toxicity.   
The present study established that HC is a potent and relatively safe anticancer 
compound that induces apoptosis through the inhibition of the MAPK/Erk and PI3K/ Akt 
pathways.   
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Chapter 1- Introduction 
 
1.1 Introduction to cancer    
 
Cells in living organisms are governed by a natural harmony. They grow, 
reproduce and die. In order to replace them, undifferentiated stem cells start 
differentiation into new specialized cells, maintaining order in life. This biological 
balance can be broken when cells start growing and dividing endlessly, giving rise to 
tumor formation (Weinberg, 2013). A tumor is considered benign when it does not 
invade neighboring tissues or metastasize (Weinberg, 2013). It has a slower growth rate 
than a malignant tumor and is usually surrounded by an outer connective tissue surface 
(Baba and Câtoi, 2007). A tumor becomes malignant when it becomes invasive. A 
malignant tumor invades nearby tissues and gives rise to distant metastases through the 
circulatory or lymphatic systems (Weinberg, 2013). Despite the improvements made in 
understanding the mechanisms of cancer development and the diversity in the type of 
treatments evolved, cancer continues to be a major cause of death in the world (Johnson 
et al., 2013).     
 
1.1.1 Cancer classification  
 
Cancer treatment is multidisciplinary and a concrete diagnosis is required to build 
up a therapeutical strategy which aims at curing cancer when it hasn’t yet spread or to 
slow down its progression in the case of metastatic diseases. For this reason, histological 
analysis is essential in identifying the primary tumour anatomical site. Cancers, from a 
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histological standpoint are classified into the following categories according to Weinberg 
(2013): epithelial arising tumors, nonepithelial arising tumors and multilineage or 
unclassified tumors. Carcinomas are malignant neoplasms originating from epithelial 
cells of the internal or external lining of the body. They are the most frequently occurring 
tumors and account for 80 to 90 percent of all cancer cases. They mainly fall into two 
major categories: squamous cell carcinomas and adenocarcinomas. Squamous cell 
carcinomas are tumors that arise from epithelial cells forming protective sheets to the 
underlying cell populations as in the skin, oral cavity, gastro-intestinal tract and upper 
and lower respiratory tracts. Adenocarcinomas are tumors that can secrete muco-
protecting substances into their underlying ducts or cavities as in the lung, breast, gastro-
intestinal tract, prostate and female reproductive system. The rest of malignant neoplasms 
in the body arise from nonepithelial tissues, and can be classified into three categories: 
Sarcomas, blood cell cancers and nervous system tumors. Sarcomas are tumors that 
derive from various connective tissues and originate in the embryonal mesoderm. They 
include osteosarcomas (bone originating tumors), liposarcomas (adipose tissue tumors), 
leiomyosarcomas and rhabdomyosarcomas (smooth and striated muscle tumors), 
malignant fibrous histiocytoma (adipocyte/muscle cell tumors), fibrosarcomas (fibroblast 
tumors), angiosarcomas (blood vessel tumors) and chondrosarcomas (cartilage tumors). 
Sarcomas constitute about 1% of encountered cancers, they grow fast and can reach large 
volumes. The second group of nonepithelial cancers originates from the hematopoietic 
system and includes leukemias, lymphomas and multiple myeloma. Leukemias refer to 
malignant derivatives of nonpigmented white blood cells and can be divided into acute 
lymphocytic or myelogenous leukemias, and chronic lymphocytic or myelogenous 
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leukemias. Lymphomas include tumors of the lymphoid lineages (B and T lymphocytes) 
and affect mainly the lymphnodes, spleen and liver. They are grossly subdivided into 
Hodgkin’s and non-Hodgkin’s lymphomas. Another form of blood cancers is multiple 
myeloma or antibody-secreting plasma cells and it affects the whole skeleton. The third 
group of the nonepithelial tumors includes tumors which drive from the nervous system 
(central and peripheral) and originate in the embryonal neuro-ectoderm. They constitute 
about 1.3% of diagnosed cancers and include glioma, glioblastoma, astrocytoma, 
oligodendroglioma, ependymoma, neuroblastoma, meningioma, retinoblastoma, 
schwannoma, and medulloblastoma. Other tumors do not match with these classifications 
and include melanomas, germinal tumors, neuro-endocrine and other forms of 
unclassified cancers. Melanomas are tumors which originate from the melanocytes in the 
skin and can easily metastasize. Germ cell tumors are sexual cancer cells that arise during 
the embryonic development period, and include seminoma, non-seminoma embryonal 
carcinoma and teratoma. Neuro-endocrine tumors are cancers that originate from both 
nervous and endocrine systems and affect various parts of the body as the lungs in case of 
small-cell lung carcinomas and the gastro-intestinal tract where they are often called 
carcinoid tumors. A minority of tumor cases (2-4%) is formed of dedifferentiated cells 
and known as anaplastic tumors or cancer of unknown primary (CUP) (Weinberg, 2013).    
 
1.1.2 Cancer incidence 
 
Cancer is considered the second leading cause of death worldwide after 
cardiovascular diseases (Johnson et al., 2013) and is, therefore, an increasing global 
burden due to the increasing aging and world population growth alongside an increasing 
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adoption of cancer-causing behaviour such as smoking, obesity, physical inactivity, 
alcohol consumption and poor diet (Haggar and Boushey, 2009; Ferlay et al., 2015; Torre 
et al., 2015). According to the World Health Organization, in 2012, there were about 14.1 
million new cancer cases diagnosed worldwide, with 8.2 million deaths. It is also 
estimated that the global burden of cancer grows worldwide and will reach 21.4 million 
new cases by the year 2030 (Ferlay et al., 2015; Torre et al., 2015). In 2010, the 
prevalence cancer care costs in the United States, which comprise the costs for all cancer 
survivors alive in a specific year, were estimated to be 124.57 billion US dollars. These 
costs are in continuous increase due to population changes and are expected to reach 
157.8 billion US dollars by the year 2020 (Mariotto et al., 2011; Yabroff et al., 2011). 
Part of these rising costs is the financial costs of treatment. For the last twenty years, 
many new chemotherapy drugs have appeared on the market, however these are also very 
expensive. One prominent one is Paclitaxel (Taxol) costs more than 2,500 US dollars  per 
month per patient (Bach, 2009) and the new targeted therapies or immunotherapies cost 
many times that amount. In 2015 at the American Society of Clinical Oncology 
conference, a new immunotherapy doublet combination including the anti-PD-1 agent 
Nivolumab with the anti-CTLA-4 agent Ipilimumab was endorsed. This combination 
yielded a median progression-free survival of 11.4 months for patients with metastatic 
advanced malignant melanoma, and cost about 300,000 US dollars per patient. Similarly, 
using another anti-PD-1 agent Pembrolizumab in treating patients with advanced 
melanoma would result in a treatment cost of around 1 million US dollars per patient 
(Andrews, 2015).  These considerations of cost add an extra dimension to the remit and 
design for new therapeutic advancements in cancer treatment. 
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1.1.3 Cancer risk factors  
 
 Carcinogenesis is influenced by different risk factors including tobacco smoking, 
industrial pollution, increase in body mass index (BMI), alcohol consumption, food 
additives, viral and bacterial infections, hereditary factors, sun and ionizing radiation 
exposure, chemicals, stress, aging, as well as changing reproductive patterns in both more 
and less economically developed countries (Haggar and Boushey, 2009; Aktipis and 
Nesse, 2013; Johnson et al., 2013; DeVita et al., 2015). Table 1.1 summarizes some of 
their causative agents and the resulting diseases. 
Table 1. 1 Some cancer risk factors with their causative agents and resulting diseases 
(Haggar and Boushey, 2009; Aktipis and Nesse, 2013; Johnson et al., 2013; DeVita et al., 2015; 
Weiner, 2015). 
Risk Factors Causative Agents  Resulting Diseases 
Tobacco smoking Multipotent carcinogenic 
mixture, such as stable and 
unstable aldehydes, aromatic 
amines, nitrosamines and 
oxidants. 
Cancers of the mouth, larynx, 
pharynx, lungs, pancreas and 
bladder. 
Industrial Pollution Asbestos, heavy metals, 
Radon. 
Lung cancer and 
mesothelioma. 
Increase Body Mass 
Index 
Fast and fatty food, poor in 
fibers ingestion and rich in 
carbohydrates and saturated 
fatty acids. 
Breast, ovarian and 
endometrial cancers. 
Cholangiocarcinoma and 
colo-rectal carcinoma. 
Alcohol consumption Damage to body tissues, 
decrease absorption of folate, 
increase estrogen secretion, 
help tobacco harmful 
chemicals entering upper 
digestive tract. 
Liver cirrhosis and hepato-
cellular carcinoma, colo-rectal 
carcinomas, breast, head and 
neck with esophageal 
carcinomas. 
Food additives E121, 123, 210, 621. Auto immune diseases and 
other cancers. 
Viral infection Hepatitis B and C Viruses, 
Epstein-Barr Virus, Kaposi 
Liver cirrhosis with Hepato-
cellular carcinoma, laryngeal 
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Sarcoma Herpes Virus, 
Human PapillomaVirus,  
Human T-cell Leukemia-
Lymphoma Virus, Human 
Immuno-deficiency Virus. 
carcinoma, cervical and 
vulvar carcinoma, lymphomas 
and Leukemias.  
Bacterial Infection Helicobacter pylori infection. Mucosa–Associated 
Lymphoid Tissue 
Lymphomas. 
Hereditary factors Familial polyposis syndrome 
and nonpolyposis colorectal 
cancer or Lynch syndrome. 
Colo-rectal carcinomas. 
Hereditary factors BRCA1 and BRCA2. Breast and ovarian 
carcinomas. 
Sun exposure Ultra-violet radiation. Skin cancer. 
Ionizing radiation 
exposure. 
X-rays and radioisotopes. Skin cancer, leukemias and 
lymphomas. 
Chemicals Benzene, arsenic. Skin cancer, leukemias and 
lymphomas.  
Stress  Stress-mediated 
neuroendocrine hormones. 
Different kinds of cancers. 
Aging Increase free radicals, DNA 
damage, oncogene mitogenic 
signals and mutated tumor 
suppressors. 
Different kinds of cancers.  
Changing reproductive 
patterns 
Lower parity, delayed age at 
first birth and breast feeding 
abstention. 
Breast, ovarian and 
endometrial cancers. 
 
 All of these risk factors in addition to many others play a direct or indirect role in 
triggering cancer cell formation sometimes during humans’ life.   
 
1.2 Mechanisms of carcinogenesis  
 
Carcinogenesis is a multi-mechanistic process that takes place due to defects in 
different cellular regulating processes. Three groups of malfunctioning genes have been 
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identified to be involved in cancer formation. These are the proto-oncogenes, the tumor 
suppressor genes and the DNA repair genes. 
1.2.1 Genetics of cancer  
Controlled cell growth is generally maintained by different mechanisms. The first 
mechanism consists of the regulation of proto-oncogenes expression which accelerates 
cell growth. The second consists of slowing cell growth through the action of tumor 
suppressor gene products (Schneider, 2011). A third major mechanism consists of DNA 
repair genes which play an essential role in repairing defects that may affect the living 
cells by maintaining the chromosome structure intact (Christmann et al., 2003). 
Uncontrolled cell growth occurs when defects in these mechanisms take place. The 
human genome encodes between 20,000 and 25,000 protein-coding genes (Stein, 2004; 
Pennisi, 2012), however, just a small number of these protein-coding genes is associated 
with cancer development (Schneider, 2011). According to Nordling’s ‘multi-mutation 
theory’ in 1953, alterations in one gene are not enough for a normal cell to become 
cancerous. In essence, successive mutations in many genes of the same cell are necessary 
in order that a single normal cell turns out into a malignant one (Nordling, 1953). In 
1971, Knudson proposed through his ‘two-hit hypothesis’ that the development of 
retinoblastoma tumor in children is linked to a double-hit mutation: one inherited mutated 
retinoblastoma (Rb) gene associated to a second post conception environmentally induced 
mutation. If one mutation is only present, cancer development is inhibited (Knudson, 
2001). Later on, it was shown that cancer development occurs due to mutations in 
oncogenes, tumor suppressor genes and DNA repair genes which control cell 
development and proliferation (Wood et al., 2007; Schneider, 2011). When mutations in 
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proto-oncogenes occur, they convert into oncogenes leading to uncontrolled cell division. 
Human epidermal growth factor receptor 2 or HER2/neu is a proto-oncogene that is 
encoded by the ERBB2 gene. Once mutated, the over expression of this oncogene leads to 
the development of an aggressive, recurrent, metastatic breast cancer (Mitri et al., 2012) 
(Table 1.2). KRAS, NRAS, and BRAF are oncogenes that encode proteins involved in the 
mitogen-activated protein kinase (MAPK) signaling pathway, which regulates cell 
proliferation and survival. Mutations in these genes are found in about 45%, 4%, and 8% 
of metastatic colorectal cancer, respectively (Douillard et al., 2013) (Table 1.2). 
Similarly, if mutations occur in tumor suppressor genes, the resulting proteins lose their 
role in sustaining cellular homeostasis and become no longer capable of preventing tumor 
formation (Rak et al., 2000; Klemin, 2008; Schneider, 2011). BRCA1 and BRCA2 are 
tumor suppressor genes which encode proteins that are implicated in repairing damaged 
DNA. Mutation in BRCA1 and BRCA2 can disable the proteins from matching the DNA 
double-stranded breaks, leading to the appearance of a hereditary breast and ovarian 
cancer syndrome (Yoshida and Miki, 2004; Silver and Livingston, 2012) (Table 1.3). The 
tumor suppressor p53 (gene TP53) has been named ‘guardian of the genome’ due to its 
crucial role in maintaining genetic stability and preventing cancer formation. TP53 
encodes for a transcription factor protein that upon activation can promote DNA repair or 
stimulate apoptosis when damage is beyond repair (Rivlin et al., 2011; Surget et al., 
2014). Inactivation of the gene TP53 by mutation, deletion, hypermethylation or viral 
encoding proteins can dysregulate p53 protein and enhance aggressive and therapy-
refractory cancer formation (Hollstein et al., 1991; Surget et al., 2014). Mutations in 
TP53 are the most frequently encountered genetic changes in various human cancers, 
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such as brain tumors, breast, colorectal, esophageal, liver, lung carcinomas, sarcomas, 
leukemias and lymphomas (Martinez et al., 2003; Rivlin et al., 2011) (Table 1.3). The 
third group of genes responsible for cancer development is the DNA repair gene group. 
These gene products normally play a substantial role in repairing any defect that may 
affect the living cells by maintaining the chromosome structure intact. Mutation of these 
genes can also be a major cause in tumor appearance (Christmann et al., 2003). BLM 
(Bloom Syndrome RecQ Like Helicase) is a DNA repair gene, which upon mutation, 
becomes responsible for an autosomal recessive inherited disorder, the Bloom syndrome. 
This syndrome is characterized by short stature, and highly predisposes to the formation 
of cancer and other diseases (Bischof et al., 2001; Schneider, 2011) (Table 1.4). The 
mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 are being implicated in 
repairing and fixing any defect that may arise in cellular DNA. Any defect in MMR genes 
may lead to DNA microsatellite instability (MSI) and promotes carcinogenesis (Buecher 
et al., 2013) (Table 1.4). Lynch syndrome or hereditary nonpolyposis colorectal cancer 
(HNPCC), is an autosomal dominant disorder that increases the risk of many types of 
cancer, including endometrial, ovarian, stomach, small intestine, hepatobiliary tract, 
upper urinary tract, brain, skin, and particularly colon cancer. Lynch syndrome is directly 
associated with inherited mutation in the mismatch repair (MMR) genes MLH1, MSH2, 
MSH6 and PMS2 (Kastrinos et al., 2009) (Table 1.4). A combination of all three 
phenomena is more likely to be responsible for tumor development than the occurrence 
of just one gene anomaly (Schneider, 2011). Tables 1.2, 1.3 and 1.4 represent some 
prominent oncogenes, tumor suppressors and DNA-repair genes respectively with their 
functions and resulting type of cancer formation in case of their deficiency or mutation.  
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Table 1. 1 Some Oncogenes and their implicated activities  
Oncogenes Protein function Neoplasms 
Growth factors: SIS 
                          
                         
                          
                           
                           INT-2 
                         
                          TRK 
 
Platelet derived growth 
factor. 
 
 
 
Fibroblast growth factor. 
 
Nerve growth factor. 
Fibrosarcoma (Martinez et 
al., 2003), meningioma 
skin neoplasms (Schneider, 
2011), sarcoma (Weinberg, 
2013).  
Breast (Martinez et al., 
2003). 
Neuroblastoma (Martinez 
et al., 2003). 
Growth Factor receptors:  
erb-B1/ Her1 
 
 
 
 
erb-B2/HER2-neu 
 
 
 
 
FMS 
 
 
ROS 
 
Epidermal growth factor 
receptor. 
 
 
 
Epidermal growth factor 
receptor. 
 
 
 
Hematopoietic colony 
stimulating factor (CSF-1). 
 
Insulin receptor.                            
 
Squamous cell carcinomas 
(Martinez et al., 2003; 
Weinberg, 2013), 
glioblastomas (Weinberg, 
2013). 
Breast (Martinez et al., 
2003), ovarian (Schneider, 
2011) and gastric 
carcinoma (Weinberg, 
2013). 
Sarcoma (Martinez et al., 
2003; Weinberg, 2013) and 
AML (Weinberg, 2013). 
Astrocytoma (Martinez et 
al., 2003) and sarcoma 
(Weinberg, 2013). 
Tyrosine kinases: 
BCR-ABL 
 
 
SRC 
 
 
 
LCK 
 
 
PKKCI (PKCι) 
 
SOX 
 
Tyrosine kinase. 
 
 
Tyrosine kinase. 
 
 
 
Tyrosine kinase, associated 
with CD4 and CD8 
antigens of T cell. 
Activate the Hedgehog 
signaling pathway. 
Transcription Factor and 
regulator of cancer stem 
cell maintenance. 
 
CML (Martinez et al., 
2003; Weinberg, 2013) and 
AML (Weinberg, 2013). 
Colon cancer (Martinez et 
al., 2003; Weinberg, 2013) 
and sarcoma (Weinberg, 
2013). 
Colon cancer (Martinez et 
al., 2003) and leukemias 
(Buffière et al., 2018). 
Basal cell carcinoma of the 
lungs (Yang et al., 2010).  
Squamous cell carcinoma of 
the lungs (Mukhopadhyay et 
al., 2014) and prostate cancer 
(Kregel et al., 2013). 
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Serine-Threonine protein 
kinases:  
MOS/RAF 
 
 
 
MAPK (ERK1/2, P38, JNK,  
ERK5)  
 
 
 
 
m-TOR 
  
 
 
PI3K (AKT/PKB) 
 
 
Regulates cell growth. 
 
 
 
Regulates cell growth and 
apoptosis. 
 
 
 
 
Cell proliferation and 
differentiation. 
 
 
Regulates cell growth, 
proliferation, survival, 
differentiation and 
apoptosis. 
 
 
Melanoma, Lung, colon, 
Thyroid (papillary) 
carcinoma and sarcoma 
(Martinez et al., 2003). 
Hodgkin’s lymphoma 
(Zheng et al., 2003),  
melanoma, breast, prostate, 
NSCLC and hepatocellular 
carcinomas (Cronan et al., 
2012). 
Breast, renal, colorectal 
cancers, multiple myeloma 
and CLL (Porta et al., 
2014b).  
Lymphoma, gastric, lung 
SCC, ovarian and breast 
cancers (Weinberg, 2013).  
Guanine nucleotide binding 
protein (G binding protein): 
H-RAS 
 
 
 
K-RAS 
 
 
 
 
 
 
N-RAS 
 
 
GTPase. 
 
 
 
GTPase. 
 
 
 
 
 
 
GTPase. 
 
 
Melanoma, Lung, pancreas 
(Martinez et al., 2003), 
sarcoma and colorectal 
cancer (Weinberg, 2013). 
Colorectal, lung (Martinez 
et al., 2003; Weinberg, 
2013), pancreas, leukemia 
(Martinez et al., 2003), 
sarcoma, bladder and 
ovarian cancers (Weinberg, 
2013). 
Genitourinary tract cancer, 
thyroid, melanoma 
(Martinez et al., 2003), 
head and neck cancers 
(Weinberg, 2013). 
Cytoplasmic proteins:  
Bcl-2, Bcl-XL, Mcl-1 
 
 
 
Bax, Bak, Bik, Bim, Bid 
 
Anti-apoptotic proteins 
stimulate angiogenesis.  
 
 
Pro-apoptotic proteins 
regulate apoptotic signaling 
pathways. 
 
B-cell lymphoma (Martinez 
et al., 2003; Weinberg, 2013) 
and leukemias (Schneider, 
2011). 
Breast and renal cell cancer 
(Radetzki et al., 2002; Jin et 
al., 2012; Pandya et al., 2016). 
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Nuclear proteins: 
MYC 
 
 
 
JUN 
 
FOS 
 
Transcription factor (AP-1) 
 
 
 
Transcription factor (AP-1) 
 
Transcription factor (AP-1) 
 
Burkitt’s lymphoma 
(Schneider, 2011) and 
leukemia (Martinez et al., 
2003; Weinberg, 2013). 
Sarcoma (Martinez et al., 
2003; Weinberg, 2013). 
Sarcoma (Martinez et al., 
2003; Weinberg, 2013). 
 
Table1. 2 Tumor Suppressor Genes and their implicated activities  
Gene name Protein function  Neoplasms  
APC Regulates transcription of 
TCF target genes;   
Regulates β-catenin and 
causes its degradation.  
Familial Adenomatous Polyposis, 
colorectal carcinoma (Martinez et al., 
2003; Weinberg, 2013), gastric, 
pancreatic and prostate cancers 
(Weinberg, 2013). 
BRCA1 Involved in cell cycle 
control; functions in 
transcription, DNA binding, 
transcription coupled DNA 
repair, homologous 
recombination, 
chromosomal stability, 
ubiquitination of proteins, 
and centrosome replication. 
Breast and ovarian carcinomas 
(Martinez et al., 2003; Schneider, 
2011), prostate and colorectal cancers 
(Schneider, 2011). 
BRCA2 Transcriptional regulation of 
genes involved in DNA 
repair and homologous 
recombination. 
Breast and ovarian carcinomas 
(Martinez et al., 2003), pancreatic 
cancer and leukemia (Schneider, 
2011). 
CDH-1         
(E-cadherin) 
Cell-cell adhesion protein. Gastric cancer, lobular invasive 
breast cancer (Weinberg, 2013). 
CDKN2A Produces p16INK4 protein 
which inhibits cell-cycle in 
G1 by binding to CDK4 and 
CDK6, and p14ARF protein 
which binds and inhibits the 
p53 stabilizing protein 
MDM2.  
Melanoma and bladder with other 
cancers (Weinberg, 2013).  
DPC4/SMAD4 Regulation of TGF-β/BMP 
signal transduction. 
Pancreatic cancer (Liu, 2001). 
DCC Transmembrane receptor 
involved in axonal guidance 
via netrins. 
Colorectal cancer (Shibata et al., 
1996; Mehlen and Fearon, 2004). 
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MEN1 Intrastrand DNA crosslink 
repair. 
Parathyroid and pituitary adenomas, 
islet cell tumors, carcinoid (Giusti et 
al., 2015).  
NF1 GTPase;  
Catalysis of RAS 
inactivation. 
Neurofibrosarcoma (Martinez et al., 
2003), AML, astrocytoma and colon 
cancer (Weinberg, 2013) . 
NF2 Linkage of cell membrane 
to actin cytoskeleton. 
Schwannoma, meningioma and 
ependymoma (Weinberg, 2013). 
p53 Apoptosis;  
Cell cycle regulation; 
Transcription factor. 
Brain tumors, breast, colorectal, 
esophageal, liver and lung 
carcinomas; sarcomas; leukemias and 
lymphomas (Martinez et al., 2003; 
Schneider, 2011). 
PTC Transmembrane receptor for 
sonic hedgehog (shh). 
Basal cell carcinoma, 
medulloblastomas (Weinberg, 2013).  
PTEN Phosphoinositide 3-
phosphatase, protein 
tyrosine phosphatase. 
Glioblastoma, prostate, breast and 
thyroid cancer (Weinberg, 2013).  
RB Cell cycle regulation 
(through G1). 
Retinoblastoma, osteosarcomas, 
bladder, breast, esophageal and lung 
carcinomas (Weinberg, 2013). 
TSC1,2 TSC1 and TSC2 proteins 
form a complex that inhibits 
signaling to downstream 
effectors of mTOR. 
Tuberous sclerosis syndrome 
(seizures, mental retardation, facial 
angiofibromas, benign tumors in 
brain and other organs), 
astrocytomas, rhabdomyosarcomas 
(Northrup et al., 2015). 
VHL Regulation of transcription 
elongation through 
activation of a ubiquitin 
ligase complex. 
Von Hippel-Lindau syndrome, renal 
cell carcinoma (Weinberg, 2013). 
WT1 Transcription factor. Wilms' tumor (Martinez et al., 2003; 
Weinberg, 2013). 
 
Table 1. 3 Hereditary human DNA-repair-deficient disorders 
Deficiency Disease  
DNA cross-link repair: 
FANCA–FANCG. 
Fanconi anemia (Joenje and Patel, 2001; Shukla et 
al., 2013). 
DNA damage signaling: ATM. Ataxia telangiectasia (Christmann et al., 2003; 
Thurn et al., 2013). 
DSB repair: Nbs, Wrn, Blm, 
RecQL4. 
Nijmegen breakage syndrome, Werner syndrome, 
Bloom syndrome (Christmann et al., 2003; 
Schneider, 2011). 
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MMR: MLH1, MSH2, MSH6, 
PMS1, PMS2. 
Hereditary non-polyposis colon cancer (HNPCC) 
or Lynch syndrome (Martinez et al., 2003). 
MYH MAP (MYH-associated polyposis) Syndrome 
(Bolocan et al., 2011). 
NER: XPA–XPG, CSA, CSB. Trichothiodystrophy, Xeroderma pigmentosum, 
Cockayne’s syndrome (Christmann et al., 2003; 
Lehmann, 2003).  
Translation synthesis: XPV. Xeroderma pigmentosum variant (Christmann et 
al., 2003; Schneider, 2011).  
 
             All of these proteins and coding genes are implicated in various signal 
transduction pathways that play a crucial role in cell development, differentiation and 
growth, as well as inflammatory processes and apoptosis (Zhang and Liu, 2002). Defects 
in their expression, therefore, are likely to lie behind cancer development (Schneider, 
2011). 
1.2.2 Cellular Signal Transduction Pathways 
 
All of these aforementioned proteins play a key role in activating various 
pathways of cellular signal transduction. These pathways have substantial roles in cell 
differentiation and growth, where they relay signals from a multitude range of stimuli, 
amplify and integrate them to get an appropriate physiological cellular response such as 
proliferation, differentiation and development, as well as induction of inflammatory 
responses and cellular apoptosis (Zhang and Liu, 2002).  
 
1.2.2.1 The MAPK/ERK pathway  
 
In human cells, four MAPK families have been identified: the classical MAPK 
pathway, the Big Mitogen-activated protein Kinase 1 (BMK1), the C-Jun N-terminal 
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kinase/ stress-activated protein kinase (JNK/SAPK) and the p38 kinase, with an 
important role in cell proliferation, division, differentiation, survival and apoptosis 
(Vlahopoulos and Zoumpourlis, 2004; Cossa et al., 2013). The BMK1 pathway also 
known as extracellular signal-regulated kinase 5 (ERK5), is a newly identified member of 
the MAP kinase family, which plays an important role in the pathogenesis of 
cardiovascular disease and vascular remodeling (Izawa et al., 2007). The JNK/SAPK 
pathway is activated by stressing factors as cytokines, growth factors, oxidative stress and 
others, and plays a major role in stress signaling pathways implicated in gene expression 
and regeneration, neuronal plasticity, apoptosis, and regulation of cellular senescence. Its 
kinases are being investigated as new therapeutic approaches to diabetes, cancer or liver 
diseases (Yarza et al., 2015). The p38 pathway is also referred to as SAPKs pathway like 
JNK family, since it is activated by environmental stresses and inflammatory cytokines, 
and less by serum and growth factors. P38 pathway is a key regulator of pro-
inflammatory cytokines biosynthesis at the transcriptional and translational levels, in 
addition to the control of cell cycle or cytoskeleton remodelling. Its components are 
targets for the treatment of autoimmune and inflammatory diseases (Cuenda and 
Rousseau, 2007). 
The mitogen-activated protein kinase, MAPK/ERK pathway, originally called 
extracellular signal-regulated kinases, is also known as the Ras-Raf-MEK-ERK pathway. 
It consists of a chain of cellular proteins that transduce signals from membrane receptors 
called epidermal growth factor receptors (EGFR) to the nucleus through a cascade of 
proteins including MAPK (mitogen-activated protein kinases, originally called ERK or 
extracellular signal-regulated kinases). These communicate by phosphorylation of the 
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neighboring protein via a kinase/phosphatase cycle (Orton et al., 2005). Upon activation 
by external stimuli, such as growth and differentiation factors, the receptors of tyrosine 
kinases (RTK) autophosphorylate and trigger a chain of protein activation leading to the 
activation of Ras proteins by exchanging the Ras-bound GDP with GTP. This conversion 
is mediated by the interaction of Ras proteins with GDP/GTP-exchange factors, SOS (son 
of sevenless) (Bernards, 2003). This in turn activates the protein kinase activity of Raf 
kinase. Sequentially, Raf kinases activate the tyrosine/threonine kinases MEK1/2 (also 
known as MAPKK) by phosphorylating two serine residues. This dual phosphorylation 
leads to the activation of the mitogen-activated protein kinases (MAPKs) ERK1 and 
ERK2, which have the ability to phosphorylate over 80 substrates in the cytoplasm and 
the nucleus and can regulate gene expression and modify transcription factors and 
histones, leading to cell proliferation and survival (Dame and Spencer, 2000; Orton et al., 
2005). Active MAPKs are deactivated by a family of phosphatases termed MKPs 
(MAPK phosphatases) through dephosphorylation of threonine and/or tyrosine residues 
in ERK, RAF and SOS within the activation loop (Kondoh and Nishida, 2007) (Figure 
1.1). 
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Figure 1. 1 The MAPK/ERK signaling cascade and anticancer targeting agents. Upon ligand 
binding, RTK autophosphorylates and activates Ras via SOS exchange factors. RAS, in turn, 
activates RAF proteins, which phosphorylate and activate MEK-1/2. This dual phosphorylation 
activates ERK-1/2 that can regulate gene expression and modify transcription factors, leading to 
cell proliferation and survival. MKPs, once activated by negative feed-back, dephosphorylate 
ERK, RAF and SOS, inhibiting MAPK pathway.  
The MAPK/ERK pathway plays a major role in cell proliferation and 
differentiation. Any mutation in its proteins can provoke cancer development (Buecher et 
al., 2013). In the RAS-RAF-ERK protein-cascade, a mutation in the serine/threonine 
protein kinase BRAF, known as BRAF V600E, is implicated in about 50% of all 
malignant melanoma cases. Vemurafenib, a selective inhibitor of the mutant BRAF has 
been developed for the treatment of this metastatic disease (Ascierto et al., 2012).  
38 
 
1.2.2.2 The PI3K/AKT pathway  
 
Another outstanding intracellular signaling pathway is the phosphatidylinositol 3-
kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway, which 
regulates many physiological cell functions such as cellular differentiation, proliferation, 
survival, metabolism, autophagy, and motility (Porta et al., 2014a). PI3K is divided into 
four different classes: Class I, II, III, IV. The classifications are based on primary 
structure, regulation, and in vitro lipid substrate specificity (Leevers et al., 1999). Three 
kinds of receptors are involved in the activation ok PI3K pathway: the receptor tyrosine 
kinases (RTKs), the G protein-coupled receptors (GPCRs) and integrin receptors (New 
and Wong, 2007). GPCRs play a major in cell physiology, growth, development and 
disease control (Pierce et al., 2002). External stimuli such as growth factors, hormones or 
components of extracellular matrix, bind to the receptor tyrosine kinases (RTKs) or 
integrins in the plasma membrane and activate them by causing receptor dimerization and 
cross-phosphorylation of tyrosine residues in the intracellular domains (Nicholson and 
Anderson, 2002). The GPCRs also transactivate RTKs through the GPCR Gα or Gβγ 
subunits (Schäfer et al., 2004). The PI3K/AKT pathway becomes activated upon direct 
binding of Gβγ subunits and Ras to PI3Ks. Class I-PI3K is composed of two subunits: 
regulatory (P85) and catalytic (p110). The p85 subunit is involved in the recruitment and 
activation of PI3K after its communication with the activated receptors, while p110 is 
responsible for the formation of phosphatidylinositol-3,4,5-trisphosphate (PIP3), the 
docking site for Akt (also known as protein kinase B), from phosphatidylinositol-4,5 
bisphosphonate (PIP2) by phosphorylation of the inositol ring 3’-OH group in inositol 
phospholipids (Vanhaesebroeck and Waterfield, 1999; Katso et al., 2001). This leads to 
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the activation of Akt, which, in turn, enhances the phosphorylation of different proteins 
involved in the regulation of cell cycle, cell survival and apoptosis (New and Wong, 
2007). Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene that can 
down regulate the PI3K pathway by reducing PIP3 levels. PTEN antagonizes PI3K by 
dephosphorylating PIP3 to PIP2, limiting AKT capacity from binding to the membrane, 
and reducing its activity (Rafalski and Brunet, 2011). Mammalian target of rapamycin 
(mTOR) is a main component of the PI3K cell survival pathway. It plays a fundamental 
role in regulating cellular growth and proliferation by monitoring nutrient availability, 
cellular energy and oxygen levels, as well as mitogenic signals (Liu et al., 2009). mTOR 
is subdivided into two complexes mTORC1 and mTORC2, according to the difference in 
protein contents. mTORC1 controls cell growth and proliferation by promoting many 
anabolic processes as protein, lipids and organelles biosynthesis, and by restricting 
catabolic processes as autophagy (Laplante and Sabatini, 2009). The tuberous sclerosis 
complex (TSC) comprises two proteins TSC1 and TSC2. TSC1/2 acts as a GTPase-
activating protein (GAP) for the small Ras-related GTPase Rheb (Ras homolog enriched 
in brain). The active form of Rheb, bound to GTP, directly stimulates the mTORC1 
activity (Long et al., 2005). The overexpression of TSC1/2 inhibits mTOR function by 
converting Rheb into its inactive GDP-bound state. AKT activation down-regulates 
TSC1/2 function and leads to mTOR activation (Inoki et al., 2003). Another way of 
activating mTOR, independently of TSC1/2, is through direct phosphorylation and 
dissociation of PRAS40 from mTORC1. PRSA40 is known as a negative regulator of 
mTORC1, which acts as a direct inhibitor of substrate binding (Sancak et al., 2007; Wang 
et al., 2007). In cancer cells, the PI3K pathway is over activated or dysregulated and 
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promotes similarly various processes of cancer cellular growth, survival, angiogenesis 
and metastasis (Ersahin et al., 2015). Targeting PI3K/Akt/mTOR signaling pathway is 
being widely investigated to reduce carcinogenesis. Temsirolimus, a pro-drug whose 
primary active metabolite is rapamycin, is an mTOR inhibitor that has been approved for 
the treatment of patients with advanced stage renal cell carcinoma (Porta et al., 2014a). 
Figure 1.2 shows the PI3K/Akt/mTOR pathway. 
 
  
Figure 1. 2 The PI3K/Akt/mTOR pathway with anticancer targeting agents. The PI3K 
pathway is activated through three kinds of receptors: RTK, Integrin and GPCR. Upon external 
stimuli, the RTKs and /or Integrins become activated by direct phosphorylation. P85 subunit 
communicates with the activated receptors and induces p110 subunit to phosphorylate PIP2 into 
PIP3, which phosphorylates AKT and leads to cell proliferation and survival. GPCRs can activate 
PI3K either via transactivation of TRKs through Gα or Gβγ subunits, or by activating RAS also 
by Gα or Gβγ and causing direct PI3k activation. PTEN can antagonize PI3K by 
dephosphorylating PIP3 into PIP2. AKT activation down-regulates TSC1/2 and PRAS40, leading 
to mTOR activation. Potential anticancer agents act by direct inhibition of mTOR protein. 
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1.2.3 Hallmarks of cancer cells and carcinogenesis  
 
 Carcinogenesis is a multistep process that acquire six main biological capabilities 
by cancer cells (Hanahan and Weinberg, 2011). These hallmarks of cancer include: 
sustaining proliferative signaling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis. Later on, conceptual progress in understanding cancer development led to the 
addition of two enabling characteristics with two emerging hallmarks (Hanahan and 
Weinberg, 2011). The first characteristic of cancer cells is their ability to sustain 
proliferative signaling independently of any external stimuli. Normally, the growth 
factors are produced by one cell type to act on other cells via the ‘paracrine’ stimulation 
system in order to maintain homeostasis in cell number, tissue architecture and function. 
In contrast, cancer cells display deregulated signaling cascades that enable them to be 
unrestricted to any proliferation signal, resulting in unlimited growth. Many mechanisms 
are adopted by cancer cells to realize this independency in sustaining proliferative 
signaling (Hanahan and Weinberg, 2011; Gutschner and Diederichs, 2012). In cancer 
cells, the ‘autocrine’ stimulation system is maintained by the self-production of growth 
factors by cancer cells independently of their neighbourhood. This usually takes place by 
the production of cancer cells of growth factor ligands, to which they can respond via the 
expression of cognate receptors, resulting in autocrine proliferative stimulation (Hanahan 
and Weinberg, 2011). Another mechanism involved in the deregulation of paracrine 
receptor signaling is through the elevation of levels of receptor proteins at the cancer cell 
surface or by a structural alteration in these receptor molecules, rendering the cells 
hyperresponsive to growth factor ligands and resulting in continuous cell proliferation 
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(Hanahan and Weinberg, 2011). In addition, cancer cells may  produce paracrine signals 
to stimulate normal, tumor-associated cells (tumor stroma), which in turn yield different 
growth factors to support the cancer cells (Bhowmick et al., 2004; Cheng et al., 2008). 
Moreover, somatic mutations in different human tumors have shown to activate signaling 
pathways in cancer cells, usually triggered by activated growth factor receptors. This is 
the case in Melanoma where mutations affecting the BRAF protein structure lead to the 
activation of MAPK proliferating pathway independently of any growth factor (Davies 
and Samuels, 2010). Another mechanism implied in cancer cell self-proliferation is 
through the disruption of the negative-feedback mechanism, which role is to reduce 
different cell signaling types and ensure homeostatic regulation of the flux of signals 
coursing through the intracellular circuitry (Wertz and Dixit, 2010). This disruption of 
inhibitory proliferative signals is evident in the cases of mutations in Ras oncogene and 
PTEN tumor suppressor (Hanahan and Weinberg, 2011). RAS proteins are small 
GTPases, which act as principal regulators of many signaling cascades involved in 
different cellular processes as growth, migration, adhesion, cytoskeletal integrity, 
survival and differentiation (Rajalingam et al., 2007). Ras mutations affect the GTPase 
activity, which functions as an intrinsic negative-feedback mechanism that normally 
confirms that active signal transduction is transitory, resulting in continuous stimulation 
of cell proliferation and inhibiting apoptosis (Adjei, 2001). PTEN is known to be a 
negative regulator of PI3K pathway involved in cell proliferation and survival. It acts by 
dephosphorylating PIP3 to PIP2, the fact that reduces AKT activity by limiting its 
capacity from binding to the cellular membrane (Rafalski and Brunet, 2011). Mutated 
PTEN results in the accumulation of PIP3, which, in turn, activates AKT protein by 
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phosphorylation, the matter that leads to amplification of PI3K pathway and promotes 
cancer cell survival and proliferation (Salmena et al., 2008). All of these major factors 
and many others contribute to the ability of cancer cells to sustain proliferative signaling 
independently of external stimuli.  
Secondly, cancer cells are able to evade growth suppressors. In addition to the 
ability to induce and sustain growth-stimulatory signals, cancer cells are capable to evade 
programmes that inhibit cell proliferation. Two main tumor suppressors encoding the Rb 
and p53 proteins, which are known to be the key regulators of cell proliferation, have 
been found to be majorly affected in cancer cells (Hanahan and Weinberg, 2011). The Rb 
protein’s pathway, which is responsible for inhibition of cell proliferation by controlling 
progression from G1 into S phase, is disrupted in cancer cells. This disruption enables 
cell proliferation by liberating E2F transcription factors that mediate the expression of 
many target genes essential for cell transition from G1 into S phase (Nevins, 2001; 
Burkhart and Sage, 2008; Tsai et al., 2008). P53 or the ‘genome guardian’ plays a 
fundamental role in response to DNA damage and in maintaining genomic stability. 
Upon internal stress induced by genome damage, p53 protein gets activated by disruption 
of the Mdm2-p53 complex, which maintains p53 at low protein level, and triggers the 
transcription of p21, the powerful CDK inhibitor, in order to inactivate the G1-S/CDK 
and K2 complexes that are responsible for cell transition from G1 to S phase, resulting in 
cell cycle arrest (Koljonen et al., 2006). In case of irreparable damage, p53 can induce 
apoptosis via a wide network of signals that act through two major apoptotic pathways: 
the extrinsic or death receptor pathway, which induces apoptosis via the activation of 
Caspase cascade, and the intrinsic or mitochondrial pathway, which down-regulates the 
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anti-apoptotic Bcl-2 family proteins such as Bcl-2 and Bcl-XL and up-regulates the pro-
apoptotic proteins such as Bax and Bak via Bid activation, promoting the formation of 
the apoptosome Cyt-c/Apaf-1/Caspase-9, and consequently Caspase-mediated apoptosis 
(Haupt et al., 2003). P53 protein is being encoded by TP53 gene that is found to be 
mutated in more than 50% of human cancers (Sherr and McCormick, 2002). Moreover, it 
is well known that cell-to-cell contacts in normal cells inhibit further cell proliferation 
and conserve cells in monolayers. This facility, also known as ‘contact inhibition’ is 
absent in cancer cells (Hanahan and Weinberg, 2011). Merlin is the product of the 
neurofibromatosis type 2 (NF2) tumor suppressor gene. Merlin is a 
membrane/cytoskeleton-associated protein that mediates contact-dependent inhibition of 
proliferation by coupling cell-surface adhesion molecules such as E-cadherin to 
transmembrane receptor tyrosine kinases such as EGFR. This, in turn, strengthens the 
adhesivity of cadherin-mediated cell-to-cell attachments and limits the capability of 
growth factor receptors to release mitogenic signals (Curto et al., 2007). Loss of Merlin 
function, which results from mutation of NF2, is associated with the development of 
various cancers such as familial and sporadic nervous system tumors and mesothelioma 
(Giovannini et al., 2000; Baser et al., 2002). Another tumor suppressor involved in 
contact inhibition is the liver kinase B1 (LKB1) gene, which encodes the epithelial 
polarity protein LKB1. LKB1 regulates cell polarity, organizes epithelial structure and 
maintains tissue integrity. It also has the ability to inhibit the mitogenic effect of Myc 
oncogene in epithelial cells. Mutations in the LKB1 gene are associated with many 
cancers in addition to the Peutz–Jeghers polyposis syndrome (Hezel and Bardeesy, 2008).  
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The third trait of cancer cells is their ability to evade apoptosis. Programmed cell 
death is a biological process in multicellular organisms adopted by cells to maintain 
tissue homeostasis (Elmore, 2007). Apoptosis occurs via two pathways: the intrinsic or 
the mitochondrial pathway and the extrinsic or death pathway. In the intrinsic pathway, 
upon internal stimuli, p53 gets activated and induces cell death by down-regulating the 
anti-apoptosis family of Bcl-2 and up-regulating the pro-apoptosis proteins Bax and Bad 
via Bid activation. This leads to the formation of apoptosome Cyt-c/Apaf-1/Caspase-9 
that induces apoptosis through the activation of Caspase-3 protein. In the external 
pathway, membrane death receptors (CD95 and TRAIL-R) aggregate upon external 
stimulation by their ligands and activate the apoptotic proteases FADD and Caspase-8, 
which, in turn, activate Caspases-3,-6 and-7, inducing apoptosis through cleavage of 
ICAD/CAD or PARP (Fulda and Debatin, 2006). In cancer cells, apoptosis is usually 
avoided by different mechanisms, mainly by P53 mutation, where it is found in more 
than 50% of human cancers, or by overexpression of the antiapoptotic regulators (Bcl-2 
and Bcl-XL), or down-regulating of the proapoptotic factors (Bax, Bad, and Bim), in 
addition to many other apoptosis-avoiding mechanisms adopted by cancer cells including 
increase expression of survival signal insulin-like growth factor 1/2 (Igf1/2), which 
deficiency promotes apoptosis (Hanahan and Weinberg, 2011). Autophagy is a 
physiological intracellular degradation system that disassembles dysfunctional 
components and delivers them to the lysosome in order to maintain homeostasis 
(Mizushima, 2007). It can be stimulated by different forms of cellular stress, including 
nutrient deficiency and cell starvation,  growth factor scarcity, hypoxia, reactive oxygen 
species, DNA damage and other intracellular metabolite concentrations as damaged 
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organelles and  protein aggregates (Kroemer et al., 2010). Similar to apoptosis, autophagy 
has its own machinery with both regulatory and effector components, including Beclin-1 
protein that belongs to the pro-apoptotic BH3-only subfamily, and can interact with Bcl-2 
or PI3k pathway. Upon stimulation by stress signals, Beclin-1 can be dissociated from 
Bcl-2 to trigger autophagy. Mutation in Beclin-1 gene or in other autophagy regulators 
such as atg5 gene, which is a key regulator of autophagosome formation, resulted in 
increased cancer susceptibility in mice (Levine and Kroemer, 2008; White and DiPaola, 
2009). As a result, cell starvation, chemotherapy as well as radiation therapy may induce 
autophagy in cancer cells as a defense mechanism, impairing the cytotoxic effect of these 
stress-inducing circumstances (Mathew et al., 2009; White and DiPaola, 2009). Unlike 
apoptosis and autophagy, necrosis, a form of premature cell death caused by external 
noxious factors, results in cell membrane injury and release of cytosolic content in the 
microenvironment, inducing massive inflammatory reaction. Inflammation can release 
tumor-promoting factors and other bioactive regulatory factors that can directly stimulate 
neighboring cell proliferation and potential tumorigenesis (Grivennikov et al., 2010). As 
a consequence, necrotic cell death can be deleterious by promoting inflammatory 
environment that provides growth-stimulating factors to the existing tumor cells 
(Hanahan and Weinberg, 2011).  
The fourth characteristic of cancer cells is their capability to replicate endlessly. 
One of the main mechanisms involved in enabling cell replicative immortality is 
telomerase activation (Hanahan and Weinberg, 2011). Telomerase is a cellular reverse 
transcriptase that replaces the short sections of DNA known as telomeres. Telomeres are 
repeating DNA sequences (TTAGGG in humans) that are essential for the maintenance 
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of genomic integrity by protecting chromosomes from losing the base pair sequences at 
their ends and by inhibiting chromosomes from fusing to each other (Armanios, 2013). 
Telomeres get usually shorter with each cell division until reaching a critical length. This 
is known as Hayflick limit, which is the number of times a normal human cell population 
will divide before cell division ceases. At this limit cells either enter a ‘senescence’ phase 
and stop proliferation, or go into ‘crisis’ and end by death (Hayflick and Moorhead, 
1961). Cell senescence or crisis are both considered as protective mechanisms against 
neoplasia (Hanahan and Weinberg, 2011). Cells that evade first senescence and then 
crisis phases are termed immortalized and exhibit unlimited replicative potential. The role 
of activated telomerase is to extend the telomeres by replacing the lost DNA sections by 
new telomere repeats, enabling the cell line to divide endlessly without reaching the limit 
(Hanahan and Weinberg, 2011; Armanios, 2013). Other roles have been recently 
attributed to telomerase correlated to cell proliferation via the Wnt pathway. This 
happens through its protein catalytic subunit TERT (telomerase reverse transcriptase) by 
presenting as a cofactor of the β-catenin/LEF (Lymphoid enhancer-binding factor) 
transcription factor complex (Park et al., 2009). Another ascribed role is its involvement 
in DNA-damage repair by interacting with RMRP (RNA component of mitochondrial 
RNA processing endoribonuclease) gene to form a complex that exhibits the RdRP (RNA 
dependent RNA polymerase) activity by producing double-stranded RNAs that can be 
processed into small interfering RNA in the cell (Maida et al., 2009).  
The fifth characteristic of cancer cells is their ability to induce angiogenesis. 
Similarly to normal tissues and in order to maintain cell metabolism, tumors promote the 
generation of neovasculature through the process of angiogenesis (Hanahan and 
48 
 
Weinberg, 2011). Normally, during embryogenesis, vasculogenesis takes place by 
promoting the assembly of new endothelial cells, and angiogenesis follows by the 
sprouting of new blood vessels from the preexisting ones. This is followed by a quiescent 
phase until adulthood when angiogenesis transiently turns on in different physiological 
cases such as female reproductive cycling, and pathologically in wound healing and 
tumor growth. The quiescent vasculature becomes continuously active in cancer growth 
as an ‘angiogenic switch’ to maintain newly developed tumors (Hanahan and Folkman, 
1996). Angiogenesis is induced early in cancer development and blood vessels are 
typically aberrant either in form or in function. Precocious, convoluted capillaries sprout 
with enlarged, distorted and excessively branched vessels giving rise to 
microhemorrhagy, vessel leaking and excessive cell proliferation and apoptosis (Baluk et 
al., 2005; Nagy et al., 2010). Angiogenesis occurs via different inducers as vascular 
endothelial growth factor-A (VEGF-A), the fibroblast growth factor (FGF) family, or the 
matrix metalloproteinases (MMPs) and inhibitors as thrombospondin-1 (TSP-1) (Nishida 
et al., 2006). VEGF-A is a powerful and specific mitogen involved in stimulating and  
organizing angiogenesis all over the human life, and the VEGF signaling is being 
upregulated via three receptor tyrosine kinases (VEGFR-1–3) in hypoxia and oncogene 
signaling (Ferrara, 2010). The fibroblast growth factors are a family of heparin-binding 
growth factors that have been associated with sustaining tumor angiogenesis when they 
are chronically upregulated (Baeriswyl and Christofori, 2009). In addition, a cross-talk 
between FGF2 and VEGFs exists during angiogenesis, where FGF2 upregulates the 
expression of both FGFRs and VEGFRs in endothelial cells and a synergistic effect is 
present between them in different angiogenesis models (Pepper and Mandriota, 1998; 
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Presta et al., 2005). The matrix metalloproteinases (MMPs) are a family of degradative 
enzymes that play a major role in degrading the extracellular matrix (ECM) for a 
successful angiogenesis process (Nelson et al., 2000; Nishida et al., 2006). The role of 
MMP-9 in angiogenesis is distinct due to its regulation of the bioavailability of VEGF, 
the most potent inducer of tumor angiogenesis, by making sequestered VEGF 
bioavailable for its receptor VEGFR2 in pancreatic islet tumors, thus, enabling an 
angiogenic switch (Kessenbrock et al., 2010). In contrary, TSP-1, which is a member of 
the thrombospondin family that are involved in tissue remodeling, plays an 
antiangiogenic suppressive role by binding transmembrane receptors evoking an 
inhibitory angiogenic signal (Nishida et al., 2006; Kazerounian et al., 2008). TSP-1 may 
contribute to holding tumor growth in check during dormancy through the activation of 
TGFβ signaling pathway, without the possibility to proceed beyond this stage 
(Kazerounian et al., 2008). All of these aforementioned angiogenesis inducers and many 
others as pericytes and bone marrow-originating cells like macrophages, neutrophils, 
mast cells and myeloid progenitors collaborate together with a down regulation of 
angiogenesis inhibitors for a successful ongoing angiogenesis process (Hanahan and 
Weinberg, 2011).  
Lastly, cancer cells possess the ability to keep activating invasion and metastasis. 
E-cadherin is a key protein involved in inducing cell to cell adhesion by forming 
junctions with adjacent epithelial cells and preserving adherent cells in a quiescent state. 
It is well known that E-cadherin plays a vital role in cancer development, where 
overexpression of E-cadherin is associated with inhibition of invasion and metastasis, 
while downregulation and occasional mutation of E-cadherin are related to disease 
50 
 
dissemination and appearance of metastasis (Berx and Van Roy, 2009). The epithelial-
mesenchymal transition (EMT) is a developmental regulatory program where epithelial 
cells shed their differentiated characteristics, as cell–cell adhesion, planar and apical–
basal polarity, and lack of motility, and acquire instead mesenchymal features as motility, 
invasiveness and resistance to apoptosis (Klymkowsky and Savagner, 2009; Polyak and 
Weinberg, 2009). EMT describes a rapid and often reversible change of cell phenotype 
between epithelial and mesenchymal states. It can be activated transiently or 
permanently, and to differing degrees by cancer cells during their dissemination and 
metastasis (Polyak and Weinberg, 2009). The transforming growth factor-β (TGF-β) 
signaling pathway has been shown to be the major inducer of EMT through many of its 
transcription factors as Slug, SIP1, and Goosecoid, via activation of cytoplasmic 
signaling proteins Smads. In addition, other signaling pathways such as Wnt, MAPK and 
the Notch pathway have been shown to take part in EMT programme induction during 
different cellular events (Yang and Weinberg, 2008). Moreover, it was found that the 
transcription factors Snail and E47 involved in regulating EMT can repress E-cadherin 
gene expression, resulting in an increase in in vivo invasiveness and tumour progression 
(Peinado et al., 2004). Many other factors were also found to be involved in EMT. The 
mesenchymal stem cells (MSCs), for example, which are present in the tumor stroma, 
were found to respond to cancer cell signals by secreting the chemokine CCL5/RANTES 
(regulated on activation, normal T cell expressed and secreted), which can reciprocally 
act on cancer cells by enhancing their motility, invasion and metastatic potency (Karnoub 
et al., 2007). Besides, macrophages surrounding the tumors can promote local invasion 
by providing matrix-degrading enzymes such as MMPS and cysteine cathepsin proteases 
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to cancer cells (Palermo and Joyce, 2008; Kessenbrock et al., 2010). The possibility of 
reversibility of the invasive growth programme EMT was shown to be possible. Cancer 
cells that have disseminated from a primary tumor to distant sites and exhibited no more 
benefit from the activated stroma and invasion/EMT-inducing signals, were found to pass 
through a reverse process, the mesenchymal-epithelial transition, where they reverted in 
their new locations to a noninvasive state (Hugo et al., 2007; Polyak and Weinberg, 
2009). In addition to the EMT programme, two distinct modes of cellular invasion have 
been recognized. The first implicates nodules of cells moving en masse into adjacent 
tissues as in the case of squamous cell carcinomas, and it is called ‘collective invasion’, 
and the second involves the slithering of individual flexible cancer cells through the 
existing interstices in the extracellular matrix. It is presently unresolved whether cells of 
both forms of invasion employ components of the EMT programme or not (Friedl and 
Wolf, 2009). Metastasis can be divided into dissemination of cancer cells from the 
primary tumor to distant tissues and the adaptation of these cells in new 
microenvironment forming colonization. While the EMT programme along with similarly 
migratory programs govern the dissemination process, colonization, however, is not 
firmly coupled with physical dissemination since in many instances, micrometastatic 
dissemination took place without evidence of macroscopic metastatic lesions (McGowan 
et al., 2009; Talmadge and Fidler, 2010). Although there is no enough regulatory 
programmes to clarify the metastatic colonization process, some studies have shown that 
the capability of disseminated cancer cells to colonize macroscopically foreign tissues 
may arise during primary tumor formation as a result of tumor’s particular developmental 
path (Talmadge and Fidler, 2010). Moreover, the facility to colonize other tissues may 
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take place in response to the selective pressure on the already disseminated cancer cells to 
adapt to growth in foreign tissue microenvironments. Such metastatic cells are able to 
further disseminate to new sites as well as back to the primary tumor (Kim et al., 2007). 
Colonization is unlikely to be exclusively dependent upon cell-autonomous processes; it 
definitely necessitates the formation of a permissive tumor microenvironment composed 
of critical stromal supportive cells (Hanahan and Weinberg, 2011).  
The enabling characteristics that were later on added to the hallmarks of cancer 
included genome instability with mutation and tumor-promoting inflammation. The 
genome instability and mutability endow genetic alterations to be conveyed from one cell 
to a daughter one resulting in a subsequent succession of clonal expansions with mutant 
genotypes. This usually occurs by inhibiting various components of the DNA-
maintenance machinery, such as the TP53, the ataxia telangiectasia mutated (ATM) and 
cyclin-dependent kinase inhibitor 2A (CDNK2A), where inactivating mutations or 
epigenetic repressions take place rendering them lose their regulatory function of 
detecting any DNA damage, repairing it and blocking any mutagenic molecule before 
damaging DNA and thus lead to increased cancer development (Negrini et al., 2010; 
Hanahan and Weinberg, 2011). The tumor-promoting inflammation is considered as the 
second enabling characteristic. In case of inflammation, many bioactive molecules are 
collected in the tumor microenvironment as growth factors, proangiogenic factors and 
matrix-modifying enzymes in order to sustain proliferation, inhibit apoptosis and 
facilitate angiogenesis, the fact that contributes to cancer progression and metastases 
(Hanahan and Weinberg, 2011). Moreover, inflammatory cells can release reactive 
oxygen species (ROS) and reactive nitrogen intermediates (RNI) which are highly 
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mutagenic for neighboring cells, leading to a rapid evolution into a malignant state 
(Grivennikov et al., 2010).  
The emerging hallmarks include deregulating cellular energetics and avoiding 
immune destruction. Deregulating cellular energetics involves the capability to adjust 
cellular metabolism in order to support and maintain the uncontrolled neoplastic 
proliferation and growth. Glycolysis is a major mode of energy production acting by 
converting glucose into pyruvate in the cytosol and then into carbon dioxide in the 
mitochondria, releasing ATP as a source of energy under an aerobic condition. In case of 
anaerobic conditions, glycolysis is being completed by fermentation in order to release 
energy to the cell. In cancer cells and under either aerobic or anaerobic condition, the 
glycolysis mode of energy production is being preserved mostly by the overexpression of 
RAS and MYC oncogenes and mutation in TP53 tumor suppressor, the fact that conserves 
cell growth and proliferation and avoids apoptosis (Jones and Thompson, 2009; Hanahan 
and Weinberg, 2011). Evading immunological destruction is considered the second 
emerging cancer hallmark. It is well known that the immune system monitors the 
emergence of cancer cells, recognizes and eliminates them before their proliferation into 
tumors (Burnet, 1957). Tumor appearance, however, takes place when cancer cells 
succeed in escaping the immune destruction by inactivating some components of the 
immune system that are released to eliminate them. The immunosuppressive cytokine 
transforming growth factor–β (TGF-β), for example, can be secreted by cancer cells to 
paralyze infiltrating cytotoxic T lymphocytes (CTL) and natural killer cells (NK) and 
hence inhibit the antitumor immune responses and lead to cancer appearance (Yang et al., 
2010). Another mechanism in evading immune control by cancer cells occurs by 
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recruiting the inflammatory actively immunosuppressive cells, such as the regulatory T 
cells and myeloid-derived suppressor cells in order to suppress the actions of cytotoxic 
lymphocytes and inhibit both innate and adaptive immunity (Ostrand-Rosenberg and 
Sinha, 2009; Mougiakakos et al., 2010). This fact allows cancer cells to evade 
immunological destruction mainly by T and B lymphocytes, macrophages, and natural 
killer cells (Hanahan and Weinberg, 2011).  
All of the aforementioned hallmarks represent major characteristics adopted by 
cancer cells to maintain their survival and avoid any suppressing factor that may inhibit 
their proliferation throughout their developmental process. 
1.2.4 Regulation of cell death in cancer: necrosis and apoptosis  
  
Cell death is a physiological process that takes place as a result of cell aging, or in 
case of diseases, injuries or any malformation defect in cell development. Necrosis and 
apoptosis are two of the most implicated and well-known mechanisms in cell death 
(Elmore, 2007). Necrosis is a form of premature cell death, caused by external noxious 
factors such as infection, toxins or trauma, which results in cell membrane injury, leading 
to rupture and release of the cytosolic content into the extracellular space. This can 
provoke detrimental inflammatory responses to the organism (Proskuryakov et al., 2003; 
Bruce et al., 2007). Apoptosis, or programmed cell death, is a physiological process that 
occurs in multicellular organisms. It is a vital component of various processes, such as 
cell turnover and development, aging and maintaining tissue homeostasis (Elmore, 2007). 
It also occurs as a defense mechanism in immune reactions or upon tissue damage by 
diseases and harmful agents (Norbury and Hickson, 2001). Apoptosis can be triggered by 
55 
 
both physiological and pathological stimuli and comprises a series of morphological and 
biochemical alterations. These changes include membrane blebbing and cell shrinkage, 
followed by pyknosis or nuclear chromatin condensation, cytoplasmic condensation, and 
ending in karyorrhexis or nuclear DNA fragmentation, (Zamzami and Kroemer, 1999; 
Rogalińska, 2002; Bruce et al., 2007). Many other pathways have been discovered, later 
on, that can play a non-small role in programmed cell death, including autophagy, which 
is a functional intracellular degradation system that takes down dysfunctional 
machineries and brings them down into special autophagosomes to maintain homeostasis 
(Mizushima, 2007). Necroptosis, another form of programmed necrotic death, is a 
genetically controlled multi-step cellular leakage adopted bycells as a defense mechanism 
against viral and other intracellular infections in addition to cardiac diseases and gastro-
intestinal disorders (Linkermann and Green, 2014). Other programmed cell death include 
oncosis, which is an ATP depletion-related cell death (Weerasinghe and Buja, 2012), 
pyroptosis that is an inflammatory form of cell death (Fink and Cookson, 2006), and 
anoikis that results from inadequate cell–matrix interactions (Douma et al., 2004).  
1.2.4.1 Programmed cell death pathways 
 
Apoptosis occurs through two main pathways: the extrinsic or receptor pathway, 
and intrinsic or mitochondrial pathway, which often cross-talk. In the first one, specific 
membrane receptors, called death receptors, belonging to the Tumor Necrosis Factor 
(TNF) receptors superfamily as CD95 (APO-1/Fas) and TRAIL-R (TNF-related 
apoptosis-inducing ligand Receptor), aggregate upon stimulation by their specific ligands 
(CD95-R and TRAIL respectively), and activate both FADD (Fas-associated death 
domain) and Caspase-8 molecules (apoptotic proteases), forming a death-inducing 
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signaling complex (DISC). In turn, Caspase-8 causes direct cleavage of the downstream 
effector Caspases (Caspases-3, -6 and -7), turning on the Caspase-3 molecules and 
leading to cell apoptosis via different mechanisms. Specifically, Caspase-3 activates the 
endonuclease CAD (Caspase-activated DNase), which cleaves DNA into many 
oligomeric fragments, by cleaving its inhibitor ICAD (inhibitor of Caspase-activated 
DNase) and releasing CAD from this complex. CAD, in turn, begins degrading 
chromosomal DNA in the nuclei and causes chromatin condensation (Fulda and Debatin, 
2006; Elmore, 2007). Poly ADP-ribose polymerase (PARP) is a family of nuclear 
proteins involved in regulating many cellular processes and mainly DNA repair and 
genomic stability (Herceg and Wang, 2001). PARP is involved in detecting and repairing 
early DNA damage as single-strand DNA breaks. Caspase-3, -6 and -7, as ‘executioner’ 
Caspases, can cleave PARP, thus, depriving the enzyme from its DNA repairing activity 
(Walczak and Krammer, 2000; Saelens et al., 2004; Fulda and Debatin, 2006). Moreover, 
the effector Caspases (Cas-3, -6 and -7) have the ability to cleave different nuclear and 
cytoskeletal proteins including the cellular filament main component cytokeratins, the 
plasma membrane cytoskeletal protein alpha fodrin, the nuclear matrix-forming protein 
NuMA (nuclear mitotic apparatus protein 1) and many others, participating in preparing 
the final morphological and biochemical modifications observed in apoptotic cells (Slee 
et al., 2001; Fulda and Debatin, 2006). In addition, Caspase-3 is being involved in 
inhibiting the role of gelsolin, an actin-binding protein that regulates actin filament 
polymerization and causing signal transduction, resulting in disruption of the 
cytoskeleton, intracellular transport, cell division, and signal transduction (Kothakota et 
al., 1997; Slee et al., 2001; Walsh et al., 2008). Alternatively, the death receptor mediated 
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apoptosis process can be disrupted by a protein called c-FLIP [cellular FLICE (FADD-
like IL-1β-converting enzyme) inhibitory protein], which can bind to FADD and 
Caspase-8 in the DISC complex, inhibiting their interaction and rendering them 
ineffective (Elmore S, 2007).  
In the intrinsic pathway, various routes can be followed to cause apoptosis. The 
activation of Caspase-8 proteases directly affects a family of proteins known for their 
regulation of apoptosis, known as the Bcl-2 family proteins. Some proteins in the Bcl-2 
family induce apoptosis as Bax, Bak, Bad, Bim and Bid, while others inhibit apoptosis as 
Bcl-2, Bcl-x(L) and Bcl-w (Adams and Cory, 2007). As a result of Caspase-8 activation, 
truncated Bid becomes activated and leads to the release of Cytochrome-c from the 
mitochondria through the up-regulation of Bax molecule that creates channels in lipid 
membranes, enabling the passage of Cytochrome-c to the cytoplasm, and down-
regulation of Bcl-2 that can deregulate Bax by preventing its homo-oligomerization 
(Martinou and Youle, 2011). The release of Cytochrome-c creates the Cyt-c/Apaf-
1/Caspase-9 complex, which activates Caspase-3 and leads to cell death again via either 
ICAD/CAD or PARP polymerase cleavage.  
Once activated, the catalytic activity of Caspases can be counteracted by members 
of the inhibitor of apoptosis protein family (IAP). The X-linked IAP (XIAP) and Survivin 
proteins are being the most implicated in Caspase activity inhibition. XIAP has the ability 
to directly inhibit Caspase function by competing for distinct binding domains, hindering 
the Caspase catalytic site and rendering them nonfunctional (Tamm et al, 1998; Hensley 
et al, 2013). Survivin is considered as the fourth most upregulated gene in human solid 
cancers, and it is mainly involved in cell survival, promoting proliferation and enhancing 
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invasion (Church and Talbot, 2012). Survivin acts by directly binding to Caspases-3 and -
7 and inhibiting their protease ability (Tamm et al., 1998). Later experiments, however, 
indicated that Survivin acts by inhibiting Pro-Caspase-9, preventing its recruitment to the 
Cyt-c/Apaf-1/Caspase-9 apoptosome complex, via a cofactor known as  the hepatitis B 
X-interacting protein (HBXIP), leading to apoptosis inhibition (Marusawa et al., 2003). 
Currently, various clinical trials are trying to target Survivin in cancer therapeutics (Mita 
et al., 2008; Church and Talbot, 2012). However, all IAP family activity can be 
counteracted by a variety of proapoptotic proteins and mainly Smac/DIABLO and 
OMI/Htra2 (Saelens et al., 2004). The apoptogenic factor Smac/DIABLO (second 
mitochondria-derived activator of Caspase)/ (direct inhibitor of apoptosis protein (IAP)-
binding protein with low PI) is a mitochondrial protein that can promote Caspase 
activation by binding to IAPs, inhibiting their Caspase-binding activity and thus freeing 
Caspases to trigger apoptosis (Bai et al., 2014). HtrA2/Omi (high-temperature 
requirement A2/ Omi stress-regulated endoprotease) is a mitochondrial-located serine 
protease that regulates mitochondrial homeostasis and promotes cell survival. However, 
under stressful conditions its function turns out into proapoptotic by binding to IAPs and 
causing a proteolytic degradation of these proteins, leading to Caspase activation and 
apoptosis (Saelens et al., 2004).  
A third way of the intrinsic pathway action is through the secretion in the cell of 
AIF (apoptosis-inducing factor). AIF is a mitochondrial protein that is able to mediate 
cell death independently of Caspases (Joza et al., 2009). Upon ATP depletion, AIF gets 
stimulated and is released from the mitochondria to the nucleus where it mediates 
chromatin condensation and large-scale DNA fragmentation (Daugas et al., 2000; Fulda 
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and Debatin, 2006; Joza et al., 2009). Similarly, Endonuclease G is a Caspase-
independent pro-apoptotic protein that is released from the mitochondria during apoptosis 
and translocates to the nucleus where it cleaves nuclear chromatin to produce 
oligonucleosomal DNA fragments (Li et al., 2001; Zanna et al., 2005; Elmore, 2007) 
(figure 1.3). 
 
Figure 1. 3 The extrinsic and intrinsic apoptotic pathways. Membrane Death receptors (CD95 
and TRAIL-R) aggregate upon stimulation by their ligands and activate FADD and Caspase-8 
apoptotic proteases. In the Extrinsic (Receptor) Pathway, Caspase-8 causes cleavage of Caspase-
3, turning it on and causing Apoptosis either via ICAD/CAD cleavage or via PARP cleavage. In 
the Intrinsic (mitochondrial) Pathway, cleavage of Caspase-8 leads to the activation of Bid 
protein, which up-regulates Bax and down-regulates Bcl-2. This allows the release of the 
Mitochondrial Cytochrome-c, which creates the Cyt-c/Apaf-1/Caspase-9 complex that, in turn, 
activates Caspase-3, and leads to cell death. Moreover, the release of the apoptogenic factors 
Smac/DIABLO or HtrA2/Omi from the mitochondria inhibits the inhibitory apoptotic protein 
(IAP) family, which leads to the activation of Caspase-3 protein. The secretion of the apoptosis-
inducing factor (AIF) or the Caspase-independent pro-apoptotic protein (Endo G) by the 
mitochondria is another way of causing cell death, independently of Caspases and via DNA 
fragmentation.  
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The perforin/granzyme pathway is T lymphocytes and natural killer cells 
mediated cytotoxic pathway. This granule secretion pathway involves the secretion of the 
transmembrane pore-forming molecule perforin with a subsequent intracellular delivery 
of a family of granule-associated-serine proteases, which activate both Caspase-
independent (granzyme A) and dependent (granzyme B) apoptotic pathways to confirm 
the death of target cell (Metkar et al., 2002; Elmore, 2007). Granzyme B pathway utilizes 
the intrinsic mitochondrial pathway to activate Caspase-3 and induces apoptosis by 
cleaving ICAD/CAD complex (Bots and Medema, 2006; Elmore, 2007). Granzyme A, 
however, promotes apoptosis in a Caspase independent way. Granzyme A activates DNA 
nicking via the immuno-surveillant DNAse NM23-H1, a tumor suppressor gene product 
(Fan et al., 2003). Granzyme A cleaves the nucleosome assembly protein SET that 
inhibits the NM23-H1 gene. SET complex is an endoplasmic reticulum-associated 
complex composed of 3 DNases (the base excision repair endonuclease APE1, 5′-3′ 
exonuclease TREX1, and endonuclease NM23-H1), and has a chromatin protective role 
and DNA preserving function, in addition to his inhibition to NM23-H1 gene. Cleaving 
SET complex by Granzyme A contributes to the release of NM23-H1 inhibition and 
causes apoptosis via DNA degradation, in addition to disrupting both DNA preservation 
and chromatin structure integrity (Lieberman and Fan, 2003; Elmore, 2007).   
Another form of programmed cell death is autophagy, which is a physiological 
intracellular degradation system that disassembles dysfunctional components and delivers 
them to the lysosome in order to maintain homeostasis (Mizushima, 2007). Autophagy is 
divided into three types: macroautophagy or the main pathway, which is necessary to get 
rid of damaged cell organelles or unused proteins (Levine et al., 2011), microautophagy 
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which consists of direct engulfment of cytoplasmic material into the lysosome via cellular 
invagination (Česen et al., 2012) and the Chaperone-mediated autophagy or CMA, which 
is a specific pathway that involves the recognition of hsc70 (Heat shock 70 kDa protein 
8) recognizing site proteins and forming together a CMA-substrate/chaperone complex 
that allows the protein get into the lysosome for degradation (Bandyopadhyay et al., 
2008). Autophagy  can be stimulated by different forms of cellular stress, including 
nutrient deficiency and cell starvation, growth factor scarcity, hypoxia, reactive oxygen 
species, DNA damage and other intracellular metabolite concentrations as damaged 
organelles and  protein aggregates (Kroemer et al., 2010). Mammalian autophagy is a 
multistep procedure that begins with the phagophore assembly site (PAS) formation, 
followed by the phagophore elongation and expansion, then comes the autophagosome 
development and closure, pursued by autophagosome maturation via cutting and fusion 
with an endosome and/or lysosome, and ending by breaking down and degradation of the 
autophagosome inner membrane and cargo, besides recycling of the resulting 
macromolecules (Yang and Klionsky, 2010). There are a lot of autophagy-
related proteins, referred to as the “core” molecular machinery, which are encoded by the 
autophagy-related genes (ATG) and are involved in autophagy process. They are divided 
in four different groups and include the following proteins: Firstly, the Atg1/unc-51-like 
kinase complex (ULK1/2) that plays a key role in the induction of autophagy by acting 
downstream of the target of rapamycin (TOR) complex 1 (TORC1), and forming a 
complex with Atg1 and the scaffold protein FIP200 that get phosphorylated upon nutrient 
starvation (Jung et al., 2009). Secondly, two ubiquitin-like protein (Atg12 and Atg8/LC3) 
conjugation systems are involved in the elongation and expansion of the phagophore 
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membrane, to form with many other Atg proteins a large multimeric complex called the 
Atg16L (Yang and Klionsky, 2009). In the third place comes the class III 
phosphatidylinositol 3-kinase/Vacuolar protein sorting34 (PI3K/Vps34) complex 
including hVps34, Beclin 1 (a homolog of Atg6), and p150 (a homolog of Vps15), which 
plays a major role in autophagy regulation either at early stage by promoting 
autophagosome formation or at late stage by enhancing autophagosome maturation by 
recruiting various Atg machinery (Yang and Klionsky, 2010). And lastly, the mammalian 
Atg9 (mAtg9) and vacuole membrane protein 1 (VMP1) are two transmembrane proteins 
essential in mammalian autophagosome development. The mAtg9 protein is a 
multispanning protein needed for autophagosome formation in yeast, by coupling of the 
Atg9 vesicles, during starvation, with fusion of the autophagosomal outer membrane with 
the vacuolar membrane (Yamamoto et al., 2012). The VMP1 is a Beclin 1 binding 
protein that interact together through VMP1-Atg domain for autophagosome formation in 
rapamycin-induced autophagic cells (Ropolo et al., 2007). VMP1 also potentiates the 
translocation of Beclin 1 and LC3 to autophagosomes upon autophagy stimulation 
through its interaction with TP53INP2 (tumor protein 53-induced nuclear protein 2), 
which is an essential protein for autophagosome development (Nowak et al., 2009). 
Autophagy is regulated by different signaling pathways that often cross-talk. Upon 
external stimulation by growth factors, PI3K/m-TOR pathway as well as Ras protein gets 
activated. Ras, in turn, activates both MAPK and PI3K signaling pathways. AKT and 
ERK1/2 act by phosphorylating and inhibiting the GTPase-activating protein complex 
TSC1/TSC2, leading to Rheb-GTPase stabilization and activating mTORC1 that inhibits 
autophagy (Furuta et al., 2004; Yang and Klionsky, 2010). However, it was also shown 
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that Ras may induce autophagy through the MAPK pathway, thus playing opposing roles 
in autophagy regulation (Pattingre et al., 2003). Similarly, p53 has dual regulatory roles 
in autophagy induction. Upon activation by internal and genotoxic stresses, p53 induces 
autophagy via activation of 5' adenosine monophosphate-activated protein kinase 
(AMPK) that stimulates TSC1/2 complex to inhibit the mTORC1 pathway (Feng et al., 
2005). P53 can also induce autophagy through the activation of DRAM (damage-
regulated autophagy modulator) gene, which is a p53 target gene encoding a 
lysosomal protein that induces macroautophagy (Crighton et al., 2006). However, an 
inhibitory role of cytosolic (but not nuclear) p53 in autophagy was also detected, and this 
may lie behind the strong oncogenic action in certain p53 mutant cells (Morselli et al., 
2008). Autophagy can be induced by metabolic stress. Raised AMP/ATP ratios resulting 
from energy depletion, or an increase in the concentration of cytoplasmic free Ca2+ or in 
cytokines as TRAIL, cause the AMP-activated protein kinase that plays a role in cellular 
energy homeostasis, to get phosphorylated and activated by the liver kinase B1 (LKB1), 
calcium-calmodulin-dependent kinase kinase 2  (CaMKKβ) and TGFβ-activated kinase 1 
(TAK1), respectively. AMPK acts by phosphorylating and activating the TSC1/2 
complex, leading to mTORC1 inactivation and autophagy induction (Høyer-Hansen et 
al., 2007; Herrero‐Martín et al., 2009). The Bcl-2 apoptotic protein family also plays a 
double role in autophagy process. The anti-apoptotic proteins (Bcl-2, Bcl-XL, Bcl-w and 
Mcl-1) can inhibit autophagy since the binding of Bcl-2 to Beclin 1 disrupts the 
association of Beclin 1 with Vps34, reduces Beclin 1-associated Vps34 PI3K activity and 
thus inhibits autophagy. The pro-apoptotic BH3-only proteins (Bad, BNIP3, Bik, Noxa 
and Puma), however, can induce autophagy by disrupting competitively the inhibitory 
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interaction of Beclin 1 and Bcl-2/Bcl-XL via the substitution of the BH3-binding groove 
of Bcl-2 or Bcl-XL, hence freeing the Beclin 1 complex with its coactivators UVRAG, 
Ambra1 and Bif-1 from the inhibitory effect of Bcl-2 (Maiuri et al., 2007; Levine et al., 
2008). Another mechanism for the dissociation of Beclin 1 from Bcl-2 involves the 
phosphorylation of Bcl-2 by the stress-activated c-Jun N-terminal Kinase 1 (JNK1) 
during starvation, releasing again the Beclin 1/coactivators complex to induce autophagy 
(Wei et al., 2008). 
Necroptosis, or regulated necrosis, is a genetically controlled cell death process. It 
is characterized by cytoplasmic granulation, along with organelle and/or cellular swelling 
and end up with cellular leakage (Berghe et al., 2014). Necroptosis can be adopted by the 
organism as a defence mechanism against viral and other intracellular infections, as well 
as in various disorders such as cardiac diseases, ischemia, pancreatitis and inflammatory 
bowel syndrome and Crohn’s disease (Linkermann and Green, 2014). It is a new form of 
programmed necrosis where it can substitute apoptosis in case of blocking of Caspase-8 
apoptosis signaling pathway by endogenous or exogenous factors such as mutations or 
viruses (Linkermann and Green, 2014). Necroptosis can be induced by the stimulation of 
the TNF receptor superfamily including TNFR1, which upon external stimulation triggers 
the recruitment of TRADD/RIP1/TRAF2/CYLD/ cIAP1/2 complex that enhances three 
different modes of signaling. In case of ubiquitination of the receptor-interacting kinase 1 
(RIP1) by c-IAP1/2, the NF-κB pathway becomes stimulated and cell survival takes place 
(Su et al., 2015). Besides, deubiquitination of RIP1 by the cylindromatosis (CYLD) 
enables the formation of Caspase-8/FADD/RIP1 complex that promotes apoptosis via 
Caspase-8 activation (Su et al., 2015). However, in case of Caspase-8 deactivation by c-
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FLIP or Caspase-8 deletion or FADD inhibition/deletion, Caspase-8 fails to cleave RIP1 
and the key molecule in necroptosis RIP3 leading to their trans-phosphorylation and the 
development of a filamentous-like complex, the necrosome that acts as the transducer of 
the necroptotic signal (Berghe et al., 2014; Su et al., 2014; Su et al., 2015). Consequently, 
the RIP1-RIP3 necrosome recruits and activates the mixed lineage kinase domain like 
(MLKL) pseudo kinase MLKL and the phosphoglycerate mutase 5 PGAM5. The 
phosphorylation of MLKL by RIP3 causes oligomerization of MLKL, allowing it to 
move freely into plasma membranes and organelles leading to disruption of membrane 
integrity and resulting in necroptosis (Wang et al., 2014; Su et al., 2015). Afterward, 
PGAM5S (a short form of PGAM5) recruits and activates the mitochondrial fission factor 
dynamin-related protein 1(Drp1) to cause mitochondrial fission, which is considered as 
an early and obligatory step for necrosis accomplishment (Wang et al., 2012).  
Many other pathways are also adopted by cells in different situations, such as 
oncosis, which is a form of accidental cell death resulting from ATP depletion in 
response to myocardial ischemia and other infectious toxins (Weerasinghe and Buja, 
2012). Oncosis is considered a prelethal pathway characterized by cellular and organelle 
swelling, blebbing, and increased membrane permeability, resulting from the 
accumulation of sodium and chloride ions within the cell accompanied with water influx 
after deactivation of sodium and potassium ATPase within the compromised cell 
membrane post ATP depletion, leading to necrotic cell death (Fink and Cookson, 2005; 
Weerasinghe and Buja, 2012). Pyroptosis is an inflammatory novel form of cell death 
that occurs most frequently upon bacterial (Fink and Cookson, 2006) or viral infection 
(Doitsh et al., 2014). It is a Caspase-1 dependent pathway that can induce inflammation 
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by releasing inflammatory cytokines (IL-1β and IL-18) via pore formation and causing 
DNA fragmentation upon activation of Caspase-1 by a big molecular complex termed the 
pyroptosome or inflammasome (Fantuzzi and Dinarello, 1999; Fink and Cookson, 2005). 
Anoikis is a term that indicates a programmed cell death resulting from loss or inadequate 
cell–matrix interactions. It is considered a physiological barrier to metastasis (Douma et 
al., 2004). Anoikis is partly mediated by activation of the death receptor pathway of 
Caspase activation (Frisch and Screaton, 2001) and by activation of Caspase-8 (Aoudjit 
and Vuori, 2001). Metastatic cancer cells avoid anoikis process via the inhibitory protein 
FLIP, which directly binds to Fas-associated death domain protein and inhibits Caspase-8 
activity, thus allowing circulation of cancer cells and facilitating the development of 
secondary tumors in distant organs (Mawji et al., 2007).  
 
1.2.4.2 Apoptosis related proteins and carcinogenesis 
 
 The human B-cell lymphoma, or Bcl-2 Family, includes cytoplasmic proto-
oncogenes that are implicated in different types of cancer such as breast, prostate, 
melanoma, and lung carcinomas (Hanahan and Weinberg, 2000). The members of Bcl-2 
family are divided into two subclasses based on the presence of one or more “Bcl-2 
homology” domains (BH1, BH2, BH3 and BH4), which are crucial for dimers formation. 
The structural and functional characteristics of dimers formation and proteins activation 
identify the cell apoptotic rate (Reed et al., 1996; Yip and Reed, 2008). The anti-
apoptotic Bcl-2 proteins, such as Bcl-2, Bcl-XL, Bcl-w and Mcl-1, conserve all four BH 
domains. The pro-apoptotic Bcl-2 proteins are subdivided into those with several BH 
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domains (BH1, BH2 and BH3), such as Bax and Bak, and those which have only the 
BH3 domain, such as Bim, Bid and Bad (Reed et al., 1996; Petros et al., 2004).  
 Caspases are a family of endoproteases that play basic roles in regulating cell 
inflammation and apoptosis (McIlwain et al., 2013). They are classified into 
inflammatory (Caspase-1, 4, 5 and 12), or apoptotic (Caspase-2, 3, 6, 7, 8, 9 and 10). 
Apoptotic Caspases are subclassified according to their mechanism of action into initiator 
Caspases such as Caspase-2, -8,-9 and -10 or executioner Caspases such as Caspase-3, -6 
and -7 (Riedl and Shi, 2004; Tait and Green, 2010; Fava et al., 2012; McIlwain et al., 
2013). These proteases are initially produced as an inactive form (Pro-Caspases) and can 
be activated either by dimerization (Caspase-8 and 9), or by cleavage (Caspase-3, 6 and 
7) in response to different apoptotic stimuli (Riedl and Shi, 2004). Upon activation, the 
initiator Caspase cleaves the executioner Pro-Caspase dimers, creating a conformational 
change in their active sites, leading in turn to the formation of a mature active protease 
(Riedl and Shi, 2004). Once activated, one active executioner Caspase can cleave and 
stimulate other executioner proteases, leading eventually to apoptosis (McIlwain et al., 
2013). Many cancers have been correlated to mutations in Caspase formation. Defects in 
Caspase-8, for example, are being observed in advanced gastric and colorectal cancers, 
and mutations in Caspase-7 are found in head and neck, esophageal and colorectal 
carcinomas (Olsson and Zhivotovsky, 2011). 
 PARP or poly ADP-ribose polymerase is a family of nuclear proteins involved in 
the regulation of many cellular processes such as DNA repair, genomic stability, 
chromatin functions and programmed cell death (Herceg and Wang, 2001). PARP 
consists of four domains: a DNA binding domain, a Caspase cleaved domain, a catalytic 
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domain and an auto-modification domain. PARP can detect and respond to early DNA 
damage. It initiates an immediate response to external stimuli causing single-strand DNA 
breaks (SSB). Once PARP detects SSB, it binds to DNA molecule and starts the synthesis 
of a polymeric adenosine diphosphate ribose (PAR) chain, which in turn, activates other 
DNA-repairing enzymes (Isabelle et al., 2010). PARP can induce cell necrosis by 
depleting the cell content from NAD+, which is needed as substrate to produce ADP-
ribose monomers, resulting in ATP depletion and cell lysis and death. PARP can also 
cause apoptosis via the production of polymeric adenosine diphosphate ribose or PAR 
chain, which stimulates the mitochondria to release the apoptosis-inducing factor or AIF 
(Yu et al., 2006). Other studies have shown that cleavage of PARP by Caspase-3 can also 
lead to apoptosis, where PARP can be cleaved into two fragments (89- and 24-kDa) 
leading to the loss of the enzyme activity and hence preventing its action in response to 
DNA strand breaks (Le Rhun et al., 1998; Boulares et al., 1999).  
DNA alterations which usually occur due to environmental injuries, toxic 
metabolic products, and erroneous DNA replication can be classified into: base 
modifications, single strand breaks (SSB), double strand breaks (DSB) and intrastrand or 
interstrand cross-links. Various DNA repair mechanisms have evolved to repair these 
lesions, and include: the base excision repair (BER), the nucleotide excision repair 
(NER), the mismatch repair (MMR), the recombinational repair comprising homologous 
recombination (HR) and non-homologous end-joining (NHEJ), and the direct repair 
mechanisms (Davar et al., 2012). The main mechanism of DNA SSB repair consists of 
BER pathway via the PARP family of enzymes (majorly PARP-1 that accounts for more 
than 90% cellular PARP activity) (Dantzer et al., 1999). In case of BER impairment, 
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PARP’s role in DNA repair is inhibited. The single strand breaks accumulate and become 
DSBs. The cell relies on other repair pathways, mainly HR and NHEJ. In case of BRCA-
mutations, the HR repair mechanism is defective. Patients are then more susceptible to 
impairment of the BER pathway. In such cases, PARP inhibitors succeeded in causing 
apoptosis (Chen, 2011). Olaparib is an oral PARP inhibitor that has been approved for the 
treatment of patients with BRCA-1 and BRCA-2 breast or ovarian cancers (Livraghi and 
Garber, 2015). 
  
1.2.5 The role of free radicals and oxidants in carcinogenesis 
 
A free radical is any atom or molecule that is formed out of an unpaired electron 
in an atomic orbital, and is capable of independent existence (Lobo et al., 2010). The 
presence of unpaired electron renders the radicals unstable and highly reactive. There are 
two main classes of free radicals, the reactive oxygen species (ROS) and reactive 
nitrogen species (RNS). They are generated in the body by various endogenous systems 
and in particular by neutrophils and macrophages during inflammation, and by 
mitochondria-catalyzed electron transport reactions (Cadenas, 1989). Exposure to 
external radiations (UV light, X-rays and gamma rays) cigarette smoking, air pollutants, 
and industrial chemicals also play an exogenous role in free radical formation (Bagchi 
and Puri, 1998). ROS includes different molecules, as superoxide (O2
•−), hydroxyl radical 
(HO•), peroxynitrite (OONO−) and hydrogen peroxide (H2O2) (even if H2O2 is not 
considered a free radical, but it enters in the free radical pathway formation) (Waris and 
Ahsan, 2006; Vera-Ramirez et al., 2011; Halliwell, 2012). RNS mainly includes the 
Nitric oxide radical (NO•) which is formed in higher organisms from the oxidation of L-
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arginine to citrulline by the enzyme nitric oxide synthase (Dröge, 2002). At lower 
concentrations, free radicals can be beneficial for the organism as in the antibacterial 
defense mechanism, where phagocytes release free radicals to get rid of noxious invading 
microbes. Another beneficial role of ROS and RNS is their regulation of intracellular 
signaling cascades in different nonphagocytic cells as fibroblasts, endothelial cells, 
vascular smooth muscle cells, cardiac myocytes, and thyroid cells (Sandoo et al., 2010). 
This role is mainly attributable to Nox1 and Nox2 proteins which produce O2
•− by 
catalyzing the reduction of molecular oxygen using NADPH as an electron donor (Brown 
and Griendling, 2015). At higher concentrations, due to excessive production of free 
radicals and the inability of cells to destroy them, a deleterious process known as 
oxidative stress takes place. This can mediate serious damage to cell structures including 
cell membranes, proteins, lipids, lipoproteins and DNA (Poli et al., 2004; Pham-Huy et 
al., 2008). In the vessel, for example, excessive increase in the level of O2
•− can severely 
affect the vascular tone, gene expression, inflammation, cellular growth, signaling, and 
apoptosis (Fukai and Ushio-Fukai, 2011). 
It is well established that cancer development is characterized by a three stage 
process: initiation, promotion and progression. ROS can act in all of these stages of 
carcinogenesis by reacting with DNA and damaging the deoxyribose backbone, causing 
nitrogen base alterations, DNA cross-linking and other mutations in the genes, ending up 
in cancer formation (Dizdaroglu et al., 2002; Klaunig and Kamendulis, 2004). This DNA 
damage can result in transcription arrest, induction of signal transduction pathways, 
replication errors, and genomic instability, all of which are associated with 
carcinogenesis (Marnett, 2000; Cooke et al., 2003). 
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1.2.6 Antioxidant defense mechanisms 
 
Antioxidants are reducing agents that are able to limit oxidative cellular damage 
which results from oxidative stress. They aim to neutralize the excess of free radicals, to 
protect the cells against their toxic effects and to contribute to disease prevention (Pham-
Huy et al., 2008). Neutralizing oxidative damage occurs either by scavenging free 
radicals through the acceptance or donation of electron(s) to abolish the unpaired state of 
the radicals, or by chelating redox metals and preventing the hydroxyl group formation, 
or even by decomposing the lipid hydroperoxides and repairing the peroxyl radicals. 
Antioxidants also have the ability to regenerate other antioxidants and modulate cell 
signaling pathways to prevent cancer formation (Gupta and Sharma, 2006; Valko et al., 
2006; Lü et al., 2010). Antioxidants are known to be either endogenous or exogenous. 
The endogenous antioxidants are subdivided into enzymatic and non-enzymatic defense 
systems. The enzymatic antioxidants comprise superoxide dismutase (SOD), catalase 
(CAT), glutathione peroxidase (GPx), glutathione reductase (GRx) and glutathione 
transferase (GTx) (Pham-Huy et al., 2008; Manda et al., 2009). These all play a first role 
of defence by maintaining a biological balance between them and free radicals by 
decreasing the ROS and RNS level and  preventing oxidative damage. SOD, for example,  
catalyses the redox disproportionation or dismutation of the ROS superoxide (O2−) 
radical into oxygen (O2) and hydrogen peroxide (H2O2), which, in turn, is catalyzed by 
catalase into water and oxygen (Chelikani et al., 2004; Hayyan et al., 2016). Glutathione 
transferases also play an important role in the detoxification of xenobiotics in mammals, 
such as carcinogens, drugs, environmental pollutants, food additives, hydrocarbons, and 
pesticides. They protect cells by conjugating the thiol group of glutathione to the 
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electrophilic compounds of xenobiotics, rendering the conjugates more soluble so that 
they can be readily excreted out of the cells (Laborde, 2010). The non-enzymatic 
antioxidants are also classified as metabolic or nutrient antioxidants. The metabolic 
antioxidants are products of body metabolism and include lipoid acid, glutathione, L-
ariginine, coenzyme Q10, melatonin, uric acid, bilirubin, metal-chelating proteins, 
transferrin, and plasma protein thiols (Dröge, 2002; Valko et al., 2006). Coenzyme Q10, 
for example, is an endogenous potent antioxidant found in most aerobic organisms and is 
a member of the mitochondrial respiratory chain, where it is needed for energy 
production and to maintain cell metabolism by synthesizing adenosine triphosphate 
(ATP). CoQ10 helps to neutralize free radicals, stabilizes the cell membranes and 
maintains a redox homeostatic function. CoQ10 plays a significant role in boosting the 
immune system and helps prevent or treat many diseases as cardiovascular diseases, 
cancer, periodontal diseases, mitochondrial disorders, diabetes, Parkinson's disease, 
acquired immune deficiency syndrome (AIDS), gastric ulcers, allergy, migraine 
headaches, kidney failure, muscular dystrophy, and aging (Turunen et al., 2004; Saini, 
2011). The nutrient antioxidants are considered exogenous. They are diet-derived 
supplements and comprise vitamin E, C and A, carotenoids, trace metals (selenium, 
manganese, zinc), flavonoids, phenols, terpenes, omega-3 and omega-6 fatty acids (Valko 
et al., 2006; Pham-Huy et al., 2008; Racchi, 2013). All the non-enzymatic antioxidants 
constitute the second line of homeostatic defence by reducing free radicals to less harmful 
molecules (Racchi, 2013). Many data have shown the relation between nutrient 
antioxidants and cancer prevention. One systemic review of trials and meta-analysis 
revealed statistically significant beneficial results for vitamin E and C in cancer 
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treatment. Vitamin C in combination with BCG (an established bladder cancer treatment) 
was found to be beneficial in a trial of bladder cancer in preventing new tumor 
occurrence (Lamm et al., 1994; Coulter et al., 2006). Vitamin E also in combination with 
omega-3 fatty acid increased survival in patients with advanced metastatic solid cancers 
(Lamm et al., 1994; Coulter et al., 2006). 
  
1.2.7 Cytokines and carcinogenesis 
 
Cytokines are low-molecular weight cell secreted proteins and play a major role 
in cell communication and signaling. They are considered to be immunomodulating, and 
can act in an autocrine (acting on self-secreting cells), paracrine (acting on nearby cells) 
and endocrine (acting on distant cells) signaling pathways. There are different kinds of 
cytokines, such as lymphokines (lymphocyte-made cytokines), monokines (monocyte-
made cytokines), chemokines (cytokines with chemotactic activities), and interleukins 
(leukocyte-made cytokines and act on other leukocytes) (Zhang and An, 2007). Some 
cytokines are produced by activated macrophages and play a major role in the pro-
inflammatory process. These include IL-1β, IL-6, and TNF-α and are involved in the 
process of pathological pain. Interleukin-1β, for example, is released by monocytes and 
macrophages during cell injury, infection, invasion, and inflammation (Özaktay et al., 
2006). The immunoregulatory role of cytokines appears in the anti-inflammatory 
cytokines, such as IL-1 receptor antagonist and Interleukins- 4, 10, 11, and 13. Other, 
such as Leukemia inhibitory factor, interferon-alpha, IL-6, and transforming growth 
factor (TGF)-β are considered both anti- or pro-inflammatory cytokines. Specific 
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cytokines receptors for Tumor Necrosis factor (TNF-α), Interleukins-1 and 18 control the 
pro-inflammatory cytokine response by inhibiting their effect (Zhang and An, 2007). 
Chemokines, like monocyte chemoattractant protein (MCP-1), Interleukin-8, 
lymphotactin and fraktalkine are involved in the activation and migration of leukocytes, 
and play a major role in host defense mechanism (Zlotnik and Yoshie, 2000). 
Chronic inflammation can provoke cancer formation. This process takes place by 
promoting different cytokines, growth factors and other cell survival signals, 
proangiogenic factors and extracellular matrix-modifying enzymes in order to avoid 
apoptosis and promote carcinogenesis process (Dranoff, 2004; Hanahan and Weinberg, 
2011; Landskron et al., 2014). Pro-inflammatory cytokines were particularly thought to 
be involved in tumor development, such as Tumor Necrosis Factor alpha (TNF-α), 
Interleukin-6 and Transforming Growth Factor (TGF-β) (Landskron et al., 2014). TNF-α 
was majorly associated with cancer development, invasion and distant metastases (Wang 
and Lin, 2008). It is now evident, however, that TNF-α  plays a contradictory role in both 
cancer formation and treatment (Mocellin et al., 2005; van Horssen et al., 2006; Tse et 
al., 2012). TNF-α can induce apoptosis by binding to its receptor TNFR-1 which is 
ubiquitously expressed in all cells. TNFR-1 is an important member of the death receptor 
family. It binds to TNFR-associated death domain (TRADD) which triggers a 
downstream cascade of proteins that are responsible for intracellular intrinsic apoptotic 
pathway (van Horssen et al., 2006; Wang and Lin, 2008). TRADD binds to Fas-
associated protein with death domain (FADD), also called MORT1, and lead to cleavage 
of Pro-Caspase-8 into active form Caspase-8, which up-regulates the pro-apoptotic 
molecules Bid and Bax, and down-regulates the anti-apoptotic molecule Bcl-2. This 
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activation leads to the mitochondrial release of Cytochrome-c that follows two pathways 
in causing apoptosis. The first pathway is through forming a complex with APAF and 
Caspase-9 (Cyt-c/Apaf/Caspase-9), activating Caspase-3 that triggers a chain of Caspases 
(Casp-6 and -7) and ends in cleaving ICAD (inhibitor of Caspase-activated DNase) 
molecule to release CAD.  The CAD then acts by cleaving DNA into different oligomeric 
fragments (Elmore, 2007). The second pathway of causing DNA fragmentation and 
apoptosis is by producing DNAse Endonuclease-G (Endo-G) by the mitochondria. Once 
released from the mitochondria, Endo-G can act directly on the chromatin DNA, cleaving 
them into oligonucleosomal DNA fragments independently of Caspases (Li et al., 2001; 
Elmore, 2007). Alternatively, members of the inhibitor of apoptosis protein family (IAP) 
can act as inhibitors of the catalytic activity of Caspases in triggering apoptosis (van 
Horssen et al., 2006). The X-linked IAP (XIAP), survivin and the cytoplasmic inhibitor 
of apoptosis (c-IAP1/2) proteins have the ability to disrupt function of Caspases by 
competitively binding to distinct domains in Caspases-3 and -7, thus interrupting 
apoptosis (Aggarwal et al., 2004; Wei et al., 2008). Moreover, XIAP, the strongest IAP in 
Caspase inhibition, can prevent Caspase-9 dimerization and activation by forming 
through its BIR3 domain a heterodimer with Caspase-9 monomer. It also retains the 
active site of Caspase-9 in an inactive confirmation, thus preventing its catalytic activity 
(Shiozaki et al., 2003). Cell proliferation is activated via other pathways including the 
mitogen-activated protein kinase (MAPK) and cJun N-terminal kinase (JNK) pathways. 
Both MAPK and JNK kinases act on the FOS family and JUN transcription factors as 
cFos and cJun by phosphorylating them, and ending in cell proliferation. Cell 
proliferation also occurs via activation of TRAF-2 and RIP (receptor-interacting protein) 
76 
 
to nuclear factor kappa B (NF-κB) transcription factor. This happens by activating NF-
κB–inducing kinase (NIK), which inhibits the function of κB kinase complex (IKK) by 
its phosphorylation on critical serine residues, hence resulting in its degradation by the 
proteasome, the fact that leads to NF-κB activation and cell proliferation (Mocellin et al., 
2005; van Horssen et al., 2006; Tse et al., 2012). Tumor cells escape TNF-induced 
cytotoxicity by activation of NF-κB cell proliferation mechanism. Numerous anti-NF-κB 
agents were shown to induce tumor death by inhibiting NF-κB activation and sensitizing 
tumor cells to TNF-induced apoptosis (Shishodia et al., 2006; Wang et al., 2006). 
Moreover, the addition of TNF to chemotherapeutic agents has been shown to have a 
beneficial therapeutic effect in the treatment of many tumors. The addition of TNF-α to 
doxorubicin in the treatment of p53 deficient cancer patients enhanced the cytotoxic 
effect of doxorubicin (Cao et al., 2005). Similarly, the combination of TNF-α to the anti-
EGFR monoclonal antibodies in the treatment of different solid tumors, sensitized the 
response to the anti-EGFRs with significant reduction in tumor size (Hambek et al., 
2001). Treatment of tumors that have acquired resistance to gefitinib, an EGFR tyrosine 
kinase inhibitor in non-small cell lung cancer, with TNF-α overcame the drug resistance 
and significantly improved the results (Ando et al., 2005). Many variables as cytokine 
dose, target cell type and cell hormonal sensitivity, greatly influence the type of activity 
to be exerted by TNF-α (Tse et al., 2012). Numerous reports have shown that the serum 
TNF-α concentration is increased in patients with chronic lymphocytic leukemia (Ahmed 
et al., 2001) or cervical carcinoma (Ferrajoli et al., 2002). Due to its dual role in 
enhancing cell proliferation or apoptosis, TNF is being investigated in both 
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carcinogenesis and cancer treatment. Figure 1.4 shows the cellular proliferation versus 
apoptosis signaling pathways of TNF.  
 
Figure 1. 3 Cell proliferation versus apoptosis signaling pathways of TNF. In the apoptosis 
pathway, TNF-α binds to its receptor TNFR-1 and activates TRADD and FADD molecules that 
cleave Pro-Caspase-8, which in turn activate various pathways of apoptosis. One way is via 
activating Bid protein, which up-regulates Bax and down-regulates Bcl-2, triggering the 
mitochondria to release Cytochrome-c that, in turn either forms a complex with APAF and 
Caspase-9, activating Caspase-3 that causes apoptosis by cleaving ICAD molecule, or by 
producing of the DNAse Endonuclease-G that can cause direct DNA fragmentation. 
Alternatively, the IAP protein family can inhibit Caspase-3 activity by a competitive binding to 
distinct domains in Caspases-3 and -7, disrupting apoptosis. XIAP can also prevent apoptosis by 
inhibiting Caspase-9 activation and disrupting Cyt-c/Apaf/Cas-9 complex formation. The 
complex TRADD/RIP/TRAF-2 is responsible for enhancing cell proliferation by the activation of 
cFos/cJun transcription factors via mitogen-activated protein kinase (MAPK) and cJun N-
terminal kinase (JNK). Another pathway that promotes cell proliferation is through the major 
signaling event of TRAF-2 and RIP activation of NF-κB transcription factor via NIK complex 
activation and (IKK) complex inhibition.   
 
1.3 Cancer therapy 
Cancer therapy is a multi-disciplinary approach where surgeons, pathologists, 
radiologists, medical oncologists and radiation oncologists cooperate for a unified aim 
that is the best care for cancer patients. Cancer can be completely cured when the tumor 
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is operable and there is neither spread to local lymphnodes nor distant metastasis. The 
role of radiotherapy in treating cancer is restricted to adjuvant therapy for local lesions as 
in breast carcinoma, or palliative in origin as in case of metastatic bone lesions. 
Chemotherapy is used in all cases of tumor invading surrounding lymphnodes (stage III), 
or distant tissues and organs (stage IV). Once cancer has spread, the treatment aims at a 
better quality of life with a longer survival (DeVita and Chu, 2008; Sudhakar, 2009; 
Padma, 2015). 
1.3.1 Current therapies  
 
Different types of treatments have been employed in cancer therapy. Hormonal 
therapy, one of the oldest anticancer treatments, is used in breast cancer patients whose 
tumors express positive estrogen receptors (ER) regardless of menopausal status. 
Estrogen acts by preventing endogenous estrogen from activating ER and promoting cell 
growth. Upon activation, the ER can translocate into the nucleus, bind to DNA and 
dysregulate the activity of gene transcription which can ultimately lead to tumor cell 
death (Riggins et al., 2005). Hormonal therapy, however, has always been associated 
with side effects such as hot flushes, heart attacks, stroke, endometrial cancer, hepatic 
cancer and others that limit their use (Krause et al., 2010). Hormonal therapy is also used 
in patients with prostate cancer, where anti-testosterone or androgen deprivation therapy 
is beneficial and affords a long survival. This therapy, however, is also accompanied by 
unpleasant side effects as hot flushes, reduction of bone mineral density, osteoporosis, 
and anemia (Brawer, 2006).  
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Chemotherapy comprises various families of cytotoxic drugs that can induce 
apoptosis or necrosis to cancer cells by targeting cellular metabolic processes as DNA, 
RNA and protein biosynthesis. Chemotherapy destroys all rapidly proliferating cells 
including bone marrow cells, digestive tract and hair follicles, leading to 
immunosuppression with leucopenia, anemia or thrombocytopenia, mucositis with nausea 
and vomiting, in addition to alopecia. The severity of side effects limits the use cytotoxic 
drugs and contributes to dosage reduction (Cheung-Ong et al., 2013). Different types of 
chemotherapy are being known, and include alkylating agents, plant alkaloids, antitumor 
antibiotics, antimetabolites, topoisomerase Inhibitors, antimicrotubules and others 
(Cheung-Ong et al., 2013; DeVita et al., 2015). Each group of chemotherapy has its mode 
of action in causing apoptosis. The Alkylating agents, for example, are major class of 
frontline antineoplastic drugs that act by inhibiting the transcription of DNA into RNA, 
resulting in disrupting protein synthesis (Fu et al., 2012). They form covalent bonds 
between their alkyl group and macromolecules possessing nucleophilic centers. Different 
types of cross-links are adopted by the alkylating agents, including interstrand cross-links 
with covalent bonds at two nucleophilic sites on different DNA bases (mostly the N7 
position of Guanine) of two opposite strands, and intrastrand cross-links with covalent 
bonds at different DNA bases of the same strand (Damia and D‘Incalci, 1998; Siddik, 
2002). This covalent interaction induced by alkylating agents causes DNA damage 
represented by distortions and unwinding in its structure. As a result, the cell cycle 
progression is disrupted in order to allow DNA repair, which if not enabled ends in cell 
death (Siddik, 2002).   
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The alkylating agents are usually divided into three different groups: classical, 
non-classical, and alkylating-like agents. The classical alkylating agents possess a 
functional alkyl group, while the alkylating-like agents are platinum-based analogs that 
lack a true alkyl group; however, they all induce cytotoxicity by causing DNA 
crosslinking. The non-classical agents are monofunctional and induce guanine and 
adenosine methylation without causing DNA crosslinking (Kim et al., 2016). The first 
class of the classical alkylating agents comprises the nitrogen mustards and includes 
drugs as Chlorambucil, Cyclophosphamide, Estramustine, Ifosfamide, Mechlorethamine, 
Melphalan, and Bendamustine. The metabolites of these compounds are hydrophilic and 
their ethylene immonium ion can bind directly to DNA. They are mostly used in treating 
hematopoietic system diseases (Takimoto and Calvo, 2008). The second class consists of 
the nitrosoureas and includes drugs as Carmustine, Lomustine and Streptozocin that are 
highly lipophilic, the fact that allows them to penetrate easily the blood-brain barrier and 
makes them useful in treating various brain tumors (Takimoto and Calvo, 2008). The 
third class includes the alkyl sulfonate as Busulfan that is characterized by an active 
sulfonate anion (Skett et al., 2007) and is used in the treatment of chronic myelogenous 
leukemia (CML), lymphomas and in inducing bone marrow transplantation (BMT) for 
refractory leukemias (Page and Takimoto, 2004). The last class comprises the aziridine as 
Thiotepa, which is characterized by a strained ring that makes it reactive (Skett et al., 
2007) and is used in ovarian, breast and bladder cancers, hodgkin’s lymphoma, chronic 
leukemias as well as in BMT induction for refractory leukemias and lymphomas (Page 
and Takimoto, 2004; Skett et al., 2007). The non-classic alkylators are monofunctional 
cytotoxic agents and include the triazenes such as Dacarbazine, Procarbazine and 
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Temozolomide drugs, which are used in the treatment of various cancers and brain 
tumors, and the methylenamine derivatives as Altretamine that is used in the treatment of 
ovarian carcinoma (Takimoto and Calvo, 2008).   
The alkylating-like agents as Cisplatin, Carboplatin and Oxaliplatin are platinum-
based equivalents that do not alkylate DNA as they are alkyl-free, but induce covalent 
DNA adducts by different means. Cisplatin [cis-diamminedichloroplatinum (II)], for 
example, is a major alkylating-like agent that is considered one of the most effective 
cytotoxic drugs used nowadays (Siddik, 2002). It achieves a covalent binding to DNA by 
forming monofunctional adducts, predominantly at the N7 position of adenine and 
guanine. The remaining Cisplatin chloride ligand in these monoadducts is then 
hydrolyzed and reacts with another purine base to form bifunctional adducts (Zwelling et 
al., 1979; Strandberg et al., 1982). Both types of cross-links (1,2- and 1,3-intrastrand 
DNA) have been known to be induced by Cisplatin in the same DNA strand, and 1,2-
interstrand DNA cross-links between opposite guanine bases are formed favorably in 
5'G–C3' sequences in case of two DNA strands (Malinge et al., 1999). Cisplatin is one of 
the most potent chemotherapy drugs used worldwide and it is being successfully used in 
many cancers including: lung, testicular, bladder, cervix, ovarian, head and neck, 
esophageal, colorectal as well as in pediatric malignancies (Desoize and Madoulet, 2002; 
Galluzzi et al., 2012). Unfortunately, many side effects have been attributed to Cisplatin 
usage, including ototoxicity, gastrotoxicity, neurotoxicity, myelosuppression, in addition 
to allergic reactions, and the major dose-limiting side effect of Cisplatin is nephrotoxicity 
that may eventually leads to renal failure (Miller et al., 2010). Due to the high toxicity 
rate ascribed to Cisplatin, similar compounds with fewer side effects were manufactured 
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to substitute its usage, mainly Carboplatin and Oxaliplatin. Carboplatin, similarly to 
Cisplatin, has active diamine platinum moiety, but it is bonded to an organic carboxylate 
group that increases its water solubility and slows its hydrolysis to the alkylating aqueous 
platinum complex, the fact that reduces its toxicity (Page and Takimoto, 2004). 
Carboplatin, however, exhibited cross-resistance with Cisplatin in Cisplatin-treated 
cancers (Gore et al., 1989; Desoize and Madoulet, 2002), and myelosuppression mostly 
expressed by thrombocytopenia was its major dose-limiting toxicity (Desoize and 
Madoulet, 2002). Oxaliplatin is a third-generation platinum-based drug that is 
characterized by di-amino-cyclohexane ring (DACH) bound to the platinum molecule 
(Page and Takimoto, 2004). It is likely due to DACH group that Oxaliplatin does not 
show cross-resistance to Cisplatin (Payne and Miles, 2008). Oxaliplatin found its efficacy 
mainly in the treatment of colorectal cancer, the fact that restricted its clinical use. It 
exhibited a dose-limiting toxicity related to its neurotoxicity expressed by sensory 
neuropathy (Desoize and Madoulet, 2002).    
Apoptosis caused by Cisplatin is believed to be via p53 activation (Siddik, 2002). 
Upon DNA damage by Cisplatin, p53 is activated by phosphorylation and disruption of 
the Mdm2/p53 complex. Activated p53 stimulates the transcription of the cyclin 
dependent kinase (Cdk) inhibitory protein p21, which causes cell cycle arrest at G1 phase 
(Lakin and Jackson, 1999; Sionov and Haupt, 1999). The cell cycle arrest induces 
different repair mechanisms to check the DNA defects and repair them. The mismatch 
repair (MMR) pathway is a major mechanism implicated in repairing the cross-links 
caused by Cisplatin in a higher affinity than other platinum-like drugs (Siddik, 2002). 
This includes a group of proteins (hMSH2, hMSH6, hMLH1 and hPMS2) that play a 
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complementary role in recognizing, binding and excising DNA defects caused by 
Cisplatin (Karran, 2001). The nucleotide excision repair (NER) system is another major 
pathway adopted by the cell to fix the Cisplatin-induced DNA defect and cause drug 
resistance (Kelland, 2007). The two NER endonucleases, Xeroderma pigmentosum group 
G (XPG) and Xeroderma pigmentosum group F/excision repair cross-complementation 
group 1 (XPF/ERCC1) excise the DNA strand that contains the damaged base in different 
directions; while XPG acts by cleaving the damaged DNA strand in 3' from the lesion, 
XPF/ERCC1 acts by cleaving in 5' from the lesion, and the resulting gap is filled in by 
DNA polymerases δ or ε (Hoeijmakers, 2001). Another important protein involved in 
recognizing the Cisplatin-induced DNA cross-links, among many other proteins, is the 
high mobility group 1 (HMG1) protein, which binds to 1,2-intrastrand AG and GG 
adducts to fix them (Donahue et al., 1990). In case of cellular failure in repairing the 
damaged DNA, apoptosis induction is then triggered. The mitochondrial apoptotic 
pathway is one of the most involved pathways in inducing apoptosis in Cisplatin-induced 
cytotoxicity. It acts by up-regulating the pro-apoptotic protein Bax by p53, resulting in an 
increase in Bax to Bcl-2 ratio and activation of the Cytochrome-c into the cytosol, thus, 
activating Caspase-9 that leads to an entry into the execution phase of apoptosis (Park et 
al., 2002). 
1.3.2 Phytotherapy 
 
Despite the improved survival rate upon usage of newly emerging drugs over the 
preexisting ones, a permanent disease cure is still not always achieved. Therefore, 
researchers are continuously looking for new remedies in cancer therapy that can be 
financially affordable and give new hopes for cancer patients. Natural product research is 
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recently extensively exploited to discover such anticancer agents, which constitute the 
basis of cancer phytotherapy.  
1.3.2.1 History of phytotherapy and cancer 
 
Historically, the study of herbs dates back 5,000 years to the ancient Sumerians 
(Sumner, 2000). They listed on clay tablets more than 250 of their used medicinal plants 
such as myrrh, opium, honey, milk, oils and others prescribed as antibiotics, antiseptics, 
laxatives and many other medicinal uses (Teall, 2014). The Ancient Egyptians (1000-
3000 years BC) used various herbs in medicine too, introducing garlic, juniper, cannabis, 
castor bean, aloe, and mandrake (Sumner, 2000; Nunn, 2002). The Old Testament also 
mentions the herb use and cultivation by Jewish people, and their usage in their daily life 
as onion, garlic, grape, wheat, stone pine, mastic, Lebanese oregano, wild mint and many 
others (Duke, 2008).   
Cancer phytotherapy has played considerable role in treating cancer all over the 
world for many decades. It has also earned a major role in research to find out the 
therapeutic role of different plants. Over 60% of the effective anticancer drugs currently 
used are derivative of natural sources including plants, marine organisms and micro-
organisms (Cragg and Newman, 2005). So far, four major classes of plant-derived 
anticancer products have been successfully introduced into to the pharmacological and 
clinical uses. The vinca alkaloids are cell cycle-specific cytotoxic drugs, interacting with 
tubulin and disrupting microtubules formation leading to metaphase arrest. Five drugs are 
known (vincristine, vinblastine, vinorelbine, vindesine and vinflunine) and are isolated 
from Catharanthus roseus plant, or Madagascar or rosy periwinkle. These drugs are 
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being used in the treatment of different blood and solid tumors such as leukemias, 
lymphomas, lung, urothelial and advanced testicular cancers (Moudi et al., 2013).  
Another class includes the Podophyllotoxins which are highly toxic agents, and are 
extracted from the roots and rhizomes of Mayapple tree. They stop DNA replication by 
blocking the topoisomerase II activity in the cell cycle, leading to apoptosis. Etoposide 
and teniposide are two representatives of this class, and are used in the treatment of 
lymphoma, bronchial and testicular cancers (Gordaliza et al., 2000). Taxus brevifolia, or 
the famous Pacific yew, is a member of Taxaceae. Taxanes, a class of diterpene alkaloids, 
are considered as key constituents of the plant, and have proved their effective anti-
neoplastic role in different types of carcinomas. Paclitaxel and its derivative docetaxel are 
used in treatment of breast, ovarian and non-small cell lung cancers (Fauzee et al., 2011). 
Moreover, docetaxel and cabazitaxel are also involved in treatment of metastatic prostate 
cancer (Paller and Antonarakis, 2011). A fourth class of drugs is the camptothecin 
derivatives, topotecan and irinotecan which were isolated from the bark and stem of 
Camptotheca acuminate or the happy tree. These drugs inhibit the DNA enzyme 
topoisomerase I, and are used in the treatment of ovarian, pancreatic, colorectal, cervical 
and small cell lung cancers (Venditto and Simanek, 2010).  
1.3.2.2 Anticancer properties of plant natural products 
 
               Terpenes, phenols and alkaloids are phytochemicals that have demonstrated 
antitumor activities through various mechanisms including their properties as powerful 
antioxidants, inhibition of cell proliferation and induction of programmed cell death or 
apoptosis (Reddy et al., 2003; Saxena et al., 2012).  
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Terpenes constitute a large and diverse class of natural compounds which are 
produced by various plants, mainly conifers. They can be classified according to the 
isoprene unit (or isopentane) in each molecule as follows: Hemiterpenes (one isoprene 
unit), Monoterpenes (two isoprene units), Sesquiterpines (three isoprene units), and so 
forth. They are major constituents of plant essential oils (Breitmaier, 2006). Terpenes or 
terpenoids when containing oxygen, exhibit many biological activities such as: 
antimicrobial, antiviral, antifungal, anti-inflammatory, as well as anticancer activities 
(Dzubak et al., 2006; Salminen et al., 2008). Monoterpene limonene, for example, one of 
the most common terpenes in nature and an important component of citrus fruits, has 
demonstrated high chemopreventive and chemotherapeutic activities against mammary 
carcinomas (Crowell, 1999; Sun et al., 2002). Sesquiterpenes, another class of terpenes 
containing three isoprene units, have demonstrated therapeutic potential in reducing the 
progression of cancer and are considered as potential anticancer agents (Modzelewska et 
al., 2005). β-Elemene, (1-methyl-1-vinyl-2,4-diisopropenyl-cyclohexane), for example, is 
a sesquiterpene extracted from the essential oils of Curcuma aromatica Salisb that has 
shown to possess promising anticancer effects against a panel of tumors including lung, 
breast, gastric, cervical, prostate, ovarian cancer, osteosarcoma and hepatocellular 
carcinoma (Dai et al., 2013). β-Elemene inhibited the proliferation of HepG2 cells in a 
time- and dose-dependent manner, caused cell cycle arrest at the G2/M phase and induced 
apoptosis by overexpression of the Fas/Fas-Ligand complex, which promotes Caspase-3 
activation and ends in DNA breakage and apoptosis (Dai et al., 2013). Moreover, 
Sesquiterpene lactones (SLs) are natural compounds with well-recognized anti-
inflammatory and anticancer effects. They are 15-carbon compounds consisting of three 
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isoprene units and a lactone group (cyclic ester) (Ghantous et al., 2010). SLs comprise a 
variety of drugs with prominent anti-inflammatory and anticancer effects as Parthenolide, 
Costunolide, Helenalin and Artemisinin. The anti-inflammatory effect of the majority of 
SLs takes place through the inhibition of pro-inflammatory cytokines, such as 
interleukins and prostaglandins related to NF-kB signaling pathway (Sobota et al., 2000; 
García-Piñeres et al., 2001; Chaturvedi, 2011). Parthenolide, for example, a major 
member of SLs, exerts its anti-inflammatory activity by inhibiting the activation of the 
transcription factor NF-kB by preventing the TNF-α-induced activation of IkB kinase 
(IKK) and IKKβ, without affecting the activation of p38 and c-Jun N-terminal kinase 
(Hehner et al., 1999). Moreover, the anti-inflammatory activity of Parthenolide was also 
manifested through the inhibition of the expression of inducible cyclooxygenase, pro-
inflammatory cytokines (Hwang et al., 1996) as well as inducible nitric-oxide synthase  
(Fukuda et al., 2000). The anticancer activity of Parthenolide, similarly to β-Elemene, 
takes place via Caspase activation through Bax proapoptotic protein upregulation and the 
release of mitochondrial Cytochrome-c (Chaturvedi, 2011). The cytotoxic activity of SLs 
is mainly attributed to the α-methylene-γ-lactone (αMγL) unit, an oxygen-containing ring 
structure with a carbonyl function, which acts by alkylating the thiol groups commonly 
found in proteins, forming adducts with cysteine residues (Kupchan et al., 1971; 
Chadwick et al., 2013). The differences in activity among various SLs is due to the 
number of alkylating structural elements in each compound, the side chain and 
lipophilicity of SLs, the molecular geometry with electronic features and the chemical 
environment or the target sulfhydryl (Ghantous et al., 2010; Chaturvedi, 2011). 
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Phenolics or phenols are a class of chemical compounds characterized by a 
hydroxyl group bonded directly to an aromatic hydrocarbon. They are classified as 
simple phenols or polyphenols according to the phenol unit number in the molecule 
(Amorati and Valgimigli, 2012). They are produced by plants and microorganisms and 
are found in various plant foods such as fruits, vegetables, cereals, olives, legumes and 
chocolate, and in beverages too such as tea, coffee, beer and wine (Dai and Mumper, 
2010). Phytochemicals, including both monophenolic and polyphenolic compounds, have 
proved their role in inhibiting the growth and the spread of cancer cells, in both in vitro 
and in vivo models. They also have been reported to inhibit angiogenesis which is 
necessary for the migration and metastasis of cancer cells (Wahle et al., 2010).  
 Flavonoids are the largest group of phenolic compounds, and are subdivided into 
flavones, flavanols, flavanones, isoflavones, and anthocyanins (Saxena et al., 2012). They 
form part in our dietary constituents. Parsley, for example, mainly includes flavones. 
Blueberries are a major source of anthocyanidins. Black tea is highly rich in flavan-3-ols. 
Green tea, red wine, dark chocolate, various berries, citrus, bananas, Ginkgo biloba and 
others are all rich in flavonoid content (Haytowitz et al., 2006). Flavonoids have been 
reported to have both chemopreventive and antiproliferative effects. Chemoprevention 
comes from the interaction with cytochrome P450, inhibiting its activity in activating 
procarcinogens and triggering cancer formation (Le Marchand et al., 2000; Chahar et al., 
2011). Their antiproliferative activity derives from the inhibition of the prooxidant 
process that causes tumor promotion. Flavonoids have the ability to inhibit xanthine 
oxidase, cyclooxygenase (COX) or lipoxygenase (LOX-55), which are major catalysts of 
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tumor promotion and therefore inhibit tumor cell proliferation (Mutoh et al., 2000; Chang 
et al., 2002; Chahar et al., 2011).  
 Phenylpropanoids are another subgroup of phenols, and are synthesized by plants 
from the amino acid phenylalanine. They include many compounds as eugenol, chavicol, 
safrole and estragole which are the primary constituents of various essential oils. The 
conversion of phenylalanine to cinnamic acid, leads to the appearance of coumaric, 
caffeic, ferulic, 5-hydroxyferulic and sinapic acid which are responsible for the aromatic 
fragrance of the flowers (Petersen et al., 2010). Many of these acids have also showed 
antiproliferative effect. Eugenol, for example, has demonstrated high cytotoxic activity 
against several tumor types: breast adenocarcinoma, melanoma cells, leukemia, colon 
carcinoma, cervical carcinoma, prostate cancer, submandibular gland adenocarcinoma 
and others (Carvalho et al., 2015).  
 Finally, alkaloids are a highly diverse group of compounds that contain a ring 
structure and a nitrogen atom. They have a wide distribution in the plant kingdom and 
exhibit significant biological activities, such as the ephedrine relieving action for asthma, 
the analgesic action of morphine, and the anticancer effects of vincristine and vinblastine. 
Successful chemotherapeutic drugs, such as camptothecin (CPT), a famous 
topoisomerase I (TopI) inhibitor, vincristine and vinblastine, which interact with tubulin 
have been developed from alkaloids (Lu et al., 2012).  
1.3.2.3 Daucus carota   
 
         One of the most promising plants under investigation for potential cancer therapy is 
Daucus carota. The wild carrot, Daucus carota (Linnaeus) ssp. carota, is a flowering 
plant of the family Apiaceae. It is an herbaceous, spiny-fruited herb, known as the ‘Bird’s 
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Nest’ in the UK, and as the ‘Queen Anne's lace’ in the USA, (Mitich, 1996). It is a tall, 
robust, variable biennial plant that grows to between 30 and 60 centimetres (1 and 2 ft) 
sometimes reaching two meters (Tohme, 2007). The flowering stems are long and devoid 
of leaves, ending in flat dense umbels composed of small and dull white flowers. The 
umbel base consists of a whorl of green bracts. Before opening, the umbels are usually 
pink, and then they turn to become bright white and rounded when in full flower form, 
and a reddish or purple flower may appear in the centre of the umbel which can reach 20 
cm in diameter (figure 1.5). One single seed is produced by each flower, of light reddish 
purple color, turning green and lastly greyish brown upon maturation. As the seeds 
develop, the umbel curls up at the edges, become more congested, take a specific 
spheroidal shape, and exhibiting a concave surface (Hoffman, 1990; Tohme, 2007).  
 
Figure 1. 4 Daucus carota plant umbel (Johnston, 2005).  
Daucus carota grows almost in the five continents, especially in moderate regions 
of Europe and Asia, as well as Africa, in addition to North and South America (Mitich, 
1996). It is abundantly found in almost all Lebanese regions (Beino, Zabbougha, 
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Heloueh, Souq el-Gharb, Rihane, Tyr, and others) (Tohme, 2007), casually, on road 
border sides and widely spread in mountains.    
 Plants have the ability to synthesize various different metabolites; some of which 
are essential for growth, survival and auto-protection against microbes and herbivores 
(Van Wyk and Wink, 2017), and others, as terpenes, phenolics and alkaloids show 
promising functions for humans such as anti-inflammatory, anti-oxidant and even 
anticancer (Pereira et al., 2012). The oil extract of the wild carrot has been shown to 
consist mainly of such metabolites as phenols, flavonoids, monoterpenes, sesquiterpenes, 
and phenylpropanoids (Gonny et al., 2004; Staniszewska et al., 2005; Maxia et al., 2009; 
Denise Otsuka et al., 2010; Shebaby et al., 2013). Nevertheless, the composition in 
percentage of the oil significantly varies with variant geographical areas (Shebaby et al., 
2013). Different components were identified in Daucus carota’s oil extract; majorly, the 
sesquiterpenes and the phenylpropanoids. According to Shebaby et al., (2013) and Taleb 
et al., (2016), the sesquiterpenes group consisted 60.61% of the oil composition, and they 
mostly included β-2-himachalen-6-ol (32.11%), α-longipinene (8.82%), α- selinene (5.69 
%), widdrol (2.45 %) and β-himachalene (2.24%). The phenylpropanoids group 
amounted about 7.38% of the oil constitution, and included elemicin (4.03%) and (E)- 
methylisoeugenol (2.21%) (Shebaby et al., 2013) . Moreover, other constituents were also 
identified as the phenolics and flavonoids. The total phenolic and flavonoid contents in 
the plant extract were 65.3 mg gallic acid equivalent/g for the phenols, and 18 mg 
quercetin equivalent/g for the flavonoids (Shebaby et al., 2013). Table 1.5 shows a 
comparison between the Lebanese Daucus carota constituents and those listed in the 
literature.  
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Table 1. 4 Main components (≥ 0.1%) of Lebanese Daucus carota’s oil extract compared to 
the literature (Shebaby et al., 2013).  
*Annotates DCOE from this study. The remaining extracts from the literature were all 
prepared by hydrodistillation.   
N.B.: the unidentified compound B was later on identified by GC-MS and NMR to be the 
sesquiterpene β-2- himachalen-6-ol (Taleb et al., 2016).  
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             Worldwide, the plant medicinal usages are widely known and range from simple 
diuretic and antilithic effects (Van Wyk and Wink, 2017), to potent anti-ulcer and 
hepatoprotective roles (Handa, 1986) in addition to both antibacterial and antifungal 
activities (Staniszewska et al., 2005; Rossi et al., 2007; Maxia et al., 2009). In European 
folk medicine, Daucus carota volatile oil has been used as an antiseptic anti-
inflammatory remedy for urinary tract infection, cystitis and prostatitis (Hoffman, 1990). 
In Lebanese folk medicine, it has been used for decades as remedy for both diabetes 
mellitus and gastric ulcer, in addition to its myorelaxant role 
(http://wildedibleplants.info). Recent studies in our laboratory have shown that the plant 
possesses an anti-inflammatory effect in its aqueous and methanolic extracts (Wehbe et 
al., 2009), an antioxidant role (Shebaby et al., 2013; Shebaby et al., 2015), and a potent in 
vitro anticancer activity (Shebaby et al., 2013; Shebaby et al., 2014; Zgheib et al., 2014; 
Taleb et al., 2016). Moreover, the oil extract was found to possess anticancer activity 
against human acute myeloid leukemic cells (Tawil et al., 2015). The Daucus carota oil 
extract (Zeinab et al., 2011) and its pentane diethyl ether fraction (Shebaby et al., 2017) 
were shown to have a promising in vivo anti-tumor effect against DMBA/TPA skin 
carcinogenesis model in mice.   
Recently, β-2-himachalen-6-ol (HC) has been isolated from the DCOE and shown to be a 
major active ingredient that is behind the anticancer effect of the plant. The mechanism 
of action of HC, however, has only been partially elucidated and no in vivo studies yet 
has been conducted to assess its effect on the carcinogenesis.  
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1.3.3 Murine models of human cancer  
 
 Murine models are used worldwide in medical testing due to the resemblance of 
their genetic, biological and behavior characteristics to those of humans (Melina R, 
2010). Moreover, they are easily housed, small and inexpensive laboratory animals.  
 
1.3.3.1 Colon cancer  
 
Colon cancer is considered the third most commonly diagnosed cancer in the 
world and second in Europe (Ferlay et al., 2015). In 2012, there were about 1,360,602 
new colon cancer cases of which 447,136 were reported in Europe (Dusek et al., 2016). 
Colon cancer is mainly due to a low fiber over fat diet, increased body mass index (BMI), 
low physical activity, cigarette smoking, alcohol consumption, diabetes mellitus, 
ulcerative colitis, Crohn’s disease, some hereditary cases (familial adenomatous 
polyposis syndrome and nonpolyposis colorectal cancer or Lynch syndrome), in addition 
to radiation therapy for another abdominal cancer (Haggar and Boushey, 2009; Johnson 
et al., 2013). Colon cancer can be surgically cured only if diagnosed and detected early. 
The role of chemotherapy, radiotherapy or targeted therapies remains palliative in case of 
metastases (Cunningham, 2010). Newly discovered monoclonal antibody drugs, such as 
angiogenesis inhibitor (Bevacizumab) and EGFR-inhibitor (Cetuximab) have improved 
the survival of patients with spread colon cancer (Formica and Roselli, 2015). In order to 
decrease the risk of colon cancer, screening programs are widely encouraged. In the 
United States screening is recommended between the age of 50 and 75 years for those 
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who are in average-risk (Bibbins-Domingo et al., 2016). For people at high risk, 
screenings usually begin at around 40 (Cunningham, 2010).  
1,2-dimethylhydrazine (DMH) or its metabolite azoxymethane (AOM) are potent 
colon carcinogens that have been frequently used to induce colon cancer  in rodents 
(Perše and Cerar, 2010; De Robertis et al., 2011). The DMH/AOM model of colon 
carcinogenesis shares many similarities to human sporadic colon cancer and is more 
potent and convenient to use than other chemical carcinogens (Perše and Cerar, 2010). 
DMH is metabolized in the liver to AOM, azoxymethane, which upon hydroxylation 
results in the formation of the reactive metabolite MAM, methylazoxymethanol, which 
can be further transported to the colon through the bile or blood to finally produce both 
highly reactive carcinogenic ions: methyldiazonium and methylcarbonium. 
Methyldiazonium can alkylate macromolecules in the colon and liver such as methylation 
of guanine, through its decomposition product methylcarbonium, leading to O6-methyl-
deoxyguanosine and N7-methyl-deoxyguanosine formation and causing DNA 
damage (Cain, 1992; Rosenberg et al., 2008). On the other hand, many histopathological 
and immunohistochemical studies have shown that similarly to human tumors, 
DMH/AOM-induced tumors are often mutated on K-ras and beta-catenin genes and 
show microsatellite instability. K-ras is a member of both PI3K and MAPK signal 
transduction pathways which are involved in cell proliferation, differentiation, survival 
and apoptosis (Jančík et al., 2010). Mutated K-ras has been detected in various types of 
human tumors and represents about 40 to 50% of all colorectal cancer cases (Jančík et al., 
2010; Perše and Cerar, 2010). In addition, K-ras also exhibited GC→AT mutations 
similarly to the GC→AT transitions induced by the pro-mutagenic lesion O6-
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methylguanine (Jackson et al., 1999). Beta-catenin is a key mediator of the Wnt 
(Wingless-type mouse mammary tumor virus integration site family member) signaling 
pathway, which is often implicated in embryogenesis and stem cell control, as a 
proliferative and self-renewal signal (Nusse et al., 2008). Mutations in CTNNB1 gene 
which encodes beta-catenin has been implicated in the development of various human 
malignancies including colorectal cancer (Polakis, 2000; Kolligs et al., 2002; Thorstensen 
and Lothe, 2003). Mutated beta-catenin acts by preventing its degradation by the 
APC/Axin/CK1/GSK3 destruction complex, which is a part of the Wnt pathway and 
responsible for beta-catenin protein degradation, the fact that leads to excessive stem cell 
renewal and proliferation, predisposing to carcinogenesis (MacDonald et al., 2009). The 
mismatch repair system (MMR) is a genetic pathway involved in repairing any base-base 
mismatches and insertion-deletion loops which arise during DNA replication (Ioana et 
al., 2010). Mutations in MMR genes lead to MMR system inactivation and accumulation 
of microsatellites in the genome, creating a microsatellite instability state which promotes 
carcinogenesis (Ioana et al., 2010). Microsatellite instability was shown to be 
significantly expressed in DMH/AOM-induced colon cancer (Perše and Cerar, 2010). In 
contrast to human tumors, DMH/AOM-induced colon cancer showed rare mutations 
(15%) at the adenomatous polyposis coli gene (Apc), and did not exhibit any mutation at 
the TP53 gene (Corpet and Taché, 2002). Mutations on K-ras and beta-catenin genes 
with high microsatellite instability result in an evident increase in mutations of colonic 
epithelial cells leading finally to the appearance of adenomas and then adenocarcinomas 
(Corpet and Taché, 2002; Perše and Cerar, 2010), as is the case in DMH/AOM-induced 
carcinogenesis model.  
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DMH-induced colon carcinogenesis is a time and dose-dependent process 
(Newell and Heddle, 2004; Ramzanighara et al., 2009; Perše and Cerar, 2010), which is 
why it is usually frequently injected (until 24 weeks). AOM, on the other hand, is  
injected once and then should be followed after 5 days by dextran sodium sulphate 
(DSS), a known inflammatory agent that can be administered orally in cycles of 5 days 
followed by 16 days of normal water, for a period of 14 weeks (Meira et al., 2008) in 
order to develop adenomas followed by colorectal carcinomas. One of the mechanisms of 
inflammation induction by DSS is by establishing linkages with colonic medium-chain-
length fatty acids (MCFAs), such as dodecanoate. The complex DSS/MCFAs forms 
nanometer-sized vesicles that can fuse with colonocyte membranes and enter the 
cytoplasm where may activate intestinal inflammatory signaling pathways (Laroui et al., 
2012). This combination of a single injection of azoxymethane (AOM) with one week 
exposure of DSS, has succeeded in the development of adenoma followed by colorectal 
carcinoma in rodents, in a relatively short period of time (De Robertis et al., 2011).    
Many experimental mice models of colorectal cancer have recently succeeded to 
present valuable experimental benefits due to their similarities to human colorectal 
tumors. The APC mutant mouse model was developed by Moser and coworkers in 1990 
via induction of mutation in the adenomatous polyposis coli gene by the mutagen 
ethylnitrosourea, and the affected mice Apc Min (multiple intestinal neoplasia) exhibited 
adenomatous lesions throughout the whole intestine, yet  rarely progressed to invasive or 
metastatic adenocarcinoma (Moser et al., 1990). Familial adenomatous polyposis (FAP) 
is an autosomal dominant disorder caused by a germline mutation in the APC gene on 
chromosome 5q21, and characterized by the existence of many adenomatous polyps in 
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the colon and rectum (Nakayama et al., 2002; Galiatsatos and Foulkes, 2006). APC 
mutations were also found to exist in 80 % of sporadic colorectal cases (Rowan et al., 
2000; Nakayama et al., 2002). APC is a tumor suppressor gene that encodes APC protein, 
a negative regulator for beta-catenin, the key mediator of the Wnt signaling pathway. 
APC mutation strongly affects the regulation of beta-catenin, the matter that triggers the 
turning on and transcription of specific cell division stimulating genes such as c-Myc, 
cyclin D1, matrilysin, gastrin, and ITF-2 (immunoglobulin transcription factor 2), and 
lead to cell overgrowth (Polakis, 2000; Kolligs et al., 2002; Thorstensen and Lothe, 
2003). The APC mutant mouse model was therefore designed to imitate human FAP 
syndrome biology and to be used for chemopreventive strategies targeting early events in 
CRC development (Karim and Huso, 2013). The Apc Min/+ mouse model is 
characterized by a mutant allele (Min) of the Apc locus, which encodes a nonsense 
mutation at codon 850 and results in the formation of intestinal adenomas (Moser et al., 
1995). A modification of Min/+ allele is Mom-1 (modifier of Min-1), which maps to 
distal chromosome 4 and strongly modifies tumor number in Min/+ murine (Dietrich et 
al., 1993). Robanus-Maandag and coworkers developed a new Apc mutant mouse, 
characterized, similarly to human FAP syndrome, by the appearance of tumors mainly in 
the large intestine. This model, FabplCre; Apc 15lox/+ (liver Fatty acid-binding protein gene 
Cre-mediated deletion of exon 15 in Apc), expressed a longer murine survival with a 
significant number of adenomas and adenocarcinomas in the large intestine as compared 
to other models. These characteristics make this model an attractive one for preventive 
and therapeutical investigations of colorectal cancer (Robanus-Maandag et al., 2010).  
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Due to the fact that DMH-inducing carcinogenesis model mimics human cancer 
development, and at the same time reproducible and results in multifocal lesions that 
could be assessed histopathologically (Newell and Heddle, 2004; Liu et al., 2015), it was 
adopted in the present work.     
 
1.3.3.2 Skin cancer  
 
Among the most common types of cancer, skin cancer is mostly prevalent among 
Caucasians and accounts for at least 40% of cases worldwide (Leiter and Garbe, 2008). In 
the United States, over 700,000 new cases of cutaneous squamous cell carcinoma are 
diagnosed annually (Karia et al., 2013). Skin cancer is usually classified as melanoma or 
non-melanoma types (Reszko A, 2011). Melanoma is less frequent, but more aggressive. 
Melanomas develop from the uncontrolled proliferation of the pigment-containing cells 
known as melanocytes. Most frequently they can derive from a single mole or nevus, that 
upon ultraviolet exposure they turn out into malignant tumors (Kanavy and Gerstenblith, 
2011). Treatment is surgical if the tumor is localized. In case of spreading, however, 
chemotherapy, interferon-α2b, radiation therapy, or new oncogene inhibitors as 
vemurafenib and dabrafenib (BRAF inhibitors), in addition to checkpoint inhibitors as 
ipilimumab and nivolumab may improve survival (McArthur, 2013). Non-melanoma 
group includes basal and squamous cell carcinomas which constitute the most common 
types of skin cancer (Lomas et al., 2012). Their incidence is directly correlated to the 
amount of ultraviolet radiation received and inversely proportional to the degree of skin 
pigmentation in a population (Suárez et al., 2007). Basal cell carcinoma is the least 
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aggressive type. It grows slowly and damages the surrounding tissue without having the 
potential to spread to distant areas, and can be treated surgically. The squamous cell 
carcinoma has the ability to metastasize and can result in death (Cakir et al., 2012). The 
treatment of squamous cell skin carcinoma is multidisciplinary and includes surgical 
excision with radiotherapy, chemotherapy (Cisplatin, 5-Fluorouracil, Bleomycin, and 
Doxorubicin) as well as monoclonal targeted therapy as the EGFR inhibitor, Cetuximab 
(Cranmer et al., 2010; Jennings and Schmults, 2010).  
7,12-dimethyl benze-anthracene (DMBA), a chemical belonging to the family of 
polycyclic aromatic hydrocarbons, is an immunosuppressor and a powerful carcinogen 
that can cause irreversible and specific mutation at the second nucleotide of codon 61 
(CAA → CTA) in the c‐Ha‐ras gene on mice skin by a single topical application (Fujiki 
et al., 1989; Filler et al., 2007). However, due to the fact that it doesn’t lead to the 
development of visible tumours when applied alone, it needs further promotion of the 
clonal expansion of the already mutated cells via another skin inflammation-mediating 
agent, the 12-O-tetradecanoayl phorobol-13-acetate (TPA), which is an active ingredient 
of the croton oil (Kolb and Davis, 2004; Rakoff-Nahoum, 2006). TPA, in turn, stimulates 
cell proliferation through rapid activation of protein kinase C (PKC), which can activate 
the MAPK signaling pathway via Raf-1 dependent (Kolch et al., 1993) and independent 
(Chao et al., 1994) mechanisms. Moreover, it was shown that TPA application can induce 
other inflammatory mediators as Tumor necrosis factor (TNF) to act as tumor promoters 
by developing keratinocyte hyperproliferation and inflammation at the site of application 
(Moore et al., 1999). Progressive TPA application enhances further genetic instability 
leading to the appearance of Squamous cell carcinomas lesions (Filler et al., 2007). 
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Teleocidin and Aplysiatoxin are TPA-like tumor promotors that act by activating PKC. 
Okadaic acid, however, is a non-TPA-like toxic polyether compound that alike Palytoxin, 
Thapsigargin, Calyculin A and Microcystin-LR can be used as tumor promoters and act 
by binding and inhibiting the phosphatase-1,2A receptors and by inducing tumor necrosis 
factor-α (TNF-α) gene expression (Suganuma et al., 1988; Fujiki and Suganuma, 1999).  
Benzo(a)pyrene (BaP), a major component of cigarette smoke, is another potent 
and well-known carcinogen (Long et al., 2000). The metabolic activation of BaP is a 
necessary step for its carcinogenic effect (Gelboin, 1980). BaP is metabolized by 
CYP1A1 and epoxide hydrolase into many reactive metabolites including the cytotoxic, 
mutagenic, and carcinogenic benzo(a)pyrene7,8-diol-9,10-epoxide (Jernström and 
Gräslund, 1994). Other BaP metabolites include quinones as benzo(a)pyrene-6,12-
quinones, 1,6-quinones, and 3,6- quinones (Gelboin, 1980), whose activation by one-
electron reducing enzymes such as cytochrome P-450 reductase leads to ROS production 
and related oxidative stress (Lorentzen et al., 1979). BaP, also, can directly bind to DNA 
and induce DNA adduct formation (Joseph and Jaiswal, 1994). Similar to DMBA, BaP is 
considered as initiative agent in the two-stage carcinogenesis model, and stimulation of 
cell proliferation using TPA or other tumor promoting factors is mandatory for the 
formation of visible tumors.  
Ultraviolet B radiation (290-320nm)  is another experimentally established model 
to induce skin carcinogenesis in animals (Ichihashi et al., 2003). It induces DNA damage, 
mainly the cyclobutane pyrimidine dimers (CPDs) and (6-4) pyrimidine-pyrimidone 
photoproducts, causing mutations at the opposite sides of the damaged DNA, leading to 
cancer development (Ichihashi et al., 2000). Moreover, both Ultraviolet radiations B and 
102 
 
A have shown to produce reactive oxygen species (ROS) in the cells, generating 8‐
Hydroxy‐2′‐deoxyguanosine (8‐OHdG), a DNA base‐modified product damage, causing 
gene mutation and abnormal cell proliferation (Hattori et al., 1996; Ahmed et al., 1999). 
In addition, the UV radiation can activate various transcription factors as AP-1 and NF-
kB that are involved in cell proliferation (Fisher et al., 1996) and tumor promotion 
(Ichihashi et al., 2003). UVB is also known to suppress the immune system and to induce 
tolerance to antigens applied topically or systemically to animals through a cytokine 
cascade including Prostaglandin E2 (PGE2), Interleukin-4 (IL-4) and Interleukin-10 (IL-
10) (Shreedhar et al., 1998). All of these tumor initiating factors are responsible for UVB 
skin cancer development.  
The DMBA/TPA skin carcinogenesis model is a well-established reproducible 
model mimicking human squamous cell carcinoma (Aoto et al., 2018). It causes 
multifocal lesions with various sizes that could be easily monitored and measured during 
the course of the study and could be evaluated histopathologically (Nanayakkara, 2016; 
Aoto et al., 2018). This model was, therefore, adopted in the present study to assess the 
anticancer activity of HC.  
 
1.3.3.3 Breast cancer 
 
Breast cancer is considered as the second most common cancer in the world after 
lung cancer, and the most frequent cancer among women with an estimation of about 
1.67 million new cases diagnosed in 2012. It ranks as the fifth cause of cancer death and 
the mortality rate reached about 522,000 cases in 2012 (Ferlay et al., 2015). It can be 
classified according to different criteria such as the anatomy where it is subdivided into 
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ductal or lobular; the invasiveness where it is known to be invasive or non-invasive; the 
location as medullary, mucinous and tubular; inflammatory, such as Paget’s disease of 
the nipple and phylloides tumors (Sharma et al., 2010); hormonal dependence (estrogen 
and progesterone) as well as human epidermal growth factor receptor 2 (Her2/neu) 
statuses (Sharma et al., 2010; Yip and Rhodes, 2014). The estrogen receptors (ER) and 
progesterone receptors (PR) are overexpressed in the majority of breast carcinomas, and 
targeting these receptors has led to a significant improvement in patients’ survival rate 
(Yip and Rhodes, 2014). The overexpression of the human epidermal growth factor 
receptor 2 in breast cancer has been associated with aggressive disease and poor 
prognosis. The discovery of the Her2/neu inhibitor drug (Trastuzumab), however, has 
resulted in significant increase in survival and disease progression rate (Ferretti et al., 
2007). Triple-negative breast cancer (TNBC) is a type of carcinoma where the tumor 
lacks the expression of ER, PR and Her2/neu. This reflects the disease aggressiveness 
and its poor specific outcomes and prognosis when compared to other types of breast 
cancers (Anders et al., 2016). The disease recurrence rate is elevated despite the systemic 
chemotherapy, and there are no approved targeted therapies for TNBC due to the 
heterogeneity of the disease, where six different TNBC subtypes were identified, each 
displaying unique characteristics (Abramson and Mayer, 2014; Collignon et al., 2016). 
The 4T1 mammary carcinoma is a transplantable and easy to manipulate tumor 
cell line that was isolated from a single spontaneously arising mammary tumor of a 
MMTV+ BALB/c mouse (Dexter et al., 1978; Aslakson and Miller, 1992). The 4T1 cell 
line is highly tumorigenic, invasive and can spontaneously metastasize to various organs 
including lymph nodes, blood, lungs, liver and others. 4T1 cell line is resistant to the 
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cytotoxic drug 6-thioguanine. This characteristic enables precise quantitation of 
metastatic cells, even when they are disseminated in distant sites and at sub-microscopic 
levels (Pulaski and Ostrand‐Rosenberg, 2001). 6-Thioguanine (6-TG) is a sulfur (thio) 
analogue of purine base guanine. It is an antimetabolite cytotoxic drug that causes cell 
death through the action of the mismatch repair mechanism (MMR), which mediates 6-
TG cytotoxicity by introducing DNA single strand breaks (SSB) at the site of 6-TG 
mismatches and then triggers signaling for a significantly increased and prolonged G2-M 
cycle arrest leading to cell death (Yan et al., 2003). The enzyme hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) is responsible for converting 6-TG to 6-
thioguanosine monophosphate (TGMP) (Gillin et al., 1972; Fotoohi et al., 2010), which 
in high concentrations inhibits the synthesis of guanine nucleotides via the enzyme 
Inosine monophosphate dehydrogenase (IMP dehydrogenase) (Fotoohi et al., 2010). 
TGMP with other 6-TG nucleotides (6-TGN) can be integrated into DNA or RNA as 
false bases and result in strand breakage, disruption of DNA repair mechanisms, 
inhibition of replication, and interfering with the formation of new proteins and nucleic 
acids (De Boer et al., 2007). Lack of HGPRT activity due to mutation in hprt gene leads 
to thioguanine-resistant T cells (Albertini et al., 1985). Due to the lack of data that 
explain the mechanism of resistance of 4T1 cells to 6-thioguanine, mutation in hprt gene 
may be an actual explanation for it, as confirmed by Hussain and Harris (1998) that the 6-
TG-resistant cells are deficient in hprt gene (Hussain and Harris, 1998).  
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1.4 Hypothesis and thesis objectives 
 
Despite the tremendous improvements and advances in anticancer drug discovery 
and manufacture, the majority of cancer cases remain incurable and cancer continues to 
be a major cause of death in the world (Johnson et al., 2013). Conventional chemotherapy 
is often severely cytotoxic to both malignant and normal body cells (Liang et al., 2010) 
and even the newer immunotherapies are  not devoid of side effects. In addition, therapies 
that are efficacious in reducing disease across a wide range of cancers and patients still 
elude the medical profession (Iwai et al., 2017). Immunotherapy, whilst hailed as one of 
the newest approaches, is extremely expensive, with a full course costing hundreds of 
thousands of dollars often resulting in limited improvement in overall survival (Andrews, 
2015).  
In the last three decades, phytotherapy has gained acceptance with increased 
public interest in both the developing and developed countries. In the developing world, 
about 80% of the population relies on herbal medicinal products as a primary source of 
healthcare (Ekor, 2013) and in many developed countries, such as USA, Australia, 
Europe and the UK, the use of herbal therapies has become widely accepted and used as 
complementary and alternative medicine (Calapai, 2008; Passarelli, 2008; Braun et al., 
2010; Nissen, 2010). The growing public interest in phytotherapy has been attributed to 
several factors such as the efficacy, relative low toxicity and low costs when compared 
with conventional pharmaceutical products (Bandaranayake, 2006). As previously 
mentioned, Daucus carota has been shown to possess a potent in vitro anticancer 
activity (Shebaby et al., 2013; Shebaby et al., 2014; Zgheib et al., 2014; Taleb et al., 
2016), as well as in vivo protective anticancer effect (Zeinab et al., 2011; Shebaby et al., 
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2017). Recently, β-2-himachalen-6-ol has been isolated from Daucus carota oil extract 
and was shown to be responsible for the anticancer activity in vitro, however, its full 
mechanism of action has not been elucidated nor its effect in vivo on a range of cancers. 
In this thesis, we hypothesized that β-2-himachalen-6-ol is a potent anticancer 
agent, inducing apoptosis through a direct effect on pro- and anti-apoptotic proteins and 
via an inhibition of the MAPK and PI3K pathways. The aim of the present work, 
therefore, was to investigate all the above parameters using in vitro and in vivo anticancer 
models.  
1.4.1 The specific objectives of this work, therefore, were as follows: 
 
• Daucus carota oil extraction and purification of HC according to Taleb et al 
(2016). 
• Investigate the anticancer effect of HC against a panel of colon and skin cancer 
cell lines by studying cell viability using the WST-1 cell proliferation assay. 
• Elucidation of the mechanism of action of HC against SW1116 colon cancer cells 
and HaCaT-ras II-4 skin cancer cells using flow cytometry and western blot 
experiments to assess the effect of HC on cell cycle and the level of pro- and anti-
apoptotic proteins and other key proteins involved in the PI3K and MAPK 
pathways.  
• Conduct a DMH-induced colon cancer model and test the efficacy of HC as an 
anticancer agent. 
• Conduct a DMBA/TPA-induced skin cancer model and assess the effect of HC as 
a preventive and treatment anticancer agent. 
• Investigate the effect of HC on 4T1 breast cancer cell line model. 
• Assessment of the anti-oxidant role of HC by measuring the activity of Catalase, 
Superoxide Dismutase (SOD) and glutathione S-Transferase (GST) antioxidant 
liver enzymes in the serum of DMH-induced murine model carcinogenesis. 
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Chapter 2 - Materials and Methods 
2.1. Materials 
2.1.1 Cell culture media        
       
Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park Memorial Institute 
Medium (RPMI), Dimethyl sulphoxide (DMSO), 7,12-Dimethylbenz(a)anthracene 
(DMBA), 12-O-tetradecanoylphorbol-13-acetate (TPA), 1-chloro-2,4-dinitrobenzene 
(CDNB), trypan blue, pyrogallol, trypsin, fetal bovine serum, penicillin-streptomycin, 
fetal bovine serum (FBS) were purchased from Sigma-Aldrich (St. Louis, USA). 
2.1.2 Chemicals 
 
Glycine, lysis buffer solution, phosphate buffer saline (PBS), bovine serum 
albumin (BSA), tris-buffered saline with Tween 20® (TBST), sodium dodecyl sulfate 
(SDS), well plates, pentane, diethyl ether, hexane, ethyl acetate, anisaldehyde and ethanol 
were purchased from Sigma-Aldrich (St. Louis, USA). Silica gel 60 was purchased from 
ACROS organics (New Jersey, USA). All other chemicals used in the experiments were 
of analytical grade.   
2.1.3 Antibodies  
 
Primary mouse monoclonal antibodies against Bax (ab32503), Bcl-2 (ab32124), 
p53 (ab31333), p21 (ab109199), PARP (ab32138), Pro-Caspase-3 (ab32150), cleaved 
Caspase (ab90437), Actin (ab119716) proteins and HRP-conjugated secondary anti-
mouse (ab1705047) and anti-rabbit (ab1705046) antibodies were obtained from Abcam 
(Cambridge, UK). The monoclonal antibodies against Erk (sc-271270), p-Erk (sc-7383), 
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Akt (sc-5298) and p-Akt (sc-52940) proteins were obtained from Santa Cruz (California, 
USA). 
2.1.4 Kits 
 
WST-1 reagent was purchased from Roche (Mannheim, Germany). The 
fluorescein Isothiocyanate (FITC)-conjugated Annexin V/PI apoptosis detection kit was 
purchased from Abcam plc (Cambridge, UK).  
  
2.2. Tested organisms 
 
White adult BALB/c mice (12 week old) (Jackson lab, Ca, USA) were used for 
skin cancer and breast in vivo model and Black 6 (B6NTac) mice (12 week old) (Charles 
River lab, Mas, USA) for the colon cancer model in vivo experiments. They were bred in 
the animal room of the biology department at the Lebanese American University, and 
housed under optimum conditions of humidity at 50 ± 5% and temperature (22 ± 2oC). A 
12 hour light-dark cycle light was assured, and mice were kept in groups of 6, 8 or 10 in 
plastic cages and fed with commercial mouse diet and tap water. All experimental 
protocols were approved by the Animal Ethical Committee of the Lebanese American 
University, which complies with the Guide for the Care and Use of Laboratory Animals 
(Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 
2010).  
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2.3. Daucus carota sample collection and oil extraction 
 
Mature umbels from Daucus carota’s (Linnaeus) ssp carota were collected post 
their flowering period during summer time (July-August) from the Ehmej Mountain, one 
of their natural habitats in Lebanon. The “Handbook of Medicinal Herbs” (Van Wyk and 
Wink, 2017) was used in order to confirm the identity of the plants as well as a botany 
expert: Dr. A. Houri from the department of Natural Sciences at LAU. The extraction 
procedure was performed according to the method described by (Zeinab et al., 2011). 
One kilogram of Stripped umbels was preserved and air-dried in the shade, and then 
shredded for oil extraction. The leaves were immersed in 5 liters of methanol/acetone 
(1/1) for 72 hours, and the extract was then filtered and evaporated under reduced 
pressure in order to assure complete dryness. The residue was centrifuged at 15.65g, and 
the received DCOE oil was dried over anhydrous sodium sulfate. The final yield 33.2g 
(3.32%) was stored at 4°C in a closed amber bottle until further use.  
 
2.4. Daucus carota oil fractionation 
 
           Thirty grams of Daucus Carota Oil Extract (DCOE) were chromatographed on a 
Normal-Phase Silica Gel Column Chromatography (230–400 mesh), using mobile phases 
of increasing polarities and monitored by thin layer chromatography (TLC) and similar 
fractions were combined. Four fractions were obtained: F1 (colorless) was eluted with 
pentane (100%), F2 (yellow) with pentane/diethyl ether (50/50), F3 (dark green) with 
diethyl ether (100%) and F4 with chloroform/methanol (50/50). Fractions were then 
analyzed by TLC using hexane/ethyl acetate (70/30) as mobile phase, and 2% 
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anisaldehyde was used to stain the plates (Zgheib et al., 2014; Shebaby et al., 2015; Taleb 
et al., 2016). F2.1 (1 g) was further chromatographed on a silica gel column (70-230 
mesh) using a concentration gradient of hexane/ethyl acetate (90/10, 80/20 and 70/30; 
0.5L each). The major compound (β-2-himachalen-6-ol, 260 mg; 92% purity) was 
collected as yellow oil with an Rf value of 0.55 in 70/30 hexane/ethyl acetate.  
 
2.5. Gas Chromatography and Mass Spectroscopy (GC-MS) analysis of HC purity 
 
The purity of HC was analyzed using gas chromatography and mass spectrometry 
(GC-MS) (HP6890 series; Hewlett Packard, Palo Alto, CA). The carrier gas was helium 
with splitless injection and a flow rate of 1.2 ml/minute was applied. The temperature 
program was set as follows: 2.0 minutes at 70°C, then from 70° to 130°C at 8°C/minute 
and held for 5 minutes, from 130° to 180°C at 2°C/minute and held for 10 minutes, from 
180° to 220°C at 15°C/minute and held for 2 minutes and then from 220° to 280°C at 
15°C/minute and held for 22 minutes. The identification of the HC was carried out by 
matching up the mass spectrum to published structures in the literature (Taleb et al., 
2016) and according to the GC-MS libraries NIST11 and Wiley9. The percentage 
composition was calculated from the GC peak areas. 
 
2.6 Effect of HC on colon, breast and skin cancer cells 
2.6.1 Cell viability post HC treatment 
           Human colon cell lines (Caco-2, HT-29, SK-Co, SW-1116, LoVo and T-84), skin 
HaCaT-ras II-4 invasive cancer cells, 4T1 metastatic breast cancer cells and normal 
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human colon cells (CCD-33Co) were used to investigate the anticancer effect of HC. 
Major characteristics of the above cells are outlined in table 2.1.  
Table 2. 1 Different cancer and normal cell lines with their characteristics  ((ATCC), 2013).           
Cell line Tissue Disease Genes expressed 
Caco-2 Colon Colorectal 
Adenocarcinoma 
(Epithelial cell 
type) 
Keratin, retinoic acid  
binding protein 1 and  
retinol binding protein 2. 
HT-29 Colon Colorectal 
Adenocarcinoma 
Secretory component of 
IgA. Positive for CEA 
and Mucin. Oncogene 
expression: myc+, ras+, 
myb+, fos+, sis+, p53+, 
abl-, ros- and src-. 
SK-Co-1 Colon: 
Ascites 
Colorectal 
Adenocarcinoma 
Oncogene expression: 
myc+, ras+, myb+, 
fos+, sis+, p53 +, abl-, 
ros- and src-.  
SW-1116 Colon  Colorectal 
Adenocarcinoma 
(Dukes’ type A, 
Grade III) 
Positive for CEA. 
Positive for expression 
of c-myc, K-ras, H-ras, 
myb, sis, p53 and fos 
oncogenes. 
LoVo Colon: left 
supra-
clavicular 
region 
Colorectal 
Adenocarcinoma 
(Dukes’ type C, 
grade IV) 
Positive for CEA. 
Antigen expression: 
HLA A11, B15, B17, 
Cw1, Cw3. Positive for 
expression of c-myc, K-
ras, H-ras, N-ras, Myb, 
sis, p53 and fos 
oncogenes. 
T-84 Colon: lung Colorectal 
Adenocarcinoma 
Positive for CEA. 
Positive for keratin by 
immunoperoxidase 
staining. 
CCD-33Co (Colon 
Normal Cell Line) 
Colon Not applicable Cell line with a trisomic 
N7 karyotype, 47,XY,+7 
in the majority of cells.  
HaCaT-ras II-4 (Skin 
Cancer Cell Line) 
Skin 
(epidermis 
Immortalized 
adherent 
keratinocytes) 
Squamous cell 
carcinoma  
TP-53 mutation.  
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4T1 (Breast Cancer 
Cell Line) 
Mammary 
Gland 
(BALB/c 
mice)  
Metastatic breast 
cancer 
6-thioguanine resistant 
cell line.  
 
 
Cell lines were plated in 96-well plates in RPMI medium supplemented with 10% 
Fetal Bovine Serum and 1% Penicillin / Streptomycin, at a density of 1x 105 cells/ml and 
maintained at 37°C in a 5% CO2 humidified incubator for 24 hours. Treatment with 
different concentrations of HC (1, 5, 10, 15 and 25µg)/ml DMSO was performed, and 
incubated for 24 and 48 hours. At the end of treatment period, cell proliferation was 
measured by the WST-1 cell proliferation assay which is based on the enzymatic 
cleavage of the Tetrazolium salt WST-1 (Roche Applied Science, Penzberg, Germany) to 
Formazan by mitochondrial dehydrogenases present in metabolically active and viable 
cells. An increase in dehydrogenase activity leads to an augmentation in the amount of 
formazan dye produced, which reflects the number of metabolically active cells in the 
culture. The absorbance of detected formazan was quantitatively measured at 450 nm by 
a Multiskan FC ELISA reader microplate (Thermo Fisher Scientific, Rockford, IL, USA). 
Cells were plated in triplicates and experiments were repeated three times. 
 
2.6.2 Cell cycle analysis   
 
            Cell cycle analysis using flow cytometry is mainly based on measurements of the 
cellular DNA content. By using Propidium Iodide staining, cell cycle arrest in any of its 
phases can be determined: G0 phase (quiescence or resting cell), G1 phase (preparation 
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for DNA synthesis), S phase (DNA synthesis and genome replication), G2 phase 
(interphase or preparation for division) and M phase (mitosis division) (Hans-Jürgen, 
2008). In order to study the effect of HC on cell cycle distribution, the following flow 
cytometry experiments were carried out: 1x105 cells/ml of HaCaT-ras II-4 and the 
SW1116 cell lines were cultured in 6-well plates for 48 hours, treated with two different 
concentrations of HC (10 and 25μg/ml DMSO), and then incubated for 48 hours in a 5% 
CO2 humidified atmosphere. The treated cells were harvested, washed with Phosphate 
Buffer Solution and fixed with 70% ethanol on ice. Then, cells were washed with ice cold 
PBS, resuspended in 100µl DNASE-free RNASE, and incubated for 30 minutes in the 
dark at room temperature. After that, cells were resuspended in cold PBS, transferred to 6 
ml polysterene falcon tubes, and 30µl Propidium iodide stain (Abcam, Cambridge, UK) 
was added to each tube and vortexed. Then cells were incubated in PI for 10 minutes in 
the dark, and finally, measurement of cell DNA content was carried out using a C6 flow 
cytometry (BD Accuri Cytometers, Ann Arbor, MI USA), and the population of each 
phase was determined using CFlow Plus analysis software (BD Accuri Cytometers, Ann 
Arbor, MI USA). 
2.6.3 Apoptotic cell assays   
 
The apoptotic effect of HC was determined by an Annexin V-FITC staining assay 
and measured on a C6 flow cytometer (BD Accuri Cytometers, Ann Arbor, MI USA) + 
analysis package. The HaCaT-ras II-4 and SW1116 (1x105cells/ml) were treated with 
different concentrations of HC (10 and 25µg/ml) in 6-well plates for 48 hours. Treated 
cells were harvested, washed with PBS and then centrifuged for 5 minutes at 500g. The 
cell pellet was then suspended in 0.5ml of Annexin V/PI apoptosis detection kit for 5 
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minutes at room temperature in the dark. The binding of Annexin V was analyzed by 
flow cytometry (Ex = 488nm, Em = 530nm); FL1 channel to detect Annexin V staining 
and FL3 channel to detect PI staining.  Annexin V-positive, PI-negative cells were 
counted as early apoptotic, double-stained cells were considered as late apoptotic, and PI-
positive with Annexin V-negative as necrotic.  
 
 2.6.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS_PAGE) 
and Western blotting 
 
HaCaT-ras II-4 and SW1116 Cells were cultured in 6-well plates at 1x105cells/ml 
DMSO of and incubated for 48 hours in a 5% CO2 humidified atmosphere incubator. 
Two concentrations (10 and 25µg/ml) of HC were used to treat the cultured cells. After 
48 hours of incubation, the adherent and non-adherent cells were collected on ice, washed 
twice with PBS, lysed with Laemmli buffer (10% 2-mercaptoethanol, 4% SDS, 0.004% 
bromophenol blue, 20% glycerol and 0.125 M Tris HCl, pH 6.8) and then centrifuged at 
12,000g for 10 minutes at 4°C. The cell lysate was then boiled for 5 minutes, and the 
Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA) was used in order to determine the 
cell protein concentration by adding Bradford Coomassie blue acidic dye to protein 
solution. The color change of the dye occurs in response to various protein 
concentrations. A spectrophotometer is used to measure the different concentrations at 
595 nm and to compare them with a standard curve. Equal protein concentrations of each 
sample (Control, DMSO, HC 10 and HC 25 treated lysates) were loaded and subjected to 
electrophoresis under reducing conditions by SDS-PAGE using 5% stacking gel [2ml of 
30% acrylamide mix, 3ml of 0.5M Tris-HCl (pH=6.8), 0.12ml of 10% (w/v) SDS, 6.76ml 
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of H2O, 0.12ml of 10% ammonium persulfate (APS) and 0.006ml of TEMED (N,N,N′,N′-
tetramethylelthylenediamine)], 10% separating gel [3.8ml H2O, 3.4ml Acrylamide/Bis-
acrylamide (30%/0.8% w/v), 2.6ml 1.5M Tris (pH=8.8), 0.1ml 10% (w/v) SDS, 100μl 
10% (w/v) ammonium persulfate (APS) and 10μl TEMED], and 1X running buffer [0.3% 
Tris Base, 1.4% glycine, 20% SDS, pH = 8.3] at 90 V for 30 min and then at 120 V for 2 
hours. A molecular weight marker (Bio-Rad, CA, USA) was used to identify the protein 
bands according to their molecular weight. 
PVDF membranes (Pall Corporation, Ann Arbor, USA) were used to transfer the 
proteins with a semi-dry electro blotter (PEQLAB, Erlangen, Germany) using 1X transfer 
buffer (25mM Tris base, 0.2 M glycine, 20% methanol, pH 8.5) at 10V for 90 minutes. 
Blocking buffer (1X TBS, 0.1% Tween-20 and 5% BSA) was then used to block the 
membranes for two hours. Primary mouse monoclonal antibodies to Erk, p-Erk, Bax,  
Bcl-2 and p53 proteins (Abcam, Cambridge, UK), and rabbit polyclonal antibodies to 
Actin, Caspase-3, Akt and p-Akt proteins (Santa Cruz, CA) as described in 2.1.3 were 
used to probe the membranes at dilution ranging from 1/1000 to 1/10000 overnight at 
4°C. Washing buffer (TBST) was used for 2 hours to wash away the primary antibodies, 
and horseradish peroxidase (HRP)-coupled secondary antibodies were added at a dilution 
of 1/5000 (Abcam, Cambridge, UK), in blocking buffer and left for one hour. The blots 
were subsequently washed with TBST for half an hour before detecting the proteins using 
the chemiluminescence ECL kit (Abcam plc, Cambridge, UK). Finally, the image lab 
Software (BioRad, Chemidoc imaging instrument) was used to obtain the blot images of 
the proteins. 
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2.7 In vivo murine model to assess the antioxidative effects of β-2-himachalen-6-ol 
on murine liver 
2.7.1 Experimental set-up 
 
The antioxidative effects of Daucus carota in comparison to Cisplatin (as a 
positive control) and no treatment (as a negative control) in vivo was analyzed using a 
murine model. Six groups, each of six mice were set up and treated as follows: Group I: 
No treatment (negative control). Group II: intraperitoneally treated with 50mg HC/kg bw, 
twice a week, for eight weeks. Group III: subcutaneously treated with 20 mg DMH/kg 
bw, once a week for eight weeks (positive control). Group IV: subcutaneously treated 
with 20 mg DMH/kg bw, once a week for eight weeks, followed by intraperitoneal 
injection of 50 mg HC/kg bw, twice a week for four weeks. Group V: intraperitoneally 
treated with 50 mg HC/kg bw, followed, after three days, by subcutaneous weekly 
injection of 20 mg DMH/kg bw, for eight consecutive weeks, and then followed by 50mg 
HC/kg bw, twice a week for four weeks. Group VI: subcutaneously treated with 20mg 
DMH/kg bw, once a week for eight weeks, followed by intraperitoneal weekly injection 
of 2.5mg/kg bw Cisplatin, for four weeks (figure 2.1).  
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Figure 2. 1 Treatment of mice for the investigation of Antioxidative of β-2-himachalen-6ol. 
Six groups of 6 mice each treated as follows:  
GI with no treatment. 
GII with HC (50mg/kg, IP, twice a week, for eight weeks, grey arrows). 
GIII with DMH (20mg/kg, SC, once a week for eight weeks, white arrows). 
GIV with DMH (20mg/kg, SC, once a week for eight weeks, white arrows) and followed by HC 
(50mg/kg, IP, twice a week for four weeks, grey arrows). 
GV with HC+DMH (50mg HC/kg, IP, twice a week , for 12 weeks, grey arrows, followed after 
three days from the beginning, by subcutaneous weekly injection of 20 mg DMH/kg, for eight 
weeks, white arrows). 
GVI with DMH (20mg/kg, SC, once a week for eight weeks, white arrows) and followed by 
Cisplatin (2.5mg/kg, IP, weekly injection, for four weeks, yellow arrows).  
 
At the end of the experiment (week 12), the overnight-fasted mice were sacrificed 
by cervical dislocation, and one ml of inferior vena cava blood was collected. The serum 
was analyzed for the liver function test (aspartate transaminase, AST; alanine 
transaminase, ALT and alkaline phosphatase, ALP) using commercial available kits 
(SpinReact). The livers were isolated, homogenized on ice and supernatant used for CAT, 
SOD and GST antioxidant enzymes assays. The colons of sacrificed mice were cleaned 
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with tap water and dissected longitudinally, preserved in 10% formaldehyde in order to 
be sent for histology by Dr. Carol Dagher, a licensed pathologist (details in section 2.13). 
 
2.7.2 Antioxidant Assays 
The antioxidant effect of HC on DMH–treated mice was studied by measuring the 
activity of Catalase, Superoxide Dismutase (SOD) and glutathione S-Transferase 
antioxidant liver enzymes.   
2.7.2.1 Catalase assay  
                     Catalase activity was tested on the basis of H2O2 disappearance at 240nm 
(Pedraza-Chaverrí et al., 2001). For this, 0.5g of livers from each treated mouse was 
homogenized over ice with 2ml Phosphate Buffer solution. The supernatant was then 
diluted 1/40 with PBS, added to 720µl of 30mM Hydrogen Peroxide (H2O2) in 10mM 
PBS. The H2O2 decomposition by the Catalase enzyme which is present in the samples 
was measured at 240nm by a spectrophotometer for a period of 60 seconds. The reaction 
follows first order kinetics given by the equation k = 2.3/t log (A0/A), where k is the first 
order reaction rate constant, t is the time over which the disappearance of H2O2 was 
measured, which was one minute, and A0 and A are, respectively, the optical densities at 
times 0 and 1 minute. The results were expressed in k/mg protein. 
 
2.7.2.2 Superoxide Dismutase Assay  
 
           Superoxide Dismutase activity was studied according to the inhibition rate of auto-
oxidation of Pyrogallol (Naskar et al., 2009). For this, 50µl of the homogenized liver 
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supernatant was added to 2.8ml Tris-EDTA (50mM Tris, 1.2mM EDTA; pH 8.5) and 
100µl of 2mM Pyrogallol. The Optical Density (OD) of the whole mixture was read at 
420 nm by a spectrophotometer, at zero and after three minutes, against the control set 
which consisted of both Tris-EDTA and Pyrogallol. One unit of Superoxide Dismutase 
activity is the amount of enzyme that inhibits the rate of auto-oxidation of pyrogallol by 
50%.   The results were calculated according to the following equations:  
Rate (R) = (final OD – initial OD)/3 
% inhibition= [(R control - R)/R control] x 100 
Enzyme unit (U) = (% inhibition/50) x dilution factor 
 
2.7.2.3 Glutathione S-Transferase Assay  
 
             Glutathione S-Transferase activity was studied according to the measurement rate 
of GSH conjugation with CDNB as a substrate (Habig et al., 1974). For this, 2.2ml of 0.1 
M Potassium Phosphate Buffer solution (pH 6.5) was added to 100µl of 30mM CDNB 
(1-chloro-2, 4-dinitrobenzene) and 100µl of 30mM GSH (glutathione reduced). Two 
solutions were prepared (sample and reference). After keeping both of them for one 
minute at room temperature (25oC), 600 µl of the liver supernatant was added to the 
sample solution and mixed thoroughly. The absorbance was then read at 340nm by a 
spectrophotometer after one minute, and GST activity was expressed in nmol of GSH-
CDNB formed conjugates per minute per protein, using an extinction coefficient of 
9.6mM-1 cm-1, as follows: 
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GST activity = (∆340 x3x100) / (9.6x10-3x0.6) 
where: ∆340 is absorbance of sample for 1 min at 340nm, 3 is 3ml and consists of (2.2ml 
of 0.1M potassium phosphate buffer + 100μl of 30mM CDNB + 100μl of 30mM GSH + 
600μl of the liver supernatant), 100 is dilution factor of samples, 9.6x10-3mM cm-1 
represents the molar extinction coefficient of CDNB (with path length -1cm) and the 0.6 
is the 600 μl of the liver supernatant. 
 
2.8 Effect of HC on DMH induced colon cancer in mice 
 
                   In order to assess the effect of β-2-himachalen-6-ol on liver toxicity, a murine 
colon cancer model was used.   
2.8.1 Experimental set-up 
 
Fifty male black6 mice (12 weeks old) were divided in five different groups (10 
mice/group), treated for seventeen weeks with 30mg DMH/kg mouse, subcutaneously, 
once a week (Newell and Heddle, 2004), and were labeled as follows: Group I: 18µl 
DMSO per intraperitoneal injection, dissolved in 90 µl 0.9% NaCl (equivalent to 18µl or 
25 mg HC as a negative control). Group II: 2.5mg Cisplatin per kg bw, injected 
intraperitoneally, once a week, for eight consecutive weeks (positive control). Group III: 
10mg/kg of HC dissolved in DMSO-saline solution, injected intraperitoneally once a 
week for eight consecutive weeks. Group IV: 25mg/kg of HC dissolved in DMSO-saline 
solution, injected intraperitoneally once a week for eight consecutive weeks. Group V: 
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50mg/kg of HC dissolved in DMSO-saline solution, injected intraperitoneally once a 
week for eight consecutive weeks (figure 2.2).  
 
Figure 2.2 The effect of β-2-himachalen-6-ol on liver toxicity. Five groups of ten mice each 
treated as follows: 
GI with DMH (30mg/kg, SC, weekly for 17 weeks, white arrows) and followed by DMSO (18µl, 
IP, weekly for 8 weeks, pink arrows).    
GII with DMH (30mg/kg, SC, weekly for 17 weeks, white arrows) and followed by Cisplatin 
(2.5mg/kg, IP, weekly for 8 weeks, yellow arrows).    
GIII with DMH (30mg/kg, SC, weekly for 17 weeks, white arrows) and followed by HC (10mg 
/kg, IP, weekly for 8 weeks, light grey arrows).    
GIV with DMH (30mg/kg, SC, weekly for 17 weeks, white arrows) and followed by HC (25mg 
/kg, IP, weekly for 8 weeks, dark grey arrows).    
GV with DMH (30mg/kg, SC, weekly for 17 weeks, white arrows) and followed by HC (50mg 
/kg, IP, weekly for 8 weeks, brown arrows).   
  
2.8.2. Histopathology of colons, livers and kidneys of treated mice 
 
               At the end of the experiment (week 25), the mice were sacrificed, one ml of 
inferior vena cava blood was collected, centrifuged at 176g, and the serum was analyzed 
for the liver function test (Shebaby et al., 2015). The colon, liver and kidneys were 
cleaned with tap water and the colon was dissected longitudinally, preserved in 10% 
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formaldehyde in order to be sent for histology by Dr. Carol Dagher, a licensed 
pathologist (details in section 2.13). 
2.9 A DMH inducing colon cancer along with Silymarin protection 
 
The present study aims to assess the anticancer efficacy of HC treatment while 
using Silymarin as a liver protector against long term treatment with DMH, which is 
known to induce liver toxicity. 
2.9.1 Experimental set-up 
 
 Ninety male Black6 mice, twelve-week-old, were divided in ten different groups 
(9/group), and injected subcutaneously with 30mg DMH/kg mouse, once a week for 
sixteen weeks (Newell and Heddle, 2004), and divided as follows: Group I: 16 weeks 
post-DMH injection treated with 36µl DMSO/ mouse dissolved in 72µl 0.9% NaCl 
(equivalent to 36µl or 50mg HC), intraperitoneally for 4 weeks, as negative control. 
Group II: Same as GI, but with 25mg Silymarin/kg mouse/day, administered orally after 
dissolving it with tap water. Group III: Nine mice treated, after 16 weeks of DMH 
injection, with 50mg HC/kg mouse, intraperitoneally once a week for four weeks. Group 
IV: Same as GIII, but with 25mg Silymarin/kg mouse/day, administered orally after 
dissolving in tap water. Group V: 16 weeks post-DMH injection treated with 2.5mg 
Cisplatin/kg mouse, intraperitoneally once a week for four weeks. Group VI: Same as 
GV, but with 25mg Silymarin/kg mouse/day, administered orally after dissolving in tap 
water. Group VII: 16 weeks post-DMH injection treated with 2.5 mg Cisplatin/kg and 
50mg HC/kg mouse, intraperitoneally once a week for four weeks. Group VIII: Same as 
GVII, but with 25mg Silymarin/kg mouse/day, administered orally after dissolving in tap 
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water. Group IX: 16 weeks post-DMH injection treated with 1.25 mg Cisplatin/kg and 
25mg HC/kg mouse, intraperitoneally once a week for four weeks, with 25mg 
Silymarin/kg mouse/day, administered orally after dissolving in tap water. Group X: 16 
weeks post-DMH injection treated with 50mg HC/kg mouse, as gavage, once a week for 
four weeks, with 25mg Silymarin/kg mouse/day, administered orally after dissolving in 
tap water (figure 2.3). 
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Figure 2.3 The anticancer efficacy of β-2-himachalen-6ol against DMH-induced colon 
carcinogenesis using Silymarin. Ten groups of 9 mice each treated with 30mg DMH/kg, SC, 
weekly for 16 weeks (white arrows), and then pursued as follows:   
GI with DMSO (36µl, IP, weekly for 4 weeks, pink arrows).  
GII same as GI, in addition to Silymarin (25mg/kg/day, PO, for 20 weeks, orange color). 
GIII with HC (50mg/kg, IP, weekly for 4 weeks, brown arrows). 
GIV same as GIII, in addition to Silymarin (25mg/kg/day, PO, for 20 weeks, orange color). 
GV with Cis (2.5mg/kg, IP, weekly for 4 weeks, yellow arrows). 
GVI same as GV, in addition to Silymarin (25mg/kg/day, PO, for 20 weeks, orange color). 
GVII with Cis (2.5mg/kg, yellow arrows) and HC (50mg/kg, brown arrows), weekly for 4 weeks. 
GVIII same as GVII, in addition to Silymarin (25mg/kg/day, PO, for 20 weeks, orange color). 
GIX with Cis (1.25mg/kg, light grey arrows) and HC (25mg/kg, dark grey arrows), IP, weekly for 
4 weeks, in addition to Silymarin (25mg/kg/day, PO, for 20 weeks, orange color). 
GX with HC (50mg/kg, as gavage, weekly for 4 weeks, red arrows), in addition to Silymarin 
(25mg/kg/day, PO, for 20 weeks, orange color). 
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At the end of the experiment, the mice were sacrificed, and one milliliter of 
inferior vena cava blood was collected, centrifuged at 176g, and the serum was analyzed 
for the liver function test. The colon, liver and kidneys were cleaned with tap water and 
the colon was dissected longitudinally, preserved in 10% formaldehyde in order to be 
sent for histology by Dr. Carol Dagher, a licensed histopathologist. 
 
2.10 Skin carcinogenesis promotion experiment for testing preventive effect of HC 
 
              In order to study the preventive effect of β-2-himachalen-6-ol on skin model 
carcinoma induction, forty eight female white BALB/c mice (12 weeks old), were 
divided in six groups (8/group), and were housed under optimum conditions of 
temperature (22 ± 2 oC), humidity (50 ± 5%) and alternating cycle of light and dark every 
12 hours. Animals were supplied with standard laboratory chow diet and water. Their 
dorsal surfaces were shaved using the depilatory “Nair”, a naturally made hair remover 
lotion. A single topical application of 7,12-Dimethylbenz(a) anthracene (DMBA) 
(190nmol dissolved in 0.2ml Acetone) was applied per mouse. Three weeks later on, 
TPA (8nmol dissolved in 0.2ml Acetone) was applied topically twice a week, for twenty 
consecutive weeks, in order to promote papilloma formation (Indra et al., 2007). The 
mice groups were divided as follows: Group I: Negative Control one topical DMBA 
application followed by 2 topical applications of TPA per week, for 20 weeks, and treated 
once a week with 0.9% NaCl/DMSO injected intraperitoneally (IP), thirty minutes before 
TPA application. Group II: One topical DMBA application followed by 2 topical 
applications of TPA per week, for 20 weeks, and treated once a week by 10mg HC/kg 
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mouse, intraperitoneally, thirty minutes before TPA application. Group III: One topical 
DMBA application followed by 2 topical applications of TPA per week, for 20 weeks, 
and treated once a week by 25mg HC/kg mouse, intraperitoneally (IP), thirty minutes 
before TPA application. Group IV: One topical DMBA application followed by 2 topical 
applications of TPA per week, for 20 weeks, and treated once a week by 50mg HC/kg 
mouse, intraperitoneally (IP), thirty minutes before TPA application. Group V: One 
topical DMBA application followed by 2 topical applications of TPA per week, for 20 
weeks, and treated topically, twice a week, with 200μl of 5% HC in acetone, thirty 
minutes before TPA application. Group VI: Positive Control, one topical DMBA 
application followed by 2 topical applications of TPA per week, for 20 weeks, and treated 
once a week by 2.5mg Cisplatin /kg mouse, intraperitoneally (IP), thirty minutes before 
TPA application (figure 2.4).  
N.B.: A total injection volume of 135μl was used in all experimental groups. Such a 
volume included the required dose of HC that is dissolved in DMSO and complemented 
with 0.9% NaCl to achieve the required volume. The negative control group contained in 
addition to NaCl a DMSO volume of 36µl that is equivalent to that of HC50. Cisplatin 
was taken directly from the original bottle (Ebewe, Austria) and administered IP to the 
animals (no DMSO).   
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Figure 2.4 The preventive effect of β-2-himachalen-6-ol against DMBA/TPA-induced skin 
carcinogenesis model. Six groups of 8 mice each treated with 190nmol of DMBA, applied 
topically, and after 3 weeks pursued as follows: 
GI with 2 topical applications of 8nmol TPA by week for 20 weeks (white arrows), and once a 
week by 36µl DMSO, IP, 30 minutes before TPA application (pink arrows).  
GII with 2 topical applications of 8nmol TPA by week for 20 weeks (white arrows), and once a 
week by 10mg HC/kg mouse, IP, 30 minutes before TPA application (light grey arrows). 
GIII with 2 topical applications of 8nmol TPA by week for 20 weeks (white arrows), and once a 
week by 25mg HC/kg mouse, IP, 30 minutes before TPA application (dark grey arrows). 
GIV with 2 topical applications of 8nmol TPA by week for 20 weeks (white arrows), and once a 
week by 50mg HC/kg mouse, IP, 30 minutes before TPA application (brown arrows). 
GV with 2 topical applications of 8nmol TPA by week for 20 weeks (white arrows), and twice a 
week with 200μl of 5% HC, topically, 30 minutes before TPA application (red arrows). 
GVI with 2 topical applications of 8nmol TPA by week for 20weeks (white arrows), and once a 
week by 2.5mg Cis/kg mouse, IP, 30 minutes before TPA application (yellow arrows). 
 
 
The incidence of papillomas was observed weekly for 20 weeks, where the effect 
of HC versus Cisplatin on papilloma growth was assessed through the collection of data 
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of the percent tumor incidence and average tumor yield. Tumor incidence was evaluated 
as the percentage of mice per group bearing papillomas on their back, whereas tumor 
yield was the number of lesions per mouse in each group. The tumor volume was also 
measured at week 20. The estimation of the tumor volume was performed according to 
specific reference volume models provided by our labs at LAU, where the length and 
width of the papillomas were measured by the use of a caliper, and then matched to a 
similar clay tumor model of known standardized volumes (Zeinab et al., 2011). The mice 
were also weighed at weeks 0, 12, 16 and 20.  
 
2.11 Skin carcinogenesis promotion experiment for testing therapeutic effect of HC 
 
In order to study the therapeutic effect of β-2-himachalen-6-ol on skin model 
carcinoma induction, twenty female white BALB/c mice (12 weeks old), were divided in 
four groups of five mice each. Their dorsal surfaces were shaved using the naturally 
made hair remover “Nair”. As described in 2.10, a single topical application of DMBA 
(190nmol dissolved in 0.2ml Acetone) was applied per mouse, and was followed after 
three weeks by TPA application (8nmol dissolved in 0.2ml Acetone) twice a week, for 
eighteen consecutive weeks (Indra et al., 2007). The mice groups were divided as 
follows: Group I: Negative Control, one topical DMBA application, followed by 2 topical 
applications of TPA per week, for 18 weeks, and treated once a week, starting week 12, 
with 0.9% NaCl/DMSO injected intraperitoneally (IP), thirty minutes before TPA 
application. Group II: Treatment with HC topically, one topical DMBA application 
followed by 2 topical applications of TPA per week, for 18 weeks, and starting from 
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week 12 topical treatment, twice a week, by 5%HC, thirty minutes before TPA 
application. Group III: Treatment with HC intraperitoneally, one topical DMBA 
application followed by 2 topical applications of TPA per week, for 18 weeks, and 
starting from week 12 intraperitoneal treatment, once a week by 25mg HC/kg mouse, 
thirty minutes before TPA application. Group IV: Treatment with Cisplatin, one topical 
DMBA application followed by 2 topical applications of TPA per week, for 18 weeks, 
and starting from week 12 intraperitoneal treatment, once a week by 2.5mg Cisplatin/kg 
mouse, thirty minutes before TPA application. 
N.B.: A total injection volume of 135 μl was used in all experimental groups. Such a 
volume included the required dose of HC that is dissolved in DMSO and complemented 
with 0.9% NaCl to achieve the required volume. The negative control group contained in 
addition to NaCl a DMSO volume of 18µl that is equivalent to that of HC25. Cisplatin 
was taken directly from the original bottle (Ebewe, Austria) and administered IP to the 
animals (no DMSO).  
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Figure 2.5 The therapeutic effect of β-2-himachalen-6-ol against DMBA/TPA-induced skin 
carcinogenesis model. Four groups of 5 mice each treated with 190nmol of DMBA, applied 
topically, and after 3 weeks pursued as follows: 
GI with 2 topical applications of 8nmol TPA by week for 18 weeks (white arrows), and starting 
week 12 with DMSO (18µl, IP, weekly, 30 minutes before TPA application, pink arrows).   
GII with 2 topical applications of 8nmol TPA by week for 18 weeks (white arrows), and starting 
week 12 with 200μl of 5% HC, topically, twice a week, 30 minutes before TPA application (red 
arrows). 
GIII with 2 topical applications of 8nmol TPA by week for 18 weeks (white arrows), and starting 
week 12 with HC (25mg/kg, IP, weekly, 30 minutes before TPA application, dark grey arrows). 
GIV with 2 topical applications of 8nmol TPA by week for 18 weeks (white arrows), and starting 
week 12 with Cis (2.5mg/kg, IP, weekly, 30 minutes before TPA application, yellow arrows). 
 
  
The effect of HC versus cisplatin was evaluated by collecting data of tumor yield, 
by weekly observation of the number of lesions per mouse in each group, starting from 
week 12 till week 18. The tumor volume was also measured at week 12, 14, 16 and 18. 
The estimation of the tumor volume was performed according to specific reference 
volume models provided by our labs at LAU, as described in paragraph 2.10. The mice 
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were also regularly weighed at weeks 12, 14, 16 and 18. At the end of the experiment, the 
mice were sacrificed, and one milliliter of inferior vena cava blood was collected, 
centrifuged at 176g, and the serum was analyzed for the liver function test.  
 
2.12 Breast cancer induction using the metastatic 4T1 cells 
2.12.1 Experimental set-up 
 
The 4T1 mammary carcinoma can be grown in vivo as a primary tumor in 
BALB/c mice, and can closely imitate human breast cancer. The preferred subcutaneous 
site of injection is in the abdominal mammary gland fat pad of female mice (Pulaski and 
Ostrand‐Rosenberg, 2001). 4T1 tumor cells were cultured in 12ml DMEM supplemented 
with 10% FBS (Fetal Bovine Serum) and 1x antibiotic-antimycotic (Penicillin/ 
Streptomycin/ Fluconazole), in T75 culture flasks, and incubated in a 37°C, 5% CO2 
tissue culture incubator till reaching 50-80% confluence. To harvest the cells, 5-7ml of 
serum-free medium (SFM) were used for washing, then 3ml of 0.25% trypsin/ 1mM 
EDTA solution were added to dislodge the cells, and incubated at room temperature for 2 
min. After that, 5-7ml of SFM were used to harvest the trypsinized cells from the flasks 
and then transferred to 15ml conical tubes for centrifugation in a benchtop centrifuge, at 
room temperature for 4 minutes at 112.7g. Then, the supernatant was discarded and the 
pellet resuspended with SFM as previously described. Cell count was determined using a 
hemacytometer and then adjusted to reach 1x106/ml using FSM. One-milliliter tuberculin 
syringes were filled in with 100µl cell suspension, and the 8 week-old female BALB/c 
mice (12 animals per group) were injected with 4T1 cells subcutaneously in the shaved 
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mammary gland region. The tumors were measured weekly using a Vernier caliper and 
mice were sacrificed using cervical dislocation after 5 weeks of 4T1 cells inoculation 
(Pulaski and Ostrand‐Rosenberg, 2001; Yang et al., 2012). Mice weight was also 
recorded on a weekly basis during the study period. Treatment (IP) with DMSO, HC 
(25mg/kg) and Cis (2.5mg/kg) started 3 days after 4T1 cells injection. DMSO was 
considered the negative control and used in concentration similar to that of HC (20μl/ 
injection/ mouse + 90μl NaCl), administered intraperitoneally (IP), twice weekly. HC 
was used twice weekly, while Cisplatin (positive control) once a week. At the end of 
experiment, skin tumors, lungs and livers were dissected and subjected to 
histopathological analyses. 
2.12.2 Blood extraction and colony culture 
 
The animals were sacrificed with cervical dislocation; one ml of blood was 
collected into a 1-ml tuberculin syringe containing 0.1ml heparin solution and then 
spilled into a 15-ml conical tube containing 10ml 1× Hank's Balanced Salt Solution 
(HBSS). The blood sample was centrifuged in a benchtop centrifuge for 5 minutes at 
176g at room temperature. The supernatant was discarded, the pellet washed twice with 
10ml 1x HBSS, centrifuged again and the pellet resuspended in 10ml DMEM 
supplemented with 10% FBS, 1× antibiotic-antimycotic, and 60μM 6-thioguanine. Three 
to five ml aliquots of the resuspended blood pellet were transferred to separate 10-cm 
T75 culture flasks, and the final volume of each flask was adjusted to 10ml with culture 
medium supplemented with 60 μM 6-thioguanine. The culture flasks were incubated for 
14 days in a 37°C, 5% CO2 tissue culture incubator. Later on, the culture media were 
discarded from tissue culture flasks, the cells were fixed with 5ml methanol and 
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incubated for 5 minutes at room temperature when colonies turn white in color. Methanol 
was then discarded and each flask was rinsed gently with 5ml distilled water. Five ml 
0.03% (w/v) methylene blue was added to each flask in order to stain the colonies blue, 
and flasks were incubated for 5 minutes at room temperature. The dye was then discarded 
and flasks rinsed gently with 5ml distilled water. Flasks were air dried and blue-stained 
colonies counted. 
2.12.3 Histopathology of primary tumors, lungs and livers 
 
Animal tissue samples from skin/mammary glands, liver and lungs were 
collected, preserved in 10% formaldehyde in order to be sent for histology by Dr. Carol 
Dagher, a licensed histopathologist.  
  
2.13 Histopathology 
 
Animal tissue samples from skin, colon, mammary glands, liver, lungs and kidney 
were collected, fixed in 10% neutral formalin and then embedded in paraffin. Sections 
were taken from the paraffin-embedded blocks and stained with Hematoxylin and Eosin. 
This stain is a standard stain in pathology that is composed of two dyes: Hematoxylin, a 
basic positively charged dye, stains the nuclei in dark blue since the DNA and RNA are 
acidic and negatively charged; Eosin, an acidic negatively charged dye, gives a pink-red 
color with the positively charged amino acids in the cytoplasm, cytoplasmic filaments, 
intracellular membranes and extracellular matrix (Fischer et al., 2008). Slides were 
screened under the light microscope (Zeiss). Colon, skin, mammary gland, liver, and lung 
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samples were analyzed for the presence of carcinoma and/or for the presence of 
inflammation.  
 
2.14 Statistical analysis 
 
Analysis of the data was statistically studied using one way analysis of variance 
(ANOVA). Values of the various tested parameters within each group are presented as 
Mean ± SEM. The main effect differences were significantly tested using Bonferroni post 
hoc test for multiple comparisons. All data were analyzed using the statistical package 
SPSS 18, and differences among groups were considered statistically significant only if   
p<0.05. The IC50 and IC90 were determined by a nonlinear regression curve using Prism 
Graph Pad version 5.0 software for Windows. 
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Chapter 3- β-2-himachalen-6-ol isolation and identification 
  
3.1 Rationale and Aims   
 
The wild carrot, Daucus carota (Linnaeus) ssp. carota has been the focus of 
research in our laboratory for its anticancer potential. Initial experiments revealed that 
Daucus carota oil extract (DCOE) contained several metabolites such as phenols, 
flavonoids, monoterpenes, sesquiterpenes, and phenylpropanoids (Gonny et al., 2004; 
Staniszewska et al., 2005; Maxia et al., 2009; Denise Otsuka et al., 2010; Shebaby et al., 
2013). In the Lebanese wild carrot, the sesquiterpenes group composed 60.61% of the oil 
composition and contained high levels of β-2-himachalen-6-ol (32.11%) (Shebaby et al., 
2013; Taleb et al., 2016). Further studies showed that DCOE possessed potent anticancer 
activity in vitro (Shebaby et al., 2013; Shebaby et al., 2014; Zgheib et al., 2014; Taleb et 
al., 2016) and in vivo in the  DMBA/TPA murine model of skin cancer (Shebaby et al., 
2017). More recently, β-2-himachalen-6-ol (HC) has been isolated from DCOE and was 
shown to be the active ingredient behind the anticancer effect of the plant oil extract 
(Taleb et al., 2016). Since HC is not available commercially, it was essential to isolate it 
from DCOE and confirm its purity to be able to conduct further in vitro and in vivo 
studies to elucidate the mechanism of action involved in protecting against a variety of 
cancers. The aim of this chapter, therefore, was to purify HC from Daucus carota using 
the oil extraction based on the protocol reported by Taleb et al (2016), to confirm its 
purity and structure using thin layer chromatography (TLC), gas chromatography and 
mass spectrometry (GC-MS) and nuclear magnetic resonance (NMR). 
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3.2 Isolation of β-2-himachalen-6-ol 
 
Daucus carota oil fractions 2.1, 2.2 and 2.3 were obtained according to the 
method described by Shebaby et al. (2013) and in chapter 2.5 using Silica-Gel column 
chromatography and the purity of these fractions was confirmed using TLC. Analysis of 
the TLC plates indicated that HC was mainly present in fraction 2.1 and accordingly F2.1 
was further chromatographed to yield β-2-himachalen-6-ol as yellow oil with a purity of 
92% as confirmed by GC-MS analysis (figures 3.1, 3.2).  
The major compound was visualized as a purple-pink chromophore on the TLC 
plate upon staining with anisaldehyde. HC was shown to have an Rf value of 0.55 relative 
to the mobile phase. The Rate of flow Rf represents the ratio of distance travelled by a 
compound over the distance travelled by the solvent (Taleb et al., 2016).    
 
Figure 3. 1 TLC profile of F2 sub-fraction. F2.1 using hexane/ethyl acetate (70/30) as the 
mobile phase, and eluted on a Si-Gel column. The test tubes 25-28 combined from F2.1.4 with a 
purity of 92% as confirmed by GC-MS. HC spots, observed in pink, were identified based on 
their color and an Rf value of 0.55 (arrows). Tubes 21-26 and 29-31 comprise less percentage of 
HC than 92%. The upper right arrow represents the solvent front.  
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Based on the TLC results, the sub-fraction F2.1 (pentane/diethyl ether) was also 
subjected to fractionation by column chromatography and yielded 10 sub-fractions 
(F2.1.1- F2.1.10). GC-MS analyses showed that F2.1.4 contained the highest purity of 
HC (92%) and the mass spectral analysis confirmed the mass of HC as 222.2g/mole 
(figures 3.2 and 3.3).   
  
 
Figure 3. 2 Gas Chromatogram of sub-fraction F2.1.4. Sub-fraction F2.1.4 (pentane/diethyl 
ether) was subjected to GC-MS analysis and was found to contain HC at 92%. HC showed a 
retention time, which is the time required for HC to travel through the GC column, of 22.178 
minutes. The abundance correlates to the area of the HC peak which is directly proportional to the 
concentration of the compound. 
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Figure 3. 3 Mass spectrometry of HC. MS showing HC molecular weight of 222.2 m/z (mass to 
charge ratio). The major fragment and base peak correlates to a mass of 119.1 while the fragment 
at 204.2 corresponds to the dehydrated parent molecular ion. 
  
 
 The 3-dimensional structure of HC was elucidated using 1-dimensional and 2-
dimensional NMR spectroscopy and can be seen in figure 3.4. The sesquiterpene consists 
of a 6-membered and 7-membered ring fused together with a Hydroxy-group on one of 
the bridged carbons. NMR experiments revealed that the hydrogen on C1 is coming out 
of the page relative to the hydroxyl group at C6 which is going into the page. 
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Figure 3.4 3-dimensional structure of HC as confirmed via 1-dimensional and 2-dimentional 
NMR spectroscopy (Taleb et al., 2016). 
 
 
3.3 Discussion  
 
The Daucus carota oil extract fraction F2 was shown to be the most potent 
fraction when used in viability studies against cancer cells (Shebaby et al., 2014; Shebaby 
et al., 2015a) and more recently, it has been shown that HC is the major compound of F2 
behind this anticancer activity (Taleb et al., 2016). In order to investigate the possible 
mechanism of this reported anticancer activity in vitro and in vivo, it was important to 
repeat the purification steps and confirm the components and structure of the HC from 
the Lebanese wild carrot umbels. This species was selected as it is the only reported 
species containing high levels of HC, particularly in plants harvested in July and August. 
Hence, DC oil extraction and purification of large amounts of HC was conducted based 
on the protocol reported by Taleb et al (2016).  
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The results of TLC of the F2 sub-fractions were consistent with the previously 
reported data of Taleb et al 2016, and the Rf value of HC was calculated to be 0.55. GC-
MS analysis of the isolated compound confirmed the presence of HC with a relative 
purity up to 92% and a mass of 222.2g/mole. In addition, 1-dimensional and 2-
dimensional NMR spectroscopy results also endorsed the previously reported structure by 
Taleb et al (2016).  
In conclusion, this chapter provides evidence that the isolated compound is HC 
and can be used in future experiments that cover both in vitro and in vivo studies.  
 
 
 
 
 
 
 
 
 
 
 
141 
 
Chapter 4- The anticancer activity of HC against colon cancer cell lines 
and its in vivo effect using the DMH-induced murine colon 
carcinogenesis model 
4.1 Rationale and Aims   
 
Previous studies showed that Daucus carota spp carota possesses anti-
inflammatory, anti-ulcer (Wehbe et al., 2009) and antioxidant activities (Shebaby et al., 
2013; Shebaby et al., 2015). Investigations into the active component of the plant led to 
the discovery that the oil extract of the plant (DCOE) had anticancer activities against the 
human colon and breast cancer cell lines HT-29, Caco-2, MCF-7 and MB-MDA-231 
(Shebaby et al., 2013), human acute myeloid leukemia cell lines HL60, U937, ML1, 
ML2, Mono-Mac-1, Mono-Mac-6, KG-1, MV-4-11, TF1-vRaf, TF1-vSrc and TF1-
HaRas (Tawil et al., 2015) and protected against the DMBA/TPA induced murine model 
of skin carcinogenesis (Zeinab et al., 2011). After further investigation, it was 
demonstrated that it was the pentane/diethyl ether fraction of DCOE that demonstrated 
potent anticancer activity against breast MDA-MB-231 and colon HT-29 cancer cell lines 
(Shebaby et al., 2014; Shebaby et al., 2015a) and a significant inhibition of cancer cell 
motility and invasion (Zgheib et al., 2014). More recently, in attempts to narrow down 
the active components of this extract fraction, the sesquiterpine β-2-himachalen-6-ol 
(HC) was isolated and was shown to possess potent anticancer activity in vitro against a 
wide range of cancer cells: B16F-10, Caco-2, MB-MDA-231, A549 and SF-268 (Taleb et 
al., 2016). In the same study, HC was shown to have very low toxicity in mice with an 
LD50 > 6000 mg/kg body weight (Taleb et al., 2016).   
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Since these reports, no in vivo studies assessing the anticancer activity of HC have 
been reported in the literature, however, the in vivo anticancer activity of DCOE (Zeinab 
et al., 2011) or its F2 fraction (Shebaby et al., 2017) have been reported against the 
DMBA/TPA skin carcinogenesis murine model.  
The aim of this chapter, therefore, was to assess the anticancer activity of HC 
against a panel of several different colon cancer cell lines (Caco, HT-29, SK-Co, SW-
1116, LoVo and T-84) and to investigate this activity in vivo using the DMH-induced 
colon cancer model in mice. Shebaby and colleagues (2015a) also reported that the F2 
fraction, containing HC as a major component, exerted its anti-proliferative activity via 
partial inhibition of the MAPK and PI3K pathways and caused significant increases in 
the percentage of cells in the sub-G1 phase, and apoptosis/necrosis (Shebaby et al., 
2015a). Therefore, the present study also aimed to elucidate the mechanism of action of 
HC by assessing the protein levels of Erk/p-Erk (MAPK pathway) and Akt/p-Akt (PI3K 
pathway) and other important proteins such as p53, p21, Bax, Bcl-2,Caspase-3 and PARP 
involved in the regulation of apoptosis. The effect of HC on cell cycle by quantifying 
DNA content post HC treatment was also investigated. Finally in this chapter, the 
combined effect of HC and the hepato-protective drug Silymarin was studied in order to 
assess the benefit of such a combination on murine liver toxicity and survival rate.  
4.2 Results 
4.2.1 The effect of HC on human colon cancer cell viability in vitro 
 
In order to study the effect of HC on cell viability, various colon cancer cell lines 
(Caco-2, HT-29, SK-Co, SW-1116, LoVo and T-84) were incubated with HC at varying 
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concentrations (1-25μg/ml) for 24 and 48 hours and the effects of HC on cell viability 
were compared to those of the carrier control (DMSO) and positive control Cisplatin 
(2.5μg/ml) or HC + Cisplatin. 
All cell lines exhibited a dose-dependent decrease in cell viability upon treatment 
with HC, with SK-Co being the most sensitive to HC treatment when compared to 
DMSO treatment alone (figure 4.1). With the exception of LoVo and SW1116 cells, a 
dose of 5µg/ml was able to cause a significant (p˂0.05) reduction in cell viability 48 
hours post HC treatment. Upon treatment with 10µg/ml HC, all cell lines showed a 
significant decrease in viability at 48 hours post-treatment (LoVo and SW1116: p<0.05; 
Caco-2, HT-29 and T-84: p<0.01; SK-Co: P<0.001). Whereas upon treatment with  
25µg/ml HC, there was a highly significant decrease in cell viability at both 24 and 48 
hours post-treatment when compared to the addition of DMSO alone (HT-29, LoVo, 
SW1116 and T-84: p˂0.01; Caco-2 and Sk-Co: p˂0.001). At a concentration of 2.5µg/ml, 
the positive control Cisplatin, resulted in a significant decrease in cell viability in all cell 
lines used after 48 hours of treatment (LoVo: p<0.05; remaining cell lines: p˂0.01). 
When Cisplatin (2.5µg/ml) was combined with HC (10µg/ml) the cell viability after 48 
hours was further decreased and was significant for all cell lines tested (HT-29, LoVo, 
SW1116 and T-84: p˂0.01; Caco-2 and Sk-Co: p˂0.001) when compared to DMSO 
group. An additive effect was also observed when comparing the combination Cis/HC to 
Cis alone [HT-29 and LoVo (p˂0.05); Sk-Co and T-84 (p˂0.01) after 24 and 48 hours of 
HC treatment, and Caco-2 P˂0.05 after 24 hours of treatment].  
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Figure 4. 2 The Effect of HC on cell viability of colon cell lines. A. Caco-2, B. HT-29, C. 
LoVo, D. SW-1116, E. Sk-Co and F. T-84. Different concentrations of HC dissolved in DMSO 
were used (1, 5, 10, 15 and 25µg/ml), 0.5% Dimethyl Sulfoxide (DMSO), 2.5µg/ml Cisplatin, 
and both Cisplatin 2.5 with 10µg/ml HC. Cells were treated for 24 hours (dark grey) and 48 hours 
(light grey) followed by measurement of cell viability using the WST-1 assay. Data are expressed 
as percentage of cell survival and are mean ± SEM from three independent experiments, where * 
denotes P˂0.05, **denote P˂0.01 and *** denote P ˂0.001 versus the DMSO group, as measured 
by one-way ANOVA.  
The inhibitory concentrations IC50 or IC90 are used to assess the inhibitory 
potency of any new drug that causes 50% or 90% inhibition of cell viability. IC90 
determination is important in showing the efficacy of a drug in causing cell death at a 
relatively lower concentration compared with other drugs of similar IC50s. In order to 
determine the concentration of HC that caused 50% inhibition  (IC50) or 90% inhibition 
(IC90) of cell viability, a logarithmic regression curve (y=-30.85ln(x)+111.44) was 
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applied. The IC50 and IC90 for all cells were calculated at 24 and 48 hours and the values 
are presented in table 4.1. SK-Co exhibited the lowest IC50 and IC90 at 24 (8 and 
19µg/ml) and 48 (5 and 18µg/ml) hours, while SW1116 showed the highest IC50 and IC90 
at 24 (18 and 36 µg/ml) and 48 (14.5 and 34 µg/ml) hours.          
Table 4. 1 The IC50 and IC90 of inhibition of cell viability by HC of colon cancer cell lines 
(Caco-2, HT-29, LoVo, SW1116, Sk-Co and T-84), measured after 24 and 48 hours of treatment 
with HC.        
 24 hours 48 hours 
 IC50 IC90 IC50 IC90 
Caco-2 9 34 7 29 
HT-29 17.5 32.5 12 28 
LoVo 16.5 30 13.5 26 
SW1116 18 36 14.5 34 
Sk-Co 8 19 5 18 
T-84 14 26 8 25 
                                                                                                                                                       
4.2.2 The effect of HC on cell viability of normal human colon cells in vitro 
             To investigate the specificity of HC on the inhibition of cell viability of cancer 
cells, a normal colon cell line (CCD-33Co) was used. CCD-33Co cells have a capacity to 
proliferate to a maximum of 29 population doublings ((ATCC), 2013), and the used ones 
had a passage number of 15. The CCD-33Co cell proliferation was very slow; therefore, 
it was necessary to monitor cell confluence in the culture flasks on a weekly basis using 
an inverted microscope. It took 13 weeks to achieve enough confluence that enabled us to 
perform the cell viability assay. This slow proliferation was confirmed by the National 
Institute of Biomedical Innovation, Health and Nutrition, JCRB Cell Bank, Osaka, Japan, 
through an email communication. These cells were cultured in a 96-well plate, and 
treated for 48 hours with two concentrations of HC (10 and 25µg/ml). Cell viability was 
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assessed using the WST-1 assay. No significant difference in cell viability between 
control and HC-treated normal colon cells was observed (figure 4.2).   
 
Figure 4. 3 The effect of HC on cell viability of normal colon cell line (CCD-33Co). HC at 10 
and 25µg/ml was added to CCD-33Co cells and incubated for 48 hours. The cell viability of the 
treated cells was compared to those treated with 0.5% DMSO alone. Data are expressed as 
percent cell survival and are the mean ± SEM from three independent experiments. 
 
4.2.3 The effect of HC on colon cancer cell cycle and apoptosis in vitro 
 
In order to test whether HC (10 and 25µg/ml) induces cell cycle arrest, the 
SW1116 cell line was used. It is a poorly differentiated grade III colorectal 
adenocarcinoma and showed relatively the highest IC50 and IC90 when treated with HC. 
Inducing cell cycle arrest post treatment with HC, therefore, could be translated into an 
inhibition of tumor growth. In order to quantify the number of cells distributed in the 
various phases of the cell cycle after 48 hours of treatment with HC, flow cytometry was 
used to assess the DNA content of cells in different phases of the cell cycle.  
Upon treatment of the cells with 10µg/ml of HC, there was a significant increase 
in the percentage of cells detected in the Sub-G1 phase (p˂0.01). This elevation was 
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accompanied by a drop in the percentage of cells detected in the G1, S (p˂0.01) and 
G2/M phases. Moreover, treatment with 25µg/ml of HC caused a significant increase in 
the percent DNA count in the Sub-G1 phase compared to DMSO treated cells (p˂0.001). 
This was also accompanied by a significant drop in G1, S and G2/M phases (p˂0.01, 
p˂0.001 and p˂0.05 respectively; figures 4.3A, 4.3B).  
 
 
Figure 4. 4 The effect of HC on the cell cycle distribution of SW1116 colon cells. (A) Cells 
were treated with 10µg and 25µg/ml HC versus 0.5% DMSO for 48 hours. The cells were then 
stained with Propidium Iodide (PI) and analyzed for DNA content by Flow Cytometry. The sub-
G1 (black) peak stands for the Apoptotic portion, the G1, S and G2 fractions are represented by 
grey, light grey and brown bars respectively. Representative data from three independent 
experiments is presented. (B) Bar graphs show the percentage of DNA cell count per phase; Sub-
G1 vs G1 vs S vs G2 phases. Data are mean ± SEM of three independent experiments, where * 
denotes P ˂0.05, ** denote P˂0.01 and *** denote P˂0.001 vs DMSO as measured by one-way 
ANOVA.  
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Since HC treatment of cancer cell lines caused significant decreases in cell 
viability and appeared to drive cells into the sub-G1 phase of the cell cycle, a more 
detailed investigation of the mechanism of cell death was carried out. Apoptosis and 
necrosis are the most implicated mechanisms of cell death, so the effect of HC treatment 
(10 and 25 μg/ml) in inducing apoptosis/necrosis in the SW1116 cell line, using cell 
staining with Annexin V and PI was measured.  
Treatment of SW1116 cells with 10µg/ml of HC caused a significant increase in 
the cells undergoing late apoptosis as detected by staining with Annexin V and PI 
(15.66%) when compared to cells treated with DMSO alone (5.61%, p˂0.05, figure 4.4).  
An increase in percentage cells in the necrotic phase (as detected by staining with PI 
alone) was also observed following treatment with HC (18.05%) when compared to cells 
treated with DMSO alone (5.11%, p˂0.001, figure 4.4). Increasing the concentration of 
HC to 25µg/ml resulted in more cells shifting towards late apoptosis (30.47%) (p˂0.01) 
and necrosis (58.01%) (p˂0.001) (figure 4.4).  
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Figure 4. 5 The effect of HC on stages of apoptosis in colon cells. (A) Flow cytometric analysis 
of Annexin V-FITC and Propidium Iodide (PI) staining to quantify HC-induced apoptosis in 
SW1116 cells. Representative, dot-plots of SW1116 cells treated with 0.5% DMSO, 10 or 
25μg/ml HC for 48 hours. Viable cells are located in the lower left quadrant (negative for both 
Annexin V and PI). Early apoptotic cells are found in the lower right region (Annexin V 
positive). Late apoptotic cells with extensive cellular and nuclear membrane damage are located 
in the upper right quadrant (double positive). Necrotic cells with heavily destroyed cell membrane 
are in the upper left region (PI positive). The results shown are representative of three 
independent experiments. (B) Bar graphs show the percentages of cells in each quadrant in non-
treated vs treated SW1116 cells. Upper left quadrant is represented in black bars, the upper right 
in dark grey, the lower left in light grey and the lower right in brown bars. Data are mean ± SEM 
of three independent experiments, where * denotes P ˂0.05, ** denote P˂0.01 and *** denote 
P˂0.001 vs DMSO as measured by one-way ANOVA.  
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 In order to elucidate the mechanism of action behind the increased levels of 
apoptosis observed in these cells following treatment with HC, the levels of key pro- and 
anti-apoptotic proteins involved in apoptosis in the colon cancer cell line SW-1116 were 
determined using Western blot analysis and densitometry and were expressed as a ratio of 
the level of actin expressed by these cells.   
It can be seen from figure 4.5 that significant decreases in the mean levels of Bcl-
2/actin (p˂0.01 for HC10 and p˂0.001 for 25μg/ml treated cells) and Pro-Caspase-3/actin 
(p˂0.01 for HC10 and HC25) were detected when compared to DMSO treated cells. The 
mean levels of p53/actin, p21/actin, and Bax/actin proteins detected were significantly 
increased (p˂0.001 in p53 and Bax, and p˂0.01 in p21) after treatment with HC 10 and 
25μg/ml. Moreover, the mean level of cleaved PARP/actin significantly increased 
(p˂0.001) for both HC10 and 25 treated cells.    
In order to assess the effect of HC treatment on two of the main survival pathways 
in cells: PI3K and MAPK, the levels of phosphorylation of the proteins Akt and Erk were 
investigated.  
A significant decrease in the phosphorylated form of Akt (p-Akt) and in the ratio 
of p-Akt/Akt (p˂0.001) in cells treated with both HC at 10 and 25μg/ml was observed 
(figure 4.5A and B). This decrease reflects a reduction in the activity of PI3K pathway. A 
similar decrease in the phosphorylated form of Erk (p-Erk) and in the ratio p-Erk/Erk was 
also observed (p˂0.001) for both HC10 and 25μg/ml treated cells. This decrease indicates 
an inhibition of the MAPK pathway.    
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Figure 4. 6 The effect of HC on apoptotic markers and survival pathway. (A) Representative 
western blots of SW1116 cells treated with HC 10 and 25µg/ml for 48 hours and probed for the 
levels of p53, p21, Bax, Bcl-2, Pro-Caspase-3, cleaved PARP, Erk, p-Erk, Akt and p-Akt. Protein 
bands were identified using the ‘Precision Plus Protein Kaleidoscope Standards’ (BIO-RAD, CA, 
USA). β-Actin levels were used as an internal protein loading control. (B) Densitometer-intensity 
data of the proteins of each blot is presented as mean ± SEM from three independent experiments, 
where * denotes P ˂ 0.05, ** denote P˂0.01 and *** denote P˂0.001, compared to 0.5 % DMSO 
as negative control, as measured by one-way ANOVA. 
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4.2.4 The effect of HC treatment on liver toxicity in a DMH-induced murine model 
of colon cancer 
 
Following the results of the effect of HC on cell viability, cell cycle and 
apoptosis/necrosis in cancer cell lines, the anti-tumor potential of HC was investigated in 
vivo starting with the effect on liver toxicity of this potential treatment.  The toxic effect 
of HC alone at 50mg/kg or in combination with DMH  (HC50/DMH, DMH/HC50) and 
DMH/Cisplatin treatment on liver toxicity was investigated by injecting 12 week old 
B6NTac mice with DMH for 8 weeks, followed by treatment with HC and/or Cisplatin 
for 4 weeks (as described in section 2.7). HC 50mg/kg mouse was used to assess the 
potential toxicity of the highest intended dose to be used. This dose is based on previous 
studies by Shebaby et al (2017). Liver toxicity was assessed by measuring the serum 
levels of 3 liver enzymes: aspartate aminotransferase (AST), alanine aminotransferase 
(ALT) and alkaline phosphatase (McClatchey and Yap), as they reflect the liver injury or 
damage that may be caused by drugs (Johnston, 1999). 
The results of these experiments are presented in figure 4.6 and demonstrate that, 
in comparison to the normal control, eight weeks of HC50 treatment (group II) did not 
have any significant effect on the mean serum activities of AST and ALP. A small but 
significant (p<0.05) increase in the mean serum levels of ALT, was observed for the 
HC50 treated mice when compared to the control group (20U/l vs 15.17U/l respectively).  
All the remaining groups treated with either DMH alone (group III), DMH prior to HC50 
(group IV), DMH prior to Cisplatin (group VI) or DMH concomitantly with HC50 (group 
V) were found to have significant increases in the mean serum levels of all the liver 
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enzymes tested. It is worth noting that when HC50 was given concomitantly with DMH, 
a lower mean ALP enzyme activity was observed (p˂0.05).  
 
Figure 4. 7 The effect of HC treatment on the mean serum levels of activity of liver enzymes 
of mice from a DMH-induced model of colon cancer. Bars denote mean serum enzyme activity 
of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase     
(ALP) in mice treated with HC, DMH alone, DMH followed by HC, HC followed by DMH and 
DMH followed by Cisplatin. Treated groups were compared with the negative control (no 
treatment). Data are Mean ± SEM, n=6, and significance was tested using one-way ANOVA, 
where * denotes P˂0.05 and **P˂0.01.    
 DMH is a known oxidative agent that induces oxidative stress enzymes, 
inflammation and tumor promotion in the colons of injected animals (Hamiza et al., 
2012). Assessment of homogenized liver antioxidant enzyme activities Catalase (CAT), 
Glutathione S-Transferase (Silver and Livingston) and Superoxide Dismutase (SOD) was 
also conducted to identify any antioxidant effect of HC.  
It can be seen from the data in figure 4.7, that all groups of mice exhibited similar 
SOD activities with respect to the control group. Treatment of mice with HC50 for 8 
weeks (group II) did not affect either the CAT or the GST activities, however, a 
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significant increase in CAT activity was observed in all DMH-treated groups (groups III, 
IV, V and VI; p˂0.05). Although a similar effect was observed with GST activity, mice 
in the HC+DMH group (group V) had significantly (p<0.05) lower levels of GST activity 
than that of the DMH treatment alone group (group III).   
 
Figure 4. 8 The effect of HC on the activity of antioxidant enzymes (Superoxide Dismutase, 
Catalase and Glutathione S-Transferase) in homogenized liver supernatants. Bars denote 
mean antioxidant enzyme activity in mice treated with HC, DMH alone, DMH followed by HC, 
HC followed by DMH and DMH followed by Cisplatin. Data are Mean ± SEM, n=6 and 
significance was tested according to one-way ANOVA, where *denotes P˂0.05 as compared with 
the negative control (no treatment) and ** denote P˂0.05 in comparison to group III (DMH-treated 
group). 
As a murine model of colon cancer, DMH treatment induces the development of 
dysplastic precancerous lesions in the colon of mice (Santiago et al., 2007; Rosenberg et 
al., 2008). Histopathological analysis of colon biopsies from all the groups of mice (I-VI) 
was carried out, therefore, to investigate whether HC treatment had affected the 
development of these lesions.   
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The results revealed that all mice in group III (DMH treatment alone) had 
developed colon focal dysplasia, characterized by glands lined by atypical cells showing 
hyperchromatic nuclei, prominent nucleoli and cell stratification. Mitotic figures are also 
identified. These atypical cells are confined to the basement membrane to the gland 
without invasion of the lamina propria (figure 4.8A). Mice in groups IV, V and VI 
(DMH+HC, HC+DMH and DMH+Cisplatin treatment) showed colon focal dysplasia in 
66.7%, 50% and 66.7% respectively, biopsies from groups I and II (control and HC 
treated mice) showed normal colon histopathology (figure 4.8B).      
 
Figure 4. 9 The presence of precancerous lesions in the colons of DMH-treated murine 
groups compared to HC-treated groups. (A) Representative picture of hematoxylin and eosin 
staining of colon sections from DMH and DMH with HC or Cisplatin treated mice. The arrows in 
micrograph A indicate colon dysplasia, characterized by mitotic figures (upper right), intact 
lamina propria (lower right), prominent nucleoli (upper left) and hyperchromatic nuclei with cell 
stratification (lower left) in groups III, IV, V and VI (the figure is from group III). (B) 
Representative picture of hematoxylin and eosin staining of colon sections from group II (HC- 
treated), the same picture was observed in group I (negative control). The arrow indicates normal 
colon cells with intact lamina propria (upper arrow), regular columnar cells (middle arrow) and 
normal mucin-secreting goblet cells (lower arrow). Both images are at 20x magnification. 
 4.2.5 The effect of HC on a DMH-induced murine model of colon cancer in vivo 
Following analysis of the results of the 8 week DMH-induction of colon cancer 
and in order to achieve a maximal colon cancer incidence in mice as described by Newell 
and Heddle (2004), a treatment period of seventeen weeks with DMH was adopted. A 
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significant number of mice, however, were lost in the different groups by the end of the 
experiment. Only 7, 8, 3, 6 and 3 out of 10 mice survived until the end of treatment in the 
control, Cisplatin, HC10, HC25 and HC50 treated groups respectively, with the majority 
of the mice being lost during the DMH treatment period (3, 1, 6, 4 and 6 in the  control, 
Cisplatin, HC10, HC25 and  HC50 group respectively).  
4.2.5.1 The effect of HC treatment on colon cell morphology and tumor incidence in 
a DMH-induced murine model of colon cancer  
 
 In order to assess the presence of colon cancer in the DMH-treated mice, it was 
necessary to undertake histopathological analysis on the isolated colons of the various 
treated groups. This was achieved by hematoxylin and eosin staining as previously 
described. In addition, the incidence of cancer present in the surviving mice was 
recorded. 
In the control group (DMH + DMSO), histopathological analysis revealed that all 
surviving animals had developed cancer by the end of the experiment due to the presence 
of atypical glands invading the lamina propria with high ratio of nucleus over cytoplasm 
(figures 4.9A and 4.9E). In the Cisplatin treated group, 75% (6/8) of surviving mice 
developed colon cancer and 25% (2/8) had normal colon histopathology, identified by 
glands lined by regular cells (figures 4.9B and 4.9E). In the group of HC10 treated mice, 
33.3% (1/3) of surviving mice showed dysplasia and the rest (2/3) developed colon 
cancer (figures 4.9C and 4.9E) whereas in the group of HC25 treated mice, 17% (1/6) of 
animals had no signs of colon cancer (figures 4.9B and 4.9E). Finally, in the HC50 
treated group of mice, one surviving animal (33%) was cancer free and 67% (2/3) mice 
displayed a small focal dysplasia, (Figure 4.9D; Figure 4.9E). 
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Figure 4. 10 The effect of HC on colon cell morphology in a DMH-induced murine model of 
colon cancer. Representative histopathological analysis of colon biopsies from mice treated for 
seventeen weeks with DMH, followed by eight weeks with DMSO, HC or Cisplatin. (A) The 
arrow in the micrograph indicates Colon adenocarcinoma (glands lined by atypical cells invading 
the lamina propria) from mice treated with DMSO (magnification x20). (B) The arrow in the 
micrograph represents normal colon (glandular epithelium lined by regular columnar cells) of 
animals treated HC25mg/kg (Magnification x10). The same staining pattern was observed in 
Cisplatin treated mice (25%). (C) The arrow in the micrograph represents colon with 
adenocarcinoma in animals treated with HC10mg/kg (magnification x20). The same pattern was 
observed in Cisplatin (75%) and HC25 (83%) treated mice. (D) The arrow in the micrograph 
shows normal colon of the surviving animal treated with 50mg/kg HC (magnification x10). (E) 
Bars denote percent surviving mice at the end of experiment with colon cancer detected 
histopathologically.   
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4.2.5.2 The effect of HC treatment on colon tumor size in a DMH-induced murine 
model of colon cancer 
 
In order to assess the effectiveness of HC in protecting mice against DMH-
induced colon cancer development, the size of isolated tumors (measured in millimeters 
using a microscope micrometer) in the resected colons from mice treated with HC and 
Cisplatin was evaluated. The control group exhibited the highest mean tumor size 
(6.0mm), whereas the tumors from the mice in the Cisplatin group had a mean size of 
1.75mm. Whilst no cancer was discerned in the HC50 group, the mean tumor size in mice 
from the HC10 and HC25 groups was 1.3mm and 2.5mm respectively (Figure 4.10).   
 
Figure 4. 11 The effect of HC on colon tumor size in a DMH-induced murine model of colon 
cancer. Average colon tumor size in millimeters, compared to DMSO treated group (control). 
The values are expressed as Mean ± SEM, where *denotes P˂0.05 compared with DMSO as 
measured by ANOVA. 
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4.2.5.3 The effect of HC on liver function in a murine module of DMH-induced 
colon cancer 
 
In a similar fashion to the initial 8 week DMH-induction of colon carcinogenesis 
model, the liver function of the mice treated for seventeen weeks with DMH injections 
followed by eight weeks of HC treatment hepatotoxicity was assessed by the activity of 
the liver enzymes AST, ALT and ALP in the serum of the surviving, treated mice. 
Animals treated with HC at 10 and 25mg/kg displayed lower mean enzyme activities as 
compared to controls reaching significance for ALT in mice treated with HC at 10mg/kg 
(p<0.05, table 4.2). At the higher concentration of HC (50mg/kg), all liver enzyme 
activities had higher mean serum levels than that of the control liver enzymes. Due to the 
large amount of variation in these levels, however, these differences did not reach 
statistical significance. Animals treated with Cisplatin showed similar levels of activity 
for ALT and AST when compared to the DMSO control, whilst ALP activity was 
significantly higher (p<0.05, table 4.2).  
 
Table 4. 2 Liver enzyme activity in the serum of mice treated with HC, Cisplatin and 
DMSO. The values are expressed as mean ± SEM, where *denotes P˂0.05 compared with 
DMSO, as analyzed by ANOVA.  
 DMSO Cis 2.5mg/kg HC 10mg/kg HC 25mg/kg HC 50mg/kg 
AST (U/l) 140.3 ± 22 140.9 ± 16.1 110 ± 4.1 124.9 ± 8.4 179.8 ± 46.6 
ALT (U/l) 58.1 ± 7.2 43.4 ± 5.8 28.8 ± 2.5* 55.4 ± 10.8 69.9 ± 14.6  
ALP (U/l) 106 ± 18.3 183.7 ± 16.1* 98.4 ± 18.3 88.5 ± 15 238.2 ± 44.7  
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4.2.5.4 The effect of HC on liver and kidney morphology in mice with DMH-induced 
colon cancer 
 
DMH has been reported to cause severe liver damage (Castleden and Shilkin, 
1979) and one of the side-effects of the use of Cisplatin, is nephrotoxicity (Miller et al., 
2010). It was, therefore, necessary to compare the morphology of liver and kidney tissues 
from the mice in all of the treatment groups. This was achieved as described in 2.13 using 
Hematoxylin and Eosin stains. 
The histological analysis showed that 43% of animals treated with DMH for 
seventeen weeks followed by eight weeks with DMSO exhibited liver toxicity as 
evidenced by portal chronic inflammation (characterized by lymphocyte predominance, 
figure 4.11A). Upon treatment with Cisplatin, 25% of mice developed liver toxicity 
(portal and lobular inflammation around necrotic hepatocytes) and 75% showed kidney 
interstitial inflammation (aggregates of lymphocytes between renal tubules; figure 
4.11B). All mice treated with HC showed normal kidney morphology (normal appearing 
glomeruli with absence of interstitial inflammation and normal proximal convoluted 
cortical tubules) at all doses, and no liver toxicity at the low and medium doses (10 or 
25mg/kg) was observed (figures 4.11C and D). This is consistent with the biochemical 
analysis. However, at 50mg/kg HC, 67% of the mice showed liver toxicity.   
 
161 
 
 
 
Figure 4. 12 Histopathological analyses of liver and kidney from HC treated mice in a 
DMH-induced murine model of colon cancer. (A) Severe liver toxicity after DMH treatment. 
Arrow indicates area of portal chronic inflammation lined with lymphocytes. The same staining 
pattern was also present in Cis (25%) and HC50 (67%) treated mice. (B) Kidney inflammation 
after cisplatin treatment. Arrow indicates chronic inflammation with lymphocyte predominance in 
the interstitium between tubules of 75% of the Cis treated mice. (C) Normal liver after treatment 
with HC (10 and 25mg/kg). Arrow indicates areas of normal hepatocytes with absence of 
inflammation. The same staining pattern was also observed in Cis (75%) and HC50 (33%) treated 
mice. (D) Normal kidney after treatment with HC (10, 25 and 50mg/kg). Arrows indicate normal 
glomeruli (lower right arrow), area of normal proximal convoluted cortical tubules with normal 
renal cells (left upper and lower arrows). All images are at magnification x20.   
  
 
4.2.6 The effect of HC and Silymarin on a DMH-induced murine model of colon 
cancer 
 
  Silymarin is a liver protector, known to possess strong antioxidative properties 
(Ferenci, 2016) and  the ability to promote hepatocyte regeneration, reduce inflammation  
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and inhibit fibrogenesis triggered by oxidative stress or as a feature of chemical- and 
drug-induced hepato-toxicity (Feher and Lengyel, 2012). Since HC treatment of mice 
with DMH-induced colon cancer showed signs of liver toxicity at a dose of 50mg/kg, the 
potential benefit of co-treating these mice with Silymarin was investigated. A minimum 
of 15 weeks is usually required for colon cancer induction (Perše and Cerar, 2010). To 
this end, mice were treated with DMH (30mg/kg) for sixteen weeks, followed by four 
weeks of HC or Cisplatin with or without Silymarin at 25mg/kg/day (equivalent to 
0.75mg/mouse/day). In addition, an HC gavage treated group was added in order to 
assess the oral effect of HC administration in inhibiting cancer formation and/or inducing 
hepato-toxicity. 
To test for liver toxicity, mean liver enzyme activities (AST, ALT and ALP) were 
determined for all groups of mice. A Non-significant decrease in the mean levels of the 
liver enzymes tested was observed in the DMH DMSO mice with Silymarin treatment as 
compared to DMH DMSO group (figure 4.12). Similarly, DMH HC treated animals with 
and without Silymarin exhibited a non-significant decrease in the mean serum AST and 
ALT activities, with a significant decrease in the level of ALP upon incubation with 
Silymarin (p<0.05) when compared to the DMH DMSO mice. The DMH Cisplatin 
treated group showed a significance decrease in the level of ALT upon incubation with 
Silymarin and upon treatment with HC and Silymarin. The gavage treated groups showed 
a non-significant decrease in the serum activity of AST, ALT and ALP. 
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Figure 4. 13 The effect of HC/Silymarin treatment on serum liver enzyme activities in a 
DMH-induced murine moduel of colon cancer. Bars denote mean serum enzyme activity of 
aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase 
(ALP) in mice treated with HC, HC with Silymarin, Cisplatin, Cisplatin with Silymarin, Cisplatin 
with HC, Cisplatin with HC and Silymarin, Cisplatin with HC half doses with Silymarin and HC 
gavage with Silymarin. Treated groups were compared to negative control (DMSO). Data are 
Mean ± SEM, n=9, and significance was tested using one-way ANOVA, where * denotes P˂0.05.  
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The percentage survival of the mice ranged between a maximum of 100% with 
HC50 treatment and a minimum of 67% with Cisplatin 1.25/HC25/S treatment (figure 
4.13.A). The percentage survival with cancer was lowest for HC50/S and highest for 
Cisplatin 2.5/S (88.9%) followed by DMSO (87.5%) (figure 4.13B). Histopathological 
analysis of the kidneys, revealed that certain animals developed interstitial chronic 
inflammation (figure 4.13C) with highest incidence in Cisplatin 2.5/S (100%) followed 
by Cisplatin 2.5 (67%) and Cis2.5/HC50 (57%) treated mice, whilst the lowest incidence 
was observed in DMSO (0%) and HC50 (0%) groups of mice.  
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Figure 4. 14 The effect of HC/Silymarin treatment on survival in a DMH-induced murine 
model of colon cancer. (A) Bars denote percent alive mice at the end of experiment. (B) Bars 
denote percent alive mice at the end of experiment with colon cancer detected 
histopathologically. (C) Bars denote percent mice with inflammed, histopathologically detected 
kidneys.  
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4.2.7 Comparison among the three DMH-induced colon carcinogenesis experiments   
 
           After performing the three experimental protocols using DMH as colon cancer 
inducer, it was necessary to compare the data obtained regarding liver enzymes activity 
(table 4.3), mice survival (table 4.4) and cancer incidence in surviving mice (table 4.5). 
The results in table 4.3 showed that extending DMH treatment to either 16 or 17 weeks 
resulted in a significant increase in the activities of liver enzyme, as it is a dose and time-
dependent process (Jackson et al., 1999; Perše and Cerar, 2010; Abd-Elmoneim et al., 
2013). A 16-week period of DMH treatment, therefore, caused significantly less toxicity 
on murine livers than the 17-week period of treatment. When Silymarin was used 
concomitantly with DMH, there was a non-significant improvement in the liver enzyme 
activities in all treated groups except for ALT activity in the Cisplatin treated group 
(p˂0.05). The results in table 4.4 revealed that mice survival is mainly affected by the 
duration of DMH treatment rather than the presence or absence of Silymarin. This effect 
was highly observed in HC treated group, where 7 out of 10 mice were lost, keeping in 
mind that 6 out of 7 mice were lost during the DMH treatment period. The number of 
surviving mice with cancer (table 4.5), however, was significantly improved when 
Silymarin was combined with HC (25% in HC/S treated group versus 67% in HC treated 
group alone).  
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Table 4. 3 Liver enzyme activity in the serum of mice treated with DMH, Cisplatin and HC 
in 3 different experiments. Experiment I (8 weeks of DMH 20mg/kg followed by 4 weeks of 
HC 50mg/kg or Cis 2.5mg/kg treatment). Experiment II (17 weeks of DMH 30mg/kg followed by 
8 weeks of HC 50mg/kg or Cis 2.5mg/kg treatment). Experiment III (16 weeks of DMH 30mg/kg 
followed by 4 weeks of HC 50mg/kg or Cis 2.5mg/kg treatment). The values are expressed as 
mean ± SEM, where *denotes P˂0.05 and ** denote P˂0.01 compared with DMH group, as 
analyzed by ANOVA.  
Liver enzymes 
(U/l) 
Experiment DMH 
 
Cis 2.5mg/kg HC 50mg/kg 
AST I 50±3.5 52±2.8 45± 1.45 
II 140.3 ± 22 140.9 ± 16.1 179.8 ± 46.6 
III 91±6.5 73.2±3.4 74.1±4.3 
III 
with Silymarin 
84.3±2.2 65.6±4.1 70.9±6.1 
ALT I 26±4.7 26±1.4 20±1.05 
II 58.1 ± 7.2 43.4 ± 5.8 69.9 ± 14.6 
III 48.8±3.3 43.9±4.0 46.7±4.8 
III 
with Silymarin 
47±2.75 26.4±5.02* 39.6±2.85 
ALP I 85±5.6 93±9.7 62±2.55** 
II 106 ± 18.3 183.7 ± 16.1* 238.2 ± 44.7 
III 81.7±10.0 75.5±8.7 58±9.8* 
III   
with Silymarin 
78.2±11.6 61.5±6.5 55.1±6.0** 
 
 
Table 4. 4 Mice survival after treatment with DMH, Cisplatin and HC in 3 different 
experiments. Experiment I (8 weeks of DMH followed by 4 weeks of HC or Cis treatment). 
Experiment II (17 weeks of DMH followed by 8 weeks of HC or Cis treatment). Experiment III 
(16 weeks of DMH followed by 4 weeks of HC or Cis treatment).  
Mice survival DMH 
 
Cis 2.5mg/kg HC 50mg/kg 
Experiment I (n=6) 6 (100%) 6 (100%) 6 (100%) 
Experiment II (n=10) 7 (70%) 8 (80%) 3* (30%) 
Experiment III (n=9) 8 (89%) 9 (100%) 9 (100%) 
Experiment III (n=9) 
with Silymarin 
8 (89%) 9 (100%) 8 (89%) 
*6/7 mice were lost during the DMH treatment period. 
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Table 4. 5 Surviving mice with cancer after treatment with DMH, Cisplatin and HC in 3 
different experiments. Experiment I (8 weeks of DMH followed by 4 weeks of HC or Cis 
treatment). Experiment II (17 weeks of DMH followed by 8 weeks of HC or Cis treatment). 
Experiment III (16 weeks of DMH followed by 4 weeks of HC or Cis treatment).  
Surviving mice with 
cancer 
DMH 
 
Cis 2.5mg/kg HC 50mg/kg 
Experiment I 
(Colon dysplasia) 
6/6 (100%) 4/6 (67%) DMH/Cis 4/6 (67%) DMH/HC 
3/6 (50%) HC/DMH 
Experiment II 
(Colon cancer) 
7/7 (100%) 6/8 (75%) 0/3 (0%) 
2/3 (67%) (colon 
dysplasia) 
Experiment III 
(Colon cancer) 
7/8 (87.5%) 7/9 (78%) 6/9 (67%) 
Experiment III with 
Silymarin (colon 
cancer) 
7/8 (87.5%) 8/9 (89%) 2/8 (25%) 
 
 
 
4.3 Discussion   
 
Previous studies showed that the pentane/diethyl ether fraction of DCOE causes 
significant inhibition of cancer cell motility and invasion (Zgheib et al., 2014) and 
induces cell death when tested against different human breast and colon cancer cell lines 
(Shebaby et al., 2014; Shebaby et al., 2015a). It was also shown to protect against 
chemically-induced skin cancer (Shebaby et al., 2017). HC was then isolated and proven 
to be the most active anticancer component of the DCOE pentane/diethyl ether fraction 
(Taleb et al., 2016). In this study, HC was tested for its efficacy against a panel of colon 
cancer cell lines and against DMH-induced murine model of colon carcinogenesis.    
The in vitro anticancer properties of HC were tested against six colon cancer cell 
lines (Caco-2, HT-29, SK-Co, LoVo, SW-1116 and T-84) to assess its effect on cell 
viability. In all treated cell lines, the response was dose-dependent, with the most 
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sensitive cell line to HC treatment being SK-Co and the least sensitive being SW1116. 
After 24 hours of treatment, the IC50 and IC90 ranged from 8 to 18µg/ml and 19 to 
36µg/ml respectively. Further incubation to 48 hours did not significantly alter the IC50 
and IC90 values, indicating that HC exerts its full activity 24 hours post treatment. Unlike 
HC, Cisplatin showed maximum activity 48 hours post treatment. Concomitant treatment 
with both compounds showed a greater cytotoxic effect than when each compound was 
used alone, indicating a possible additive effect. Previous studies on CaSki cancer cells 
showed that Cisplatin had a dose-dependent cell growth inhibition with an IC50 of 29.74 
μM/ml (equivalent to 8.9μg/ml) (Byun et al., 2013). In the present study, the IC50 of 
Cisplatin on the tested cell lines was in the range of 2.6μg/ml after 48 hours of treatment. 
When Tetraarsenic oxide (3.72μm/ml) was used in combination with Cisplatin, a 
synergistic effect was observed (Byun et al., 2013). Tetraarsenic oxide (TAO) is a new 
arsenic compound that has shown to possess a promising anticancer effect against human 
cervical cancer cell growth (Kim et al., 2005). TAO also exhibited a synergistic effect 
with Paclitaxel in gastric, cervix and head and neck cancer cell lines (Chung et al., 2009) 
The high toxicity of all arsenic compounds, however, limit their use (Roy et al., 2008). 
In order to ensure the specificity of HC for cancer cells, the effect of HC was also 
tested on normal colon cell viability using the CCD-33Co cell line. HC at 10 and 
25µg/ml displayed no toxic effect on the cells 48 hours post-treatment with respect to 
their proliferation. The CCD-33Co cells, however, exhibited a significant longer doubling 
time when compared with the cancer cell lines used, therefore, it may be premature to 
make a definitive conclusion about the specificity of HC effects on cell viability to cancer 
cells until further studies on fast growing normal cells are undertaken.  
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In an attempt to identify the effect of HC (10 and 25 µg/ml) on the SW1116 cell 
cycle, which is a key player in cell division and tumor growth, flow cytometry with PI 
staining of nucleic acids was used. Upon treatment of cells with 10µg/ml of HC, there 
was a decrease in the S, G2/M as well as G1 phases with a significant increase in Sub-G1 
phase. In the Sub-G1 phase, the cell accumulation was 45.87%, versus 14.5% in the 
DMSO treated cells indicating that a large number of cells is undergoing cell cycle arrest. 
At the higher concentration (25µg/ml), HC treatment caused complete DNA 
fragmentation, as illustrated by the assembly of the cell content at sub-G1 phase, which is 
a major characteristic of late apoptosis and tumor growth inhibition (Riccardi and 
Nicoletti, 2006; Kajstura et al., 2007). Similar results were observed in Annexin V/PI 
staining experiment indicating that most cells were stained with Annexin and then PI. 
This is due to the fact that in necrotic or late apoptotic phases the plasma and nuclear 
membranes lose their integrity and permeability, thus, allowing PI to penetrate into the 
cell and stain the nucleic acids. The flow cytometry of the pentane-based fractions of 
Daucus carota was conducted by Shebaby et al in 2015 to identify the cell cycle arrest 
and apoptosis induction against HT-29 colon cancer cell line. The results showed that F1 
and F2 sub-fractions caused accumulation of the cell content in the sub-G1 phase with 
reduction of cell content in the S and G2/M phases, indicating cell cycle arrest in sub-G1 
phase. Similar results were obtained in the Annexin V/PI staining-based flow cytometry, 
where cell content was accumulated in the upper right or late apoptotic region (Shebaby 
et al., 2015a). The comparison of our results on SW1116 cell line using HC with those of 
Shebaby et al (2015) on HT-29 colon cancer cell lines using the sub-fraction of DCOE 
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containing around 60% HC, shows similar effects on the cell cycle, indicating an 
apoptotic effect of HC after inducing cell cycle arrest. 
Apoptosis, mediated by the extrinsic and intrinsic pathways, includes a panel of 
pro- and anti- apoptotic proteins that regulate the flow of the signaling cascade, ending in 
cell death and is usually evaded in cancer cells due to a mutant p53 or an up-regulation of 
the anti-apoptotic protein Bcl-2 (Giampazolias and Tait, 2016). For this reason, it was 
important to examine the apoptotic markers to confirm apoptosis induction in response to 
HC treatment. The tumor suppressor p53 is known as the ‘genome guardian’ due to its 
fundamental role in response to DNA damage and in maintaining genomic stability. The 
activation of p53 protein can lead to cell cycle arrest, senescence and apoptosis (Mirza et 
al., 2003; Yeo et al., 2016). P21 is a powerful cyclin-dependent kinase (CDK) inhibitor, 
well-known for inducing growth arrest and mediating cell senescence (Gartel and 
Radhakrishnan, 2005) and activated p53 triggers the activation of WAF1/CIP1 gene 
encoding for p21, which in turn binds to and inhibits the G1-S/CDK2 and S/CDK 
complexes, which are essential for the G1/S transition in the cell cycle. Therefore, an 
increase in p21 level leads to the inhibition of the G1-S/CDK2 and S/CDK activity and 
causes cell cycle arrest in G0/G1 phase (Koljonen et al., 2006). In the present study, the 
level of p53 and p21 proteins significantly increased after treatment with HC, leading to 
cell cycle arrest in G0/G1 (Sub-G1) phase showing that HC induces apoptosis partly via 
activation of p53/p21.   
The present results also revealed an increase in the pro-apoptotic protein Bax 
along with a decrease in the anti-apoptotic protein Bcl-2. This significant increase in the 
Bax/Bcl-2 ratio could be directly responsible for the induction of apoptosis through the 
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intrinsic apoptotic pathway (Hoshyar et al., 2013; Zhu et al., 2015) leading to increased 
cell death and thereby inhibition of proliferation and tumor growth. Decreases in pro-
Caspase-3 protein and in the anti-apoptotic protein PARP giving rise to its cleaved form 
(cleaved PARP) were also detected, further supporting that HC induces apoptosis through 
the extrinsic apoptotic pathway (Bai and Zhu, 2006; Chaitanya et al., 2010) and 
ultimately inhibiting tumor growth.  
In order to gain insight into the signaling pathways through which HC could be 
exerting its (apoptotic) effect, the main two survival pathways in the SW1116 cells were 
examined. The mitogen-activated protein kinases (MAPK/ERK) pathway plays the main 
role in a range of cellular processes including cell proliferation, survival and apoptosis. 
Constitutive activation of ERK has been implicated in cancer development in different 
types of malignancies (Dhillon et al., 2007; Yang et al., 2013) and down-regulation of 
phosphorylated-Erk (p-Erk) is also highly correlated with apoptosis (Cagnol and 
Chambard, 2010). In the present study, a significant decrease in p-Erk was observed, 
along with a decrease in the p-Erk/ Erk ratio, indicating that HC induces apoptosis partly 
via the inhibition of the MAPK pathway. The PI3K/AKT pathway is also an important 
intracellular signaling pathway that plays a major role in regulating cell differentiation, 
proliferation, survival, metabolism and apoptosis (Gupta et al., 2007; Porta et al., 2014a). 
One of the main downstream effectors of PI3K  is Akt, which upon activation enhances 
the phosphorylation of different proteins involved in cell proliferation and survival (New 
and Wong, 2007) and down-regulation of p-Akt is associated with apoptosis induction 
(Chen et al., 2008; Huang et al., 2012). In this study a significant decrease in the level of 
p-Akt was observed along with a decrease in the p-Akt/ Akt ratio, indicating that HC 
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induces apoptosis partly via the inhibition of the PI3K pathway. Similar results were 
obtained when the DCOE F2 fraction was used with the HT-29 colon cancer cell line 
(Shebaby et al., 2015a) confirming the involvement of this pathway. A down-regulation 
of p-Akt level has also been observed in Bortezomib- (an approved anticancer drug) 
inducing apoptosis in hepatocellular carcinoma cells (Chen et al., 2008) also confirming 
that this is an important and a feasible pathway for treatments to be targeted to.  
The effect of HC on colon cancer in vivo was established using the DMH-induced 
murine colon carcinogenesis model, which shares many morphological and molecular 
similarities to human sporadic colon adenocarcinomas (Perše and Cerar, 2010). In order 
to achieve a high rate of cancer incidence in mice, and due to the fact that DMH 20mg/kg 
was not enough to lead to colon cancer appearance after 8 weeks of treatment, it was 
necessary to treat the animals with a higher dose of DMH (30 mg/kg/week) and for a 
longer period (17 weeks) before any drug treatment, as it is a dose and time-dependent 
process (Jackson et al., 1999; Toth, 2003; Perše and Cerar, 2010). As a result of DMH 
toxicity, significant numbers of animals were lost during the experiment, the fact that 
might limit the feasibility of the results observed. Previous studies have reported a similar 
death rate upon treatment with 20 mg/kg/week of DMH for a period of 24 weeks 
(Castleden and Shilkin, 1979), where the mice developed ascites, pleural effusion and 
nodular livers. This high death rate observed upon long term treatment with DMH can be 
interpreted by the fact that DMH is derived from the natural toxin ‘cycasin’ which is 
highly toxic to the liver, kidneys, adrenal glands and the heart (Visek et al., 1991).  
Treatment of animals with HC at 10 and 25mg/kg for eight consecutive weeks 
after 17 weeks of DMH injection, showed no significant hepatotoxicity as determined by 
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lower levels of liver enzyme activities compared to DMH and DMSO. Moderate 
hepatotoxicity was observed at 50mg/kg HC. It is likely that the treatment of mice with 
DMH is behind the liver toxicity observed in this model rather than treatment with HC, 
where in the previous experiment mice were treated with DMH for 8 weeks and all of 
these groups exhibited significant increases in the level of AST, ALT and ALP, however, 
no significant increase in ALP activity was observed in HC50 treated group. In addition, 
where the treatment with HC50 began 3 days before DMH injection (group V), there was 
a relatively lower liver enzyme level than in other DMH-treated groups, with the largest 
drop recorded in the activity of the liver enzyme ALP. Taken together, this may indicate 
a hepato-protective role for HC.  
DMH treatment of mice caused a significant increase in the antioxidants CAT and 
GST activities due to its strong oxidative effect (Van Nieuwenhove et al., 2011). When 
HC50 treatment was given 3 days before DMH injection, the levels of GST were lower 
than other DMH treated groups which also could be correlated with the hepato-protective 
activity of HC. Similar results were reported when investigating the antioxidant effect of 
Curcumin in DMH-induced colon cancer, where the levels of CAT and GST increased 
after DMH injection and then the addition of Curcumin to DMH caused a decrease in 
their levels, indicating a strong oxidative effect of DMH and an antioxidant effect of 
Curcumin (Hussein, 2014).   
HC treatment was also shown to be effective against chemically-induced colon 
carcinogenesis. The tumor size and the percent survival of mice found histopathologically 
with cancer were lower in all HC and Cisplatin treated groups as compared to the control 
group. An incidence of cancer of 100% was observed in the control group as compared to 
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the Cisplatin treated mice (75%) and HC treatment reduced this further at all 
concentrations tested (67%, 83% and 0% respectively for the 10, 25 and 50mg/kg). With 
respect to the tumor size, there were 74%, 81%, 63% and 100% reductions in tumor size 
for Cisplatin and HC treated mice (10, 25, 50mg/kg.bw) respectively. The hepato-toxicity 
was absent in HC10 and 25mg/kg groups, while group V (HC50) displayed an 
insignificant increase in AST and ALP activities, a finding which could be related to liver 
injury caused by frequent intraperitoneal HC injections. This is supported by the data 
obtained from the subsequent experiment using Silymarin in conjunction with DMH/HC 
treatment. Cisplatin also showed normal AST and ALT liver functions, while the ALP 
enzyme increased significantly. Cisplatin is known to induce renal toxicity by injuring 
the kidney microtubules. Hepatotoxicity can also be associated to Cisplatin treatment and 
expressed by elevated liver enzyme levels, high bilirubin associated with jaundice, and 
elaborated histopathologically by the presence of injured and apoptotic hepatocytes 
characterized by karyomegaly and pyknotic nuclei with irreversible condensation of 
chromatin (El-Sayyad et al., 2009).    
Due to the high level of liver toxicity in the 17 week DMH-induced 
carcinogenesis experiment, which may have resulted in significant loss of animals, 
another experiment was conducted in the presence of Silymarin, a hepatoprotective drug 
that could potentially relieve the animals from liver toxicity. Silymarin, a liver protector, 
is a mixture of flavonolignans (Silybin A and B, silydianin, silycristin, isosilybin A, and 
B, isosilycristin, and taxifolin) and is extracted from the seeds of milk thistle (Silybum 
marianum Gaertneri) (Ferenci, 2016). It is known to possess strong antioxidative 
properties, which makes it useful in treating chronic liver diseases caused by oxidative 
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stress, such as drug- and chemical-induced hepato-toxicity. Silymarin exerts its 
antioxidant effect by promoting hepatocyte regeneration, reducing inflammatory 
reactions and inhibiting fibrogenesis in the liver (Feher and Lengyel, 2012). The length of 
DMH treatment (16 weeks) was chosen to simulate the previously performed experiment 
that assessed the anticancer effect of HC. The results revealed that Silymarin treatment 
offered a non-significant liver protection in the majority of the treated groups when 
assessing liver enzymes activity, and a significance of p˂0.05 was only limited to Cis+S 
and Cis+HC+S groups when assessing ALT activity, and to HC+S and Cis+HC+S groups 
when assessing ALP activity. The percentage of mice survival, however, was not 
significantly affected in Silymarin treated groups, and especially in HC50 treated mice 
where there was a drop in the percent of surviving mice treated with Silymarin, thereby 
confirming the lack of hepato-toxicity at high concentration of HC (50mg/kg). The 
concomitant treatment of HC50/S indicated that this is the most effective method for 
cancer treatment (in this model) which not only resulted in a lower incidence of cancer 
(25%) but was also associated with a low incidence of kidney interstitial inflammation. 
Another possible regimen for treatment was to combine Cis1.25/HC25/S which resulted 
in a low tumor incidence (33%) and low renal inflammation (29%). These two potential 
regimens also exhibited a significantly lower ALP activity when compared to control 
treated DMH-induced carcinoma mice. This relatively lower incidence of cancer 
formation in the combined drugs HC50/S or Cis1.25/HC25/S may be in correlation with 
the potential anticancer or chemoprotective role attributed to Silymarin (Feher and 
Lengyel, 2012).  These findings require further investigation to elaborate on the possible 
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synergistic effect of the combination of HC treatment with Silymarin or of HC and 
Cisplatin treatment together with Silymarin.  
While comparing the results of the three DMH-inducing murine colon 
carcinogenesis experiments, it was obvious that the time frame of DMH treatment is 
highly crucial for mice survival as shown in table 4.4. Beyond a period of sixteen weeks 
of treatment with DMH (30mg/kg), the mice survival dropped significantly from 89% or 
100% (experiment III) with or without Silymarin respectively to 30% (experiment II) in 
the HC treated group, and from 89% to 70% in the control group. In experiment I where 
animals were treated for a period of 8 weeks with DMH (20mg/kg), the mice survival 
was maintained at 100% in all groups. Such findings are in coordination with previous 
reports showing that mice survival upon DMH treatment is time and dose-dependent 
(Jackson et al., 1999; Perše and Cerar, 2010; Abd-Elmoneim et al., 2013). Although 
treatment with Silymarin showed a non-significant benefit on liver enzymes activity with 
HC treatment, the incidence of cancer dropped from 67% (experiments II and III) to 25% 
when animals were treated with Silymarin in combination with HC (experiment III). The 
use of Silymarin concomitantly with HC, therefore, provided a significant benefit when 
used for treatment of chemically-induced colon cancer in mice. 
Cisplatin is well known for its nephro-toxicity, since it causes injury to renal 
epithelial cells leading to renal dysfunction (Miller et al., 2010). Therefore, combination 
therapy with HC may provide a possible solution to this problem by decreasing its 
relative cytotoxicity. Many studies have tried to reduce Cisplatin-induced nephro-toxicity 
by glycation, which reduces the renal Organic Cation Transporter 2 (OCT2) expression 
(Thomas et al., 2004). OCT2 is responsible for renal clearance of drugs. Another 
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potential approach is via improving the body hydration with excessive normal saline and 
electrolyte replacement to increase renal excretion and reduce Cisplatin renal toxicity 
(Dumas et al., 1990).    
The histopathological analysis revealed excessive renal damage in all groups 
treated with Cisplatin alone, whereas, there was no toxicity in the HC-treated group and 
minimal renal toxicity in the HC/S or gavage HC/S groups. A significant reduction in the 
Cisplatin-induced toxicity was observed in all groups treated concomitantly with 
Cisplatin and HC. These histopathological results confirm the kidney protective role of 
HC, and a possible solution of the Cisplatin-induced nephrotoxicity. 
In conclusion, HC has the potential to act as a potent anticancer drug that exhibits 
antitumor activity against various colon cancer cell lines and in murine models of colon 
cancer. It appears to exert its anti-proliferative effect via promoting late apoptosis and 
necrosis through partial inhibition of the two main cellular survival pathways: the PI3K 
and the MAPK pathways. The anticancer activity also translated in the DMH colon 
carcinogenesis model with HC showing no significant toxicity to laboratory mice at the 
doses used. This suggests that HC could potentially be used as an adjunct to conventional 
chemotherapeutic agents, by reducing the nephrotoxicity effect as in Cisplatin 
combination, or by lowering the cancer formation incidence as seen when Cisplatin was 
combined with HC and Silymarin.  
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Chapter 5- The anticancer activity of HC on HaCaT-ras II-4 cancer 
cells and the DMBA/TPA murine model of skin carcinogenesis 
5.1 Rationale and Aims  
  
 Skin cancer is one of the commonest cancer types in the world accounting for 
about 40% of diagnosed carcinomas (Leiter and Garbe, 2008). Despite advances in 
chemotherapy and immunotherapy complete disease remission is not often achieved, 
therefore, there is still a need for in vitro and in vivo investigation of potential novel 
therapies. The human epidermal cancer cell line HaCaT-ras II-4 can induce the formation 
of squamous cell carcinoma lesions that highly resemble human skin squamous cell 
carcinoma in terms of morphology (Boukamp et al., 1988; Mueller et al., 2001). 
Although this has enabled scientists to test the anticancer properties of new compounds in 
vitro, a more physiological model is required to investigate the anticancer activities in 
vivo. To this end, the DMBA/TPA (7,12-dimethyl-benz[a]anthracene/ phorbol ester 12-
O-tetradecanoylphorbol-13 acetate) chemical tumorigenesis model has been widely used 
in promoting mouse skin squamous cell carcinoma (SCC). It highly resembles human 
SCC (Yuspa, 1998; Indra et al., 2007), allows an accelerated rate of tumor growth and 
yields clear differences in tumor appearance and size. Whilst two reports investigating 
the effect of DC crude oil and fraction 2 on DMBA/TPA-induced skin cancer have been 
published (Zeinab et al., 2011), the potential effect of the most active component of these 
preparations (HC) has not been tested in these models.  
Zeinab et al (2011) investigated the effect of HC using three modes of DCOE 
treatment (gavage, intraperitoneal and topical). Both IP and topical treatments were found 
to be the methods of choice for protection against the DMBA/TPA-induced skin cancer. 
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The present study, therefore, aimed to investigate the anticancer effect of HC on the 
HaCaT-ras II-4 cell line and DMBA/TPA skin carcinogenesis model and elucidate the 
mechanism of action involved. This was achieved by assessing cell viability, cell cycle 
arrest, apoptotic markers as well as the level of Erk/p-Erk (MAPK pathway) and Akt/p-
Akt (PI3K pathway) proteins. The effect of HC (IP and topical) treatment on papilloma 
yield, incidence, volume and pathology was also explored.    
 
5.2 Results 
5.2.1 The effect of HC on the HaCaT-ras II-4 epidermal cancer cell line viability 
 
In order to investigate the effect of HC on cell viability, HaCaT-ras II-4 cells were 
treated with HC or Cisplatin, and the percent cell viability was measured using the WST-
1 cell viability assay. A single time point of 48 hours of treatment was selected since 
studies on colon cancer cell lines (chapter 4) indicated that the maximal effect of HC on 
cell viability occurred at this time.   
A dose-dependent decrease in cell viability upon HC treatment (1-50μg/ml) with 
an IC50 and IC90 of 8 and 35µg/ml respectively was observed (figure 5.1). Similarly, there 
was a significant decrease in the mean percentage cell survival after treatment with 
Cisplatin (5µg/ml; p˂0.01) alone or the combination of Cisplatin and HC (5µg/ml, 
10µg/ml respectively; p˂0.001) when compared to DMSO treated cells.  
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Figure 5. 1 The effect of HC on cell viability of an epidermal cancer cell line. HaCaT-ras II-4 
cells were treated for 48 hours with HC (1, 5, 10, 25, and 50µg/ml), with 0.5% DMSO, and 
compared to Cisplatin 5µg/ml and Cis5/HC10µg/ml, and followed by measurement of cell 
viability using the WST-1 assay. Data are expressed as percentage of cell survival and are mean ± 
SEM for three independent experiments, where * denotes P ˂0.05, **P ˂0.01 and ***P ˂0.001 
versus the DMSO group, as measured by one-way ANOVA.    
 
5.2.2 The effect of HC on cell cycle and apoptosis in HaCaT-ras II-4 cells 
 
  As described in chapter 4, HC (10 and 25µg/ml) induced cell cycle arrest of 
SW1116 colon cancer cells and therefore, its effect  on the cell cycle of the HaCaT-ras II-
4 skin cancer cells was investigated by flow cytometry to quantify the DNA content of 
cells in different phases of cell cycle 48 hours post treatment.  
Treatment of HaCaT-ras II-4 cells with 10µg/ml of HC significantly increased the 
percentage of cells in the G1 phase compared to DMSO treated cells (p˂0.01). This 
elevation was accompanied by a significant drop in both the percentage of cells in the S 
and G2/M phases (p˂0.01 in HC10 and p˂0.001 in HC25 treated cells). Moreover, 
increasing the concentration of HC to 25µg/ml caused a significant increase in the 
percent DNA count in the Sub-G1 phase compared to both control and DMSO treated 
cells. This was also accompanied by significant decrease of cell in both the S and G2 
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phases (p˂0.001) (figures 5.2A, 5.2B) indicating that the majority of cells were 
undergoing apoptosis. 
  
Figure 5. 2 The effect of HC (10µg and 25µg) on the cell cycle distribution of HaCaT-ras II-
4 cells. (A) Cells treated (48 hours) with either 10µg or 25µg/ml HC and compared to control 
with or without 0.5% DMSO. The cells were then stained with Propidium Iodide (PI) and 
analyzed for DNA content by Flow Cytometry. The sub-G1 peak represents the apoptotic portion. 
(B) Percent of cell distribution of each phase of the cell cycle. The control group is represented by 
light brown, the DMSO group by white, the HC10 by grey and the HC25 by dark grey. Data are 
mean ± SEM of three independent experiments, where * denotes P < 0.05, ** denote P< 0.01 and 
*** denote P< 0.001 vs DMSO group, as measured by one-way ANOVA.    
In order to determine the percentage of cells undergoing apoptosis and/or 
necrosis, cells were stained with Annexin and Propidium Iodide (PI) and analyzed for 
their uptake of these dyes by flow cytometry. Treatment of HaCaT-ras II-4 cancer cells 
with 10µg/ml of HC caused a significant increase in the percentage of cells undergoing 
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late apoptosis (28%) (p˂0.05), while no significant change in the percentage of cells in 
the necrotic phase (16%) was observed. Whereas increasing the concentration of HC to 
25µg/ml caused a significant shift in the percentage of cells undergoing both late 
apoptosis (46.6%) (p˂0.01) and necrosis (39%) (p˂0.05) (figures 5.3A, 5.3B).      
   
Figure 5.3 Apoptotic effect of HC on HaCaT-ras II-4 cells. (A) Representative flow cytometric 
analysis of Annexin V-FITC and propidium iodide (PI) staining for apoptosis in HaCaT-ras II-4 
cells treated with 0.5% DMSO, 10 or 25μg/ml HC for 48 hours. Viable cells are located in the 
lower left (LL) quadrant (negative for both Annexin V and PI). Early apoptotic cells were found 
in the lower right (LR) region (Annexin V positive). Late apoptotic cells with extensive cellular 
and nuclear membrane damage were located in the upper right (UR) quadrant (double positive). 
Necrotic cells with heavily destroyed cell membrane were in the upper left (UL) region (PI 
positive). The results shown are representative of three independent experiments. (B) Mean 
percentage of cells in each quadrant in non-treated versus treated HaCaT-ras II-4 cells. The 
DMSO group is represented in white, the HC10 group in grey and the HC25 group in dark grey. 
Data are Mean ± SEM of three independent experiments, where * denotes P < 0.05 and ** denote 
P< 0.01 in comparison to the DMSO treated cells, as measured by one-way ANOVA.     
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In order to determine the mechanism of action behind the observed increases in 
apoptosis of HaCaT-ras II-4 cells treated with HC, the levels of key pro- and anti-
apoptotic proteins involved in apoptosis were determined using Western blot analysis and 
densitometry. The levels of expression of these proteins were expressed as a ratio over 
the loading control actin.  
A significant decrease in the level of p53/actin was observed in the p53 mutated 
HaCaT-ras II-4 cells (p˂0.01 and p˂0.001 for the HC10 and HC25 treated cells 
respectively) and a significant increase in the level of p21/actin was observed (p˂0.01). 
Levels of the anti-apoptotic protein Bcl-2/actin had significantly decreased after cell 
treatment with HC at 25μg/ml (p˂0.01), while no significance was observed in cells 
treated with HC at 10μg/ml. This was accompanied with a significant increase in the level 
of the pro-apoptotic protein Bax/actin (p˂0.01) for both concentrations. Moreover, the 
ratio of Bcl-2/Bax was significantly decreased in cells treated with HC at 10 and 25 
μg/ml (p˂0.01 and p˂0.001 respectively). Finally, the level of expression of active 
Caspase-3/actin (cleaved Caspase) was increased significantly in cells treated with HC at 
10 and 25μg/ml (p˂0.01and p˂0.001respectively, figures 5.4A and 5.4B).     
In order to evaluate the effect of HC treatment on the two main survival pathways 
(PI3K and MAPK) in HaCaT-ras Il-4 cells, the levels of phosphorylation of the proteins 
Erk and Akt were analyzed. A significant decrease in the ratios of p-Erk/Erk and p-
Akt/Akt were observed in cells treated with HC at 10 and 25μg/ml (p˂0.05 and p˂0.01 
respectively, figures 5.4A and 5.4B). These decreases reflect a reduction in the activity of 
both the PI3K and MAPK pathways following treatment with HC.  
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Figure 5.4 The effect of HC on apoptotic markers and the survival pathway. (A) 
Representative western blots of HaCaT-ras II-4 cells treated with either DMSO (control) or 10 or 
25µg/ml of HC for 48 hours and probed for the levels of cleaved Caspase-3 (17 KDa), p53 
(53KDa), p21 (21KDa), Bax (23 KDa), Bcl-2 (26 KDa), Erk (40 KDa), p-Erk (44 KDA), Akt (55 
KDa) and p-Akt (60 KDa). Protein bands were identified using the ‘Precision Plus Protein 
Kaleidoscope Standards’ (BIO-RAD, CA, USA). β-Actin (42 KDa) levels were used as an 
internal protein loading control.  (B) Mean ± SEM densitometer-intensity data of the levels of 
protein/actin from three independent experiments, where * denotes P ˂ 0.05, ** denote P˂0.01 
and *** denote P˂0.001, compared to 0.5 % DMSO as the negative control, as measured by one-
way ANOVA. 
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5.2.3 The effect of HC on the expression of markers of apoptosis in skin papilloma 
cells from mice with DMBA/TPA-induced skin cancer  
 
In order to determine whether the mechanism of action behind apoptosis in cells 
from mice with DMBA/TPA-induced papillomas treated with HC is similar to that 
observed in the HaCaT-ras Il-4 cells in vitro model, the levels of pro- and anti-apoptotic 
proteins were determined in isolated skin papillomas using Western blot analysis. In 
order to identify the optimum dose that induces tumor shrinkage three IP doses of HC 
were used (HC10, 25 and 50mg/kg). In addition, a topical application of 5% HC was 
applied in order to assess the effect of local treatment. Mice treatment with HC and 
Cisplatin was initiated concomitantly with TPA, thirty minutes before TPA application, 
for a period of 20 weeks. The levels of the same range of apoptotic markers were 
measured in the murine cells as the human experiments as these have been reported to be 
essential for identifying the safe starting doses for phase I protocols (Talmadge et al., 
2007).   
 Similar patterns of the levels these proteins were observed in comparison to the 
in vitro study, with the exception of the levels of expression of the p53 protein where 
significant increases in the levels of p53/actin expression were observed in animals 
treated with HC at 10, 25, 50 mg/kg and with the 5% topical application (p<0.01, p<0.01, 
p<0.001 and p<0.001 respectively) in comparison to DMSO treated animals. Significant 
increases in the levels of p21/actin (p˂0.05 for HC10 and p˂0.01 for HC25, 50 and 5% 
topical HC), Bax/actin (p˂0.05 for HC10 and 5% topical HC, p˂0.01 for HC25 and 
p˂0.001 for HC50) and active Caspase-3/actin (p˂0.05 for HC10 and 25 and p˂0.01 for 
HC50) were also detected in comparison to DMSO treated animals. However, 5% topical 
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application of HC resulted in no significant difference in the levels of active Caspase-
3/actin when compared to the negative control (DMSO treated animals). These changes 
in the levels of these proteins were accompanied by a simultaneous decrease in the level 
of Bcl-2/actin (p˂0.01) and in the ratio Bcl-2/Bax (p˂0.01) at all concentrations tested. In 
addition, there was a significant decrease in the ratio of p-Erk/Erk (p˂0.05 in HC25 and 
5% topical HC and p˂0.01 in HC10 and HC50) and p-Akt/Akt (p˂0.05 in 5% topical HC 
and p˂0.01 in HC10, 25 and 50; figure 5.5). 
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Figure 5.5 The effect of HC on apoptotic and survival pathway markers in an in vivo 
murine model of chemically induced skin cancer. (A) Representative western blots of the 
levels of apoptotic proteins in cells from skin papillomas taken from mice treated with either 
DMSO (control), 10, 25 or 50mg/kg HC or 5% topical HC for 20 weeks and probed for the levels 
of cleaved Caspase-3, p53, p21, Bax, Bcl-2, Erk, p-Erk, Akt and p-Akt. Protein bands were 
identified using the ‘Precision Plus Protein Kaleidoscope Standards’ (BIO-RAD, CA, USA). β-
Actin levels were used as an internal protein loading control. (B) Mean ± SEM densitometer-
intensity data of the level of proteins/actin from three independent experiments, where * denotes 
P ˂ 0.05, ** denote P˂0.01 and *** denote P˂0.001, compared to 0.5 % DMSO as negative 
control, as measured by one-way ANOVA. 
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5.2.4 Investigation into the protective effect of HC on the development of papillomas 
in the DMB/TPA murine model of chemically-induced skin cancer 
 
 In order to evaluate the protective effect of HC on DMBA/TPA-induced skin 
carcinoma, papilloma development was monitored in mice for a period of 20 weeks 
(Indra et al., 2007; Zeinab et al., 2011). Previous similar in vivo studies using the Daucus 
carota crude oil extract (Zeinab et al., 2011) showed that the topical and IP modes of 
treatment were more effective than gavage, and therefore, they were adopted in the 
present study.    
At week 20, all groups treated with HC (IP or topically) exhibited significant 
decreases in papilloma yield (papillomas per mouse, p˂0.001, figure 5.6A), incidence 
(percentage of mice per group bearing papillomas, figure 5.6 B), and papilloma volume 
(p˂0.05 for HC10 and 25 and p˂0.01 for HC50 and 5% HC topical; figure 5.6C) when 
compared to DMSO treated mice. Similar effects were observed in animals treated with 
Cisplatin alone, however, this did not reach significance for papilloma volume when 
compared to the DMSO treated mice (p˂0.001 for tumor yield). Comparison of the HC 
treated mice with the Cisplatin treated animals, showed no significance in the papilloma 
yield (figure 5.6A) and the incidence for the Cisplatin treated group was similar to that in 
the HC25 and 5% topical HC treated groups (figure 5.6B).  
Murine survival throughout the experiment is displayed in figure 5.6D. Both the 
control and 5% topical HC treated groups of mice exhibited similar survival rates of 50% 
at week 20. The IP HC treated groups (10, 25 and 50mg/kg) displayed increased survival 
rates (75%) and the Cisplatin group showed the lowest survival rate (25%).   
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Figure 5. 6 The effect of HC on tumour yield, incidence, volume and murine survival rates 
in the murine DMBA/TPA-induced murine model of skin cancer. The effect of 20 weeks of 
treatment of HC and Cisplatin on papilloma (A) yield (B) incidence, (C) volume (mean ± SEM at 
week 20) and (D) mouse survival  in the DMBA/TPA-induced murine model of skin cancer 
mouse. In A, B and D the control group is black, the HC 10, 25, 50 and 5% topical are 
represented in red, green, violet and light blue respectively and the Cisplatin group is orange.  * 
denotes P < 0.05, ** denote P <0.01 and *** P<0.001 when compared to 0.5 % DMSO as a 
control, as measured by one-way ANOVA.  
 
 
 
Cachexia is an involuntary weight loss associated with lipid metabolism 
alterations, causing lipodystrophy, fatigue, weakness, loss of appetite and muscle 
atrophy. In cancer patients, cachexia is related either to the cancer itself or to 
chemotherapy drugs (Garcia et al., 2013; Lobina et al., 2014). In order to assess the 
influence of HC on cachexia, mice body weight was measured at weeks 0, 12, 16 and 20 of 
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the experiment. Unlike the Cisplatin treated group which showed a significant decrease in 
body weight observed by weeks 12, 16 and 20 when compared to the control group 
(p<0.05), the HC treated groups of mice did not show any significant change in body 
weight over the experimental period (figure 5.7).    
 
   
Figure 5.7 Body weight of HC treated DMBA/TPA-induced murine model of skin cancer. 
Mean ± SEM body weight measured at weeks 0, 12, 16 and 20. Week 0 is represented by white 
bars, week 12 by light grey bars, week 16 by dark grey bars and week 20 by black bars, where * 
denotes P < 0.05 compared with baseline body weight (day 0) as measured by one-way ANOVA.  
 
At the end of the experiment, surviving mice were sacrificed and all tumors larger 
than one millimeter in diameter were dissected and subjected to histopathological 
analysis as described in 2.13.  
All tumors isolated from animals in the control group displayed incidence of 
squamous cell carcinoma. These atypical cancer cells were characterized by the presence 
of a high Nucleo-Cytoplasmic (N/C) ratio, prominent nucleoli and pleomorphism in their 
shape, the presence of keratin pearls (keratinized structures mainly found in regions of 
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atypical squamous cells forming concentric layers, figure 5.8B). In the Cisplatin group, 
one of the two surviving mice was free from papilloma, while the lesions in the other 
mouse were free of carcinoma (figure 5.8D). The HC treated mice exhibited a relative 
low incidence of squamous cell carcinoma ranging between 33% (HC10, HC25 and 
5%HC topical) and 50% (HC50) (figure 5.8C).    
 
Figure 5.8 Histopathological analysis of the effect of HC on the development of squamous 
cell carcinoma in the DMBA/TPA-induced murine model of skin cancer. Representative 
images from H and E staining of sections from papillomas removed from mice treated topically 
with DMBA, followed 3 weeks later by the topical application of TPA for 20 weeks followed by 
treatment with DMSO (negative control), IP HC (10, 25 and 50mg/kg), IP Cisplatin (2.5mg/kg) 
as a positive control and was maintained for 20 weeks. (A) The arrow in the micrograph indicates 
normal epidermal cells of a non-treated mouse (no DMBA/TPA application). (B) Atypical cells 
with high N/C ratio, prominent nucleoli and pleomorphism in cancer cells (upper and lower left-
hand arrows), and keratin pearls (right-hand arrow) DMBA/TPA DMSO treated mouse. (C) 
Regular epidermal cells in HC treated mice. (D) Regular epidermal cells in Cisplatin treated mice. 
All images are 20x magnification. 
 
The percentage of surviving mice and the percentage of surviving mice with 
histopathologically confirmed squamous cell carcinoma at week 20 are shown in figure 
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5.9. In the control group, 100% of the surviving mice (50%) developed cancer. In the HC 
treated groups, 75% of all groups with IP injections (HC10, 25 and 50mg/kg) survived 
until the end of the experiment with cancer prevalence of 33% in HC10 and HC25 and 
50% in HC50. In the 5% topical HC group, 50% of the mice survived until the end of the 
experiment with 50% cancer incidence. In the Cisplatin group only 25% of mice survived 
(2 out of 8) until the end of the experiment and their excised papillomas were free of 
squamous cell carcinoma.   
 
 
Figure 5. 9 Survival and incidence of squamous cell carcinoma in mice treated with HC in 
the DMB/TPA-induced murine model of skin cancer. The effect of 20 weeks of treatment of 
HC and Cisplatin on survival and cancer presence in the DMBA/TPA-induced murine model of 
skin cancer. The percent survival at week 20 is represented by light grey and the percentage of 
mice bearing histopathologically detected squamous cell carcinoma is represented by dark grey.   
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5.2.5 Investigation into the therapeutic effect of HC on the development of 
papillomas in the DMB/TPA murine model of chemically-induced skin cancer 
 
In order to assess the (therapeutic) effect of HC on DMBA/TPA-induced skin 
carcinoma, the present experiment was conducted. Mice were treated topically with DMBA, 
followed after 3 weeks by TPA topical application for 18 weeks. The negative control group 
included DMSO treatment. Treatment with HC (5%HC topical and HC 25mg/kg IP) and 
Cisplatin 2.5mg/kg IP (positive control) was initiated from week 12 and maintained until the end 
of experiment (week 18). Papilloma promotion in mice was observed all over the study 
period and the treatment with either HC or Cisplatin started at week 12 as described in 
2.11 in order to evaluate the therapeutic effect of HC after papilloma induction. The 
estimation of the papilloma volume was performed according to specific reference 
volume models provided by our labs (Zeinab et al., 2011).      
 A gradual but significant decrease in the papilloma yield (number of 
papillomas/mouse) in mice treated with either HC or Cisplatin was observed over the 18 
weeks of the experiment (figure 5.10A). At week 14 only the 5%HC topically treated 
group showed a significant decrease in papilloma yield (p˂0.05), at week 16 the number 
of papillomas per mouse was also reduced in the 5%HC Topical, HC25 and Cisplatin 2.5 
treated animals (p˂0.01, p<0.05 and p˂0.05 respectively) and at week 18 treatment with 
5%HC Topical, HC25 and Cisplatin 25 caused a significant decrease in papilloma yield 
in comparison to the control (DMBA/TPA DMSO treated) groups (p˂0.01 for all 
treatment groups).  
Assessment of papilloma volume (Figure 5.10B) between weeks 12 and 18 
revealed a consistent gradual increase in papilloma volume in the control group, whereas, 
at week 14, all treated groups (5%HC Topical, HC25 and Cisplatin 2.5) showed 
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regression in papilloma volume. This was significant for the 5%HC Topical treated group 
(p˂0.05). At week 16, all treated groups showed significant decrease in papilloma 
volume (p˂0.01 for HC25 and 5%HC Topical and p˂0.05 for Cisplatin 2.5). This 
significant decrease in papilloma volume was maintained until the end of the experiment 
in all treated groups of mice.  
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Figure 5. 10 The effect of HC on papilloma yield and volume with time in a DMBA/TPA-
induced murine model of skin cancer. The therapeutic effect of HC (topical and IP) and 
Cisplatin on papilloma yield (A) and volume (B) (mean ± SEM weeks 12 to 18) in the 
DMBA/TPA-induced murine model of skin cancer. In A, the control group is blue, the HC 
5%Top and 25mg/kg IP are represented in red and green respectively and the Cisplatin group in 
violet. The bars in figures B represent the control group (white), 5%HC Topical (light grey), 
HC25 (dark grey) and Cisplatin (black), where * denotes P < 0.05 and ** P˂0.01, compared to 
the DMSO treated control at the same week as measured by one-way ANOVA.    
Similarly to colon cancer, the liver is a prime target for toxicity from 
chemotherapy interventions and, therefore, the effect of HC on liver function in this 
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murine model of skin cancer was examined at the end of the experiment by determining 
the activity of the following liver enzymes: ALP, AST and ALT (as described in 2.11).  
Serum levels of both AST and ALP were comparable in the treated and control 
groups (Figure 5.11) and similar results were obtained for ALT except for a significant 
rise in the Cisplatin treated group (p<0.05). 
 
Figure 5. 11 The effect of HC on liver function test with time in a DMBA/TPA-induced 
murine model of skin cancer. Liver function as measured by the serum levels AST, ALT and 
ALP liver enzymes. Mean ± SEM enzyme activity of mice at week18. The bars represent the 
control group (white), 5%HC Top (light grey), HC25 (dark grey) and Cisplatin (black), where * 
denotes P < 0.05, compared to control at the same week as measured by one-way ANOVA.       
 
In order to assess the influence of HC on cachexia that may be induced by the 
drug, body weight was measured at weeks 12, 14, 16 and 18 of the experiment, and is 
presented in Figure 5.12. A significant decrease in body weight in the Cisplatin treated 
mice was observed by week 18 when compared to the control group (p<0.05), however, 
treatment of mice with HC did not cause any significant change in body weight over this 
period of time.   
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Figure 5. 12 The effect of HC on body weight with time in a DMBA/TPA-induced murine 
model of skin cancer. Mean ± SEM body weight of mice at 12, 14, 16 and 18 weeks. The bars 
represent the control group (white), 5%HC Top (light grey), HC25 (dark grey) and Cisplatin 
(black), where * denotes P < 0.05, compared to control at the same week as measured by one-way 
ANOVA.      
 
 
At the end of the experiment, all tumors that were bigger than one millimeter in 
diameter were dissected and subjected to histopathological analysis for signs of the 
development of SCC (as described in 2.12.3).  
Tissue from all the groups showed squamous cell carcinoma (SCC) development 
with disordered architecture and papillary proliferation of the squamous epithelium. The 
papillomas were cut longitudinally and transversely for histopathological assessment. 
Although the papillae of the HC and Cisplatin treated groups were relatively smaller than 
those of the control group, tumors of all groups were identified to have well differentiated 
SCCs with formation of keratin layers and nests of SCC invading the superficial dermis 
(figure 5.13). At high magnification, the cells were highly atypical with marked 
pleomorphism. They showed high nucleo-cytoplasmic (N/C) ratios with prominent 
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nucleoli and irregular nuclear contours. Numerous mitotic figures were also present 
which commensurate with the development of carcinoma (Figure 5.13). 
 
Figure 5. 13 Histopathological analysis of the effect of HC on DMBA/TPA-induced murine 
model of skin cancer.  Representative images from H and E staining of sections from papillomas 
removed from mice treated topically with DMBA, followed 3 weeks later by the topical 
application of TPA for 18 weeks followed by treatment with DMSO (negative control). IP HC 
(25mg/kg) and 5%HC Top treatment started at week 12. IP Cisplatin (2.5mg/kg) as a positive 
control also started at week 12, and treatment was maintained until week 18.  All (HC, Cisplatin 
and DMSO) treated papillomas showed the presence of squamous cancer cells. The arrows in (A) 
indicate disordered architecture (upper part of the figure) and papillary proliferation (lower part 
of the figure) of squamous cell carcinoma from a control (DMSO treated) sample. (B) The arrows 
indicate pleomorphism, prominent nucleoli and a high N/C ratio (left-hand arrow), and mitotic 
cells (right-hand arrow) in sections from a control (DMSO treated) sample. (C) The left arrow 
indicates keratin formation and the right arrow indicates papillary proliferation in squamous cell 
carcinoma from 5%HC Topical treated mice. (D) The left arrow indicates atypical proliferating 
cells and the right arrow dermis infiltration by similar atypical cells from a sample from HC25 
treated mice. The arrow in (E) indicates transverse and longitudinal papillae of SCC taken from a 
Cisplatin treated mouse. In (F), the left arrow indicates dermis infiltration by atypical cells and 
the right mitotic cells of a sample taken from a Cisplatin treated mouse. Slides were observed at 
the following magnifications: A, C and E at x10, and B, D and F at x40. 
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5.3 Discussion 
 
In chapter four, HC was shown to protect against chemically-induced colon 
cancer. Knowing that skin cancer accounts for about 40% of diagnosed carcinomas 
(Leiter and Garbe, 2008) and can be chemically-induced with DMBA/TPA in murine 
model, it was interesting to assess the effect of HC on such type of cancer. In the present 
study, therefore, the anticancer activity of HC was first examined against the invasive 
HaCaT-ras II-4 epidermal squamous cell carcinoma cell line, and then evaluated using 
the DMBA/TPA skin carcinogenesis murine model. 
As previously mentioned, the HaCaT-ras II-4 epidermal cancer cell line was 
selected to study HC anticancer activity because this model can lead to the appearance of 
squamous cell carcinoma lesions that highly resemble human skin squamous cell 
carcinoma in morphology (Boukamp et al., 1988; Mueller et al., 2001). Addition of HC 
to HaCaT-ras II-4 cells resulted in dose-dependent inhibition of cancer cell survival with 
an IC50 and an IC90 of 8 and 30µg/ml respectively at 48 hours post-treatment. 
Concomitant treatment by HC with Cisplatin showed better cytotoxicity of cancer cells 
than when each compound was used alone. Cisplatin is well known to cause 
nephrotoxicity, since it damages renal epithelial cells leading to renal dysfunction (Miller 
et al., 2010). For this reason, combining Cisplatin with HC may provide a possible 
solution to this problem by decreasing its relative renal toxicity as was shown in chapter 
4. Preliminary studies on HaCaT-ras II-4 cells in our lab showed that the IC50 value of 
Cisplatin was 4.6μg/ml. In the in vitro study, therefore, a dose of 5μg/ml of Cisplatin was 
used. In order to avoid Cisplatin induced nephro-toxicity upon long term treatment, a 
dose of 2.5mg/kg bw was adopted in the in vivo study (20 weeks). 
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Flow cytometric analysis of cell cycle change showed that HC treatment 
decreased the number of cells in the S and G2/M phases with an increase in Sub-G1 
phase. This was accompanied by a significant increase in cell accumulation in the G1 
phase. These cell cycle analysis data support the fact that, at low concentrations 
(10µg/ml), HC causes cell cycle arrest while inducing early apoptosis. At the higher 
concentration tested (25µg/ml), HC led to complete DNA fragmentation, as demonstrated 
by the assembly of the cell content at the sub-G1 phase, a major characteristic of late 
apoptosis (Riccardi and Nicoletti, 2006; Kajstura et al., 2007). These results are 
consistent with a dose-dependent induction of late apoptosis, indicating the promotion of 
cell death in the treated cancer cells. Similar results were obtained upon treatment of 
SW1116 colon cancer cells with HC (chapter 4) where a large number of cancer cells 
underwent cell cycle arrest. 
The mitogen-activated protein kinases (MAPK/ERK) pathway plays a major role 
in various cellar processes such as cell proliferation, survival and apoptosis. It is well 
established that activated Erk (p-Erk) is responsible for the high level of cell growth in 
different types of cancers (Dhillon et al., 2007; Yang et al., 2013) and that down-
regulation of p-Erk is highly related to apoptosis (Salminen et al., 2008). This is 
consistent with the western blot results presented in this chapter which revealed a 
significant decrease in the level of p-Erk proteins, implying that HC induces apoptosis 
partly via inhibition of the MAPK pathway. This is also in line with previous data on the 
effect of DCOE on HaCaT-ras II-4 cells, which showed similar inhibition of the MAPK 
pathway (Shebaby et al., 2017). The phosphatidylinositol-3-kinases (PI3K/AKT) 
pathway is another intracellular signaling pathway that plays a main role in regulating 
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cell proliferation and apoptosis (Gupta et al., 2007). Akt is a serine/threonine kinase that 
is known to be one of the major downstream effectors of the PI3K pathway. It leads to 
cell survival and inhibits apoptosis through the activation of the anti-apoptotic pathways 
and inactivation of the pro-apoptotic targets (Arboleda et al., 2003; Hartmann et al., 
2005). The data presented in this chapter has revealed that HC also caused a significant 
reduction in the phosphorylation of Akt, reflecting an inhibition of the PI3K/AKT 
pathway. These findings are also consistent with previous studies on HT-29 colon cancer 
cell line (Shebaby et al., 2015a), on the HaCaT-ras II-4 skin carcinoma cell line (Shebaby 
et al., 2017), as well as with our former work on SW1116 colon cancer cell line as 
discussed in chapter 4. 
The tumor suppressor protein p53 plays a fundamental role in response to DNA 
damage or other genomic instability. It is also well established that activation or an 
increase in the expression level of p53 can lead to cell cycle arrest or apoptosis (Mirza et 
al., 2003; Liu et al., 2004).  HaCaT-ras II-4 cells are p53 mutant (Boukamp et al., 1988). 
The proteins expressed by the mutant p53 gene hold incorrect amino acids that render 
them malfunctioning (Yan et al., 2011). Treatment of HaCaT-ras II-4 cells with HC led to 
a down-regulation in the protein level of the mutant p53. This may be explained through 
a possible decrease in the expression in the mutant p53 or an increase in its degradation. 
Similar results were obtained with Yan and colleagues (2011), where they studied the 
effect of Arsenic, a known cytotoxic agent, on p53 mutant HaCaT cell lines. Taking into 
consideration that mutant p53 is a malfunctioning protein, the cell cycle arrest and 
apoptotic cell death in HaCaT-ras II-4 cell lines, therefore, took place through a p53-
independent mechanism. 
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The protein p21 is a powerful cyclin-dependent kinase inhibitor that is well-
known to induce growth arrest and mediate cell senescence (Gartel and Radhakrishnan, 
2005). P21 is also considered a cell cycle regulatory protein that is able to cause cell 
cycle arrest through both p53-dependent and p53-independent mechanisms (Macleod et 
al., 1995; Gartel and Tyner, 2002; Liu et al., 2003). The results presented in this chapter 
showed that treatment of HaCaT-ras Il-4 cells with HC triggered a significant increase in 
the protein level of p21 independently of the mutated non-functional p53 (Macleod et al., 
1995; Elmore, 2007). Taken together these findings support the suggestion that cell cycle 
arrest and apoptosis in HaCaT-ras II-4 cells are mediated through the up-regulation of the 
expression of p21 in a p53-independent manner. 
The levels of several other apoptotic markers were also analyzed in order to 
elucidate the possible pathways involved in HC induced apoptosis. This included two 
major cell death regulatory genes: the anti-apoptotic protein Bcl-2 and the pro-apoptotic 
protein Bax. It has been established that the ratio of Bcl-2 to Bax proteins significantly 
drops during apoptosis (Los et al., 1999) and this is in agreement with the data presented 
in this chapter which revealed that HC treatment of HaCaT-ras II-4 cells caused an 
increase in the level of Bax and a decrease in Bcl-2 levels. Consequently, the ratio of Bcl-
2/Bax dropped significantly, which reflects apoptotic cell death through the intrinsic 
apoptotic pathway (Hoshyar et al., 2013; Zhu et al., 2015). Another protein family 
implicated in cell apoptosis is the Caspase family (Yang et al., 2002; McIlwain et al., 
2013). Treatment of HaCaT-ras II-4 cells with HC caused an increase in the activation of 
executioner Caspases, such as Caspase-3, which triggers proteolytic cleavage and 
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activation of several downstream protein targets leading to the activation of apoptosis 
(McIlwain et al., 2013).  
The chemopreventive activity of HC for skin cancer was assessed using the 
murine DMBA/TPA skin carcinogenesis model. Both topical and intraperitoneal 
treatments were effective in reducing the chemically-induced skin carcinogenesis as 
measured by papilloma yield, incidence, volume and mice survival which were 
significantly lower in the treated animals when compared to the control group. These 
results are in agreement with previous work conducted in our laboratory using DCOE 
(Zeinab et al., 2011) as well as its pentane/diethyl ether fraction (Taleb et al., 2016). 
Unlike the Cisplatin group, animals treated with HC showed decreased mortality and 
normal body weight changes.  
In order to evaluate the morphology of papillomas and quantify key proteins 
involved in apoptosis, papillomas were excised and subjected to histopathological and 
western blot analyses. Data showed similar results to HaCaT-ras II-4 cells experiment, 
where there was a decrease in the anti-apoptotic protein Bcl-2 level and an increase in the 
pro-apoptotic proteins p53, p21, Bax and cleaved Caspase-3. In addition, the ratios p-
Erk/Erk and p-Akt/Akt exhibited a significant decrease, indicating an inhibition of the 
MAPK and PI3K pathways respectively.    
Histopathological studies on isolated papillomas from the skin of HC treated 
animals confirmed the above results, as they contained a significantly lower incidence of 
squamous cell carcinoma than the control group. As to the Cisplatin group, one of the 
remaining two mice at the end of experiment displayed small papillomatous tumors on 
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the skin; yet, the histopathological study did not confirm any malignancy in these 
papillomas. This can be attributed to the cytotoxic effect of Cisplatin.  
Twenty weeks of treatment with HC showed no significant change in mean body 
weight when compared with the control group. On the other hand, Cisplatin treated 
animals exhibited a significant decrease in their mean body weight. Such a finding could 
be explained by the secondary effect of the chemotherapeutic drug on kidney function as 
previously described in chapter 4. This is also supported by the high rate of mortality 
(75%) observed in the Cisplatin treated group of mice.  
The therapeutic effect of HC was also assessed using the DMBA/TPA skin 
carcinogenesis model in mice. Histopathological analysis of the dissected papillomas 
confirmed the presence of SCC in all papillae, which were relatively smaller in the HC 
and Cisplatin treated groups, as compared to the control group. HC also proved to be 
effective in causing significant regression of the skin papilloma in both the topical and 
intraperitoneal modes of treatment, as reflected by the significant decrease in papilloma 
yield and volumes in the treated mice. These results support and complement our 
previous work that showed HC to be an effective remedy in preventing chemically 
induced skin cancer. Unlike the Cisplatin treated group, mice treated with HC conserved 
their body weight throughout the experiment without any sign of liver toxicity as 
measured by liver enzyme activities. 
 
 In conclusion, the current findings show that β-2-himachalen-6-ol possesses a 
potent anti-skin cancer activity in vitro and in vivo. Such an effect is likely to be mediated 
through the induction of apoptosis via partial inhibition of both the MAPK/ERK and 
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PI3K/AKT pathways. Both topical and IP treatments with HC were effective and with 
low toxicity when used in a preventive or treatment scenarios for chemically-induced 
skin cancer. In addition, the additive cytotoxic effect observed with the combined 
treatment with Cisplatin may be considered a potential regimen in cancer treatment for 
future studies to reduce Cisplatin side effects.  
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Chapter 6- The anticancer activity of HC on 4T1 triple negative 
metastatic breast cancer cells 
6.1 Rationale and Aims 
 
 Triple-negative breast cancer (TNBC) is an aggressive disease which lacks the 
hormonal expression and the amplification of Her2/neu proto-oncogene (Anders et al., 
2016). The overexpression of estrogen and progesterone receptors (ER, PR) in breast 
cancer can be targeted by different anti-hormonal drugs which prolong patient survival 
(Yip and Rhodes, 2014) and the overexpression of the human epidermal growth factor 
receptor 2 (Her2/neu) in breast cancer is treated with Her2/neu inhibitors which  
significantly increase patient survival (Ferretti et al., 2007). In TNBC, tumors lack the 
expression of ER, PR and Her2neu and are subdivided into different subtypes, thus 
requiring distinct treatment modalities (Abramson and Mayer, 2014). Despite 
conventional chemotherapy, the disease recurrence rate remains high and no encouraging 
targeted therapies have emerged recently (Collignon et al., 2016). The 4T1 mammary 
carcinogenesis murine cell line is a transplantable, easy to manipulate, invasive syngeneic 
xenograft model that can spontaneously metastasize to different organs, and carries a lot 
of similarities to human TNBC (Silva et al., 2016). The study of the gene expression 
signature of 4T1 cells led to the identification of Twist protein, a transcription factor that 
plays an essential role in cancer metastasis by serving as a mediator in disseminating the 
metastatic cancer cells (Goldstein et al., 2010). The implantation of the 4T1 cells into the 
mammary gland fat pad is technically easy and the measurement of primary and 
metastatic tumors is adequately manageable and enables accurate quantification of the 
tumors (Bailey-Downs et al., 2014). 6-thioguanine is an antimetabolite antineoplastic 
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drug used in the treatment of leukemia and other diseases and the 4T1 cell line has been 
shown to be resistant to 6-thioguanine. This can be exploited in precise quantification of 
metastatic cells in the blood, since all other existing cells are susceptible to 6-thioguanine 
(Pulaski and Ostrand‐Rosenberg, 2001). The 4T1 cell line was, therefore, used to assess 
the effect of HC on cell viability first using the WST survival assay, and then on a 
metastatic breast cancer model by inducing cancer formation by injecting 4T1 cells in the 
murine mammary gland fat pads and evaluating the incidence of primary tumor and 
metastatic lesion prevalence upon treatment by HC.  
 
6.2 Results 
6.2.1 Effect of HC on 4T1 cell viability 
 
4T1 breast cancer cells were treated for 48 hours with HC at a range of 
concentrations (1-25μg/ml), and the percent cell survival was measured using the WST-1 
viability assay. Cisplatin at 2.5µg/ml was used as positive control and DMSO as a 
negative control.  
A dose-dependent decrease in mean cell survival with an IC50 and IC90 of 7 and 
28µg/ml respectively was observed when 4T1 cells were treated with HC at increasing 
concentrations (figure 6.1). A significant decrease (p˂0.001) in the mean percentage cell 
survival was also observed after treatment either with Cisplatin (2.5µg/ml) or Cisplatin 
(2.5µg/ml) + HC (10µg/ml) when compared to the DMSO treated control cells. The latter 
treatment also resulted in a significantly (p<0.001) lower mean cell survival than cells 
treated with Cisplatin (2.5µg/ml) or HC (10 µg/ml) alone.   
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Figure 6. 1 The Effect of HC on cell viability of the breast cancer cell line 4T1. 4T1 cells 
were treated for 48 hours with HC (1, 5, 10, 15 and 25µg/ml), 0.5% DMSO, Cisplatin (2.5µg/ml) 
and Cis2.5/HC10µg/ml and cell viability was analyzed. Data are mean ± SEM for three 
independent experiments, where * denotes P ˂0.05, ** denote P ˂0.01 and *** denote P ˂0.001 
versus the DMSO treated group, as measured by one-way ANOVA.    
 
6.2.2 Effect of HC on a 4T1 cell induced murine model of carcinogenesis 
 
 Carcinogenesis was induced in mice by inoculating 4T1 cells in the mammary 
gland fat pad as described in section 2.12.1 and tumor development was monitored for a 
period of 5 weeks. Mice were also treated either with DMSO, HC (25mg/kg) or Cisplatin 
(2.5mg/kg) starting 3 days after 4T1 cells injection and for a period of 5 weeks. 
  In the control (DMSO) and Cisplatin groups, 11 out of 12 animals developed 
primary tumors few days post-4T1 cells inoculation, whereas 10 out of 12 animals 
showed primary tumors in the HC group. After a period of 5 weeks, all animals exhibited 
regression in the primary tumors, which were verified via histopathological analysis as 
described in section 2.12.3. Only 6 out of 12 mice were positive for primary mammary 
tumors in the DMSO group, 3 out of 12 mice in the Cisplatin treated group and 1 out of 
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12 mice in the HC treated group (figure 6.2A). While in the lungs of the control group 11 
out of 12 mice showed inflammation, only 6 out of 12 and 7 out of 12 mice developed 
inflammation in the lungs in the Cisplatin and HC treated groups respectively. In the 
liver, 3/12, 1/12 and 2/12 mice exhibited inflammation in the DMSO, Cisplatin and HC 
treated groups respectively (figure 6.2A).  
The mean mammary tumor sizes in the different groups are displayed in figure 
6.2B. While in DMSO group the mean tumor size was 13.7 mm, in the Cisplatin and HC 
groups the mean tumor sizes were 10.51 mm and 7.58 mm respectively, which was 
significantly lower in the HC group when compared to the mean tumor size of the mice in 
the control group (p˂0.05).  
The mean colony-forming units per group post 6-thioguanine treatment, as a 
measure of metastatic cells, since 4T1 cells are resistant to the cytotoxic drug 6-
thioguanine, is displayed in figure 6.2C. In the DMSO group, the mean of colony-
forming unit was 12.9 units. This number was significantly decreased in the Cisplatin 
treated group to 8.9 units (p˂0.05), and to 7.6 units in the HC treated group (p˂0.01).  
The activity of the liver enzymes ALP, ALT and AST were measured as markers 
of liver function and the results are displayed in figure 6.2.D. No significant differences 
in the activities of ALP and ALT were observed between any of the groups tested. 
However, with respect to the DMSO control, the HC group showed a significant (p<0.05) 
decrease in mean AST activity.  
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Figure 6. 2 The effect of HC on 4T1 induced carcinogenesis. (A) The effect of HC on tumor 
incidence in the mammary glands and inflammation in the lungs and livers of mice at 5 weeks 
post-treatment. The DMSO group is represented by dark grey bars, the Cisplatin group by light 
grey bars and the HC group by mid grey bars. (B) Mammary glands/skin mean tumor size 
measured in millimeters at 5 weeks post-treatment. (C) Mean number of colony forming units in 
the blood upon addition of 6-thioguanine. (D) Mean serum ALP, ALT and AST activities 
measured in unit/liter. Data are Mean ± SEM, where * denotes P < 0.05 and ** denote P <0.01 
compared with 0.5 % DMSO as a negative control, as measured by one-way ANOVA.  
 
 
 
Finally, mouse body weight was also monitored weekly during the five weeks of 
treatment. While the mean body weight in the HC treated group was comparable to that 
of the control group, mice in the Cisplatin treated group showed a progressive drop in 
body weight, reaching significance at week 5 (p˂0.05) (figure 6.3). 
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Figure 6. 3 Body weight of mice treated by 4T1 cells. Mean weekly body weight in grams was 
measured for 5 weeks.  The DMSO group is represented by dark grey bars, the HC group by mid 
grey bars and the Cisplatin group by light grey bars. Bars denote mean ± SEM, where * denotes P 
< 0.05 compared with baseline body weight (day 0) as measured by one-way ANOVA. 
   
 
6.2.3 Histopathology of mammary glands/skin, lungs and livers 5 weeks post HC 
treatment 
 
 Histopathological analysis was conducted to assess the presence or absence of 
cancer/inflammation in the isolated tissues of mice treated with DMSO, Cisplatin 
(2.5mg/kg) and HC (25mg/kg) and a diagnosis of cancer was made when the 
histopathological analyses confirmed the presence of invasive carcinoma in the dermis 
and subcutaneous tissues as described in 2.13. Where tissue was positive for cancer, the 
cells were further examined at high magnification for evidence of atypical cell/tissue 
morphology with marked pleomorphism and high nucleo-cytoplasmic (N/C) ratios with 
prominent nucleoli and irregular nuclear contours. Numerous mitotic figures were also 
noted (figure 6.4A).  
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Lung tissue with evidence of inflammation were also closely analyzed and were 
found to show both acute (neutrophil predominance) and chronic (lymphocyte 
predominance) infiltrations of white blood cells (figure 6.4C).  
Liver tissue identified with the presence of inflammation, showed acute and 
chronic inflammations at the perivenular regions (figure 6.4E).   
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Figure 6. 4 Histopathological analysis of mice organs injected with 4T1 cells and treated 
with HC. Representative sections of mammary gland/skin, lung and liver tissue taken at week 5 
and stained with haematoxylin and eosin. (A) Mammary gland with cancer of a DMSO treated 
mouse, where the arrow indicates malignant cancer cells invading the dermis and subcutaneous 
tissue. (B) Normal mammary gland tissue with arrow indicating a normal dermis of an HC treated 
mouse. (C) Inflamed lung tissue with upper and lower arrows indicating chronic (lymphocyte 
predominance) and acute inflammation (neutrophil predominance) respectively in a DMSO 
treated mouse. (D) Normal lung tissue with regular alveoli (upper arrow) and normal bronchi 
(lower arrow) in a Cisplatin treated mouse. (E) Inflamed liver tissue with arrow indicating 
perivenular inflammatory cells (neutrophils and lymphocytes) of a DMSO treated mouse. (F) 
Normal liver with arrow indicating a regular perivenular zone of an HC treated mouse. All groups 
are presented at magnification x20. 
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6.3 Discussion  
 
 The 4T1 mammary  murine cell line shares many characteristics with human 
TNBC such as the ability to spontaneously metastasize to various organs (Silva et al., 
2016). As such, it is often used to test novel treatments before phase I trials can 
commence in humans and was chosen in this study, as it is able to be reintroduced to 
mice to study the effect of HC on the metastatic potential of these cells (Khanna and 
Hunter, 2005; Talmadge et al., 2007; Kokolus et al., 2013). 
Initial experiments investigated the direct effect of HC on 4T1 cell viability. 
Treatment for 48 hours with HC resulted in a dose-dependent decrease in survival with an 
IC50 and IC90 of 7 and 28µg/ml respectively. Concomitant treatment of HC with Cisplatin 
exhibited greater cytotoxicity of the cancer cells than when each compound was used 
alone. Cisplatin is known to damage renal epithelial cells and lead to renal failure (Miller 
et al., 2010). Therefore, combining Cisplatin with HC may allow the usage of a lower 
dose of Cisplatin, which potentially could help in reducing the relative non cancer cell 
cytotoxicity of Cisplatin. 
 In order to investigate the effect of HC in vivo on the development of 
tumor and metastatic potential of this cell line, mice were injected with 4T1 cells in the 
mammary gland fat pad and treated with HC and Cisplatin. Inoculation of mice with 4T1 
cells resulted in the formation of suspected primary tumors in most animals. After 5 
weeks of 4T1 cell injection, the mammary gland primary tumors were measured and a 
decrease in mean tumor size in the Cisplatin and HC treated mice was observed, 
however, this decrease was only significant in HC treated group. Although most animals 
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exhibited tumors, histopathological analyses confirmed that half of the mice had 
developed mammary carcinoma in the control group. This number was lower in the 
Cisplatin (3 out of 12) and in the HC (1 out of 12) treated mice indicating that HC and 
Cisplatin exert a therapeutic effect in this model of carcinogenesis.  
Histopathological analyses of lung and liver tissue revealed the occurrence of 
inflammation (acute and chronic) rather than the expected metastatic tumors. While in the 
control group, 92% of animals developed lung inflammation, animals treated with either 
Cisplatin or HC had a much lower incidence of lung inflammation (50% and 58% 
respectively). The incidence of liver inflammation was much lower when compared to 
lung inflammation, however, a lower incidence was also observed in both Cisplatin and 
HC treated groups of mice. Lung and liver metastatic lesions were expected to have been 
observed, however, the documented inflammation could be indicative of a pre-cancerous 
state as it has been established that 4T1 cells cause a leukemoid reaction with 
granulocytosis predominance (mainly neutrophils) at the site of tumor occurrence 
(Redelman and Hunter, 2007). Moreover, Wculek and colleagues have identified that 
neutrophils act as the main driver of metastatic establishment within the (pre-) metastatic 
lung microenvironment in murine breast cancer models (Wculek and Malanchi, 2015). 
This mechanism is thought to be driven by neutrophil-derived leukotrienes, which help 
the colonization of distant tissues by selectively expanding the sub-pool of cancer cells 
that preserve high tumorigenic potential.  
In order to further investigate whether any metastatic activity had been initiated 
and, therefore, affected by HC treatment, the number of metastatic cells in the blood after 
5 weeks of 4T1 cell inoculation was analyzed. The collected blood was treated with the 
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cytotoxic drug 6-thioguanine to kill all cells except the resistant 4T1 cancer cells which 
were then cultured in order to count the resultant colonies after methanol fixation and 
staining with 0.03% methylene blue (Redelman and Hunter, 2007; Gebremeskel et al., 
2015). The number of 6-thioguanine resistant colonies observed in the blood of the 
treated mice was consistent with the observed primary tumor incidence and the 
inflammation in the lungs and livers of these animals. In the DMSO treated group, the 
mean number of 6-thioguanine-resistant colony-forming units was 13, which was 
significantly decreased in the Cisplatin and HC treated groups of mice. These findings 
suggest that HC treatment reduces the number of metastatic cells and thus could be of 
benefit as an anti-metastatic drug. Indeed, previous studies by Taleb et al (2016) showed 
that HC treatment reduced 2D cell motility by 58% and 3D invasion by 25%, and caused 
a two fold increase in cell adhesion in the highly motile and invasive brain astrocytoma 
SF-268 cells (Taleb et al., 2016). In metastasis, cancer cells need to attach to the 
substratum, move the anterior part forward and then detach the tail and move it forward 
toward the anterior part. This cycling of focal adhesion formation and disassembly is 
responsible for cellular crawling over the extracellular matrix (Hanna and El-Sibai, 2013; 
Khalil et al., 2014). The anti-metastatic effect of HC, therefore, may be explained by an 
inhibition of the turnover and the disassembly of focal adhesions in the treated cancer 
cells.  
The relatively lower levels of the activity of the liver enzymes ALP, ALT and 
AST observed in the serum collected from the mice inoculated with 4T1 cells and treated 
with HC also support the potential of using HC as a treatment for breast cancer. They are  
also consistent with the results using the DMH- and DMBA/TPA-induced murine cancer 
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models of colon and skin cancer (sections 4.2.5.3, and 5.2.5 respectively), where the level 
of ALP, ALT and AST liver enzymes was stable as compared with the control group for 
a total of 8 and 6 weeks of treatment with HC10 and HC25mg/kg respectively. HC, 
therefore, appears not to have a hepato-toxic effect during the treatment.  
Body weight was stable in the HC treated group of mice, while the Cisplatin 
group exhibited a significant reduction in body weight at week 5. Similar results were 
observed in our previous experiments using the DMBA/TPA-induced murine skin 
carcinogenesis model (preventive and therapeutic effect experiments; sections 5.2.4 and 
5.2.5). Unlike the Cisplatin group which showed a significant decrease in body weight 
mice treated with HC conserved a stable body weight when compared with the control 
group (DMSO). Such results support the fact that HC does not induce any cachexia even 
after 20 weeks of treatment.  
 In conclusion, HC appeared to be an effective remedy for the treatment of primary 
tumor induction since it reduced the tumor volume and the number of animals bearing 
tumors. In addition, it helped in reducing the number of metastatic cells while conserving 
normal liver function and body weight. Further studies are needed to confirm and 
consolidate these findings using other animal models.  
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Chapter 7- General Discussion and Conclusions 
7.1 Introduction 
 
Despite pharmaceutical improvements in producing new anticancer drugs, a 
complete disease cure has still not been achieved and the financial burden of newly 
developed medicines remains a major concern. Herbal medicine, therefore, has been 
extensively investigated in the past few decades in order to find alternative efficient 
anticancer remedies that could be more financially viable. As a result, a variety of 
phytochemicals or compounds have recently been recognized as useful in cancer 
treatment (Yin et al., 2013). Some of these medicinal plants have been investigated in 
relation to their complementary role in reducing chemotherapy side effects. These include  
Turmeric (Li et al., 2007) and Ginseng (Hofseth and Wargovich, 2007) and others  have 
been approved as anticancer drugs such as Taxus brevifolia (Mitchell, 1998).  
Recently, the Lebanese Daucus carota ssp carota crude oil and its fractions have 
been investigated for their anticancer activities both in vitro (Shebaby et al., 2014; 
Shebaby et al., 2015a; Taleb et al., 2016) and in vivo (Zeinab et al., 2011; Shebaby et al., 
2017) and whilst the composition of the DCOE has been described in several European 
countries (Gonny et al., 2004; Mockute and Nivinskiene, 2004; Staniszewska et al., 2005; 
Maxia et al., 2009; Denise Otsuka et al., 2010), none of these species included β-2-
himachalen-6-ol (HC) as a major component. In comparison, the pentane diethyl ether 
fraction of DCOE from the Lebanese wild species was shown to contain about 60% HC 
and exhibited significant anticancer activity against breast (MDA-MB-231) and colon 
(HT-29) cancer cell lines (Shebaby et al., 2014; Shebaby et al., 2015a) and against 
chemically-induced skin carcinogenesis (Shebaby et al., 2017). This same fraction was 
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also found to inhibit cancer cell motility and invasion in vitro (Zgheib et al., 2014) and 
more recently, HC was isolated and demonstrated to have anticancer activity against 
breast (MDA-MB231), brain (SF-268), colon (Caco-2), lung (A549) and skin (B16F-10) 
cancer cell lines (Taleb et al., 2016).  
The present study has shown HC to possess anticancer activity against a panel of 
colon (Caco-2, HT-29, LoVo, Sk-Co, SW1116 and T-84), skin (HaCaT-ras II-4) and 
breast (4T1) cancer cell lines and this activity was mainly attributed to an inhibition of 
both the MAPK and PI3K pathways in addition to direct effect on the proteins p53, p21, 
Bax, Bcl-2, Caspase-3 and cleaved PARP. The activity of HC was also translated in vivo 
using the DMH (colon), the DMBA/TPA (skin) and the 4T1 (breast) carcinogenesis 
models. 
7.2 The effect of HC on the viability of human cancer cell lines  
 
The assessment of cell viability is important as it reflects the physiological state 
of tested cells upon exposure to therapeutic drugs and the IC50 and IC90 values are 
commonly used to measure the inhibitory potency of any new drug in pharmacological 
research. In the present study, the effect of HC against colon, epidermal and breast cancer 
cell lines viability was investigated and the IC50 and IC90 were determined. All tested cell 
lines exhibited a significant dose-dependent decrease in cell survival upon HC treatment. 
After 24 hours of treatment, the calculated IC50 of the colon cancer cells ranged between 
8μg/ml (Sk-Co) and 18μg/ml (SW1116), and the IC90 ranged between 19μg/ml (Sk-Co) 
and 36μg/ml (SW1116). The wide range in differences in the IC50 and IC90 values 
observed upon HC treatment could be attributed to drug selectivity or cell resistance to 
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treatment. Such selectivity has been previously reported with Cisplatin. For instance, the 
human ovarian carcinoma cell line A2780, and its Cisplatin-resistant variant A2780cp 
had reported IC50 values of 6.5μg/ml and 39.4μg/ml respectively upon Cisplatin treatment 
(Bao et al., 2014). Cisplatin was also shown to be selective for the lung cancer cell line 
A549, with an IC50 of 7.22 μM, and ineffective against breast cancer cell line MDA-MB-
231, with an IC50 ˃200 μM (Lu et al., 2017).  
Incubation of cells with HC for 48 hours did not significantly improve the IC50 
and IC90 values for any of the cancer cell lines tested, indicating a relatively rapid drug 
action when compared with Cisplatin, that showed maximal activity after 48 hours of 
treatment. Previous studies on the pentane diethyl ether fraction of DCOE containing 
about 60% HC had IC50 values of 19 and 17.5μg/ml respectively when tested for 48 hours 
against Caco-2 and HT-29 colon cancer cell lines (Shebaby et al., 2015a). In the present 
study, HC was tested against the same cell lines (Caco-2 and HT-29), and exhibited IC50 
values of 7 and 12μg/ml respectively after 48 hours of treatment. This difference in IC50 
values observed in both studies is possibly due to the fact that HC is more than 90% pure 
compared to the 60% purity in the pentane diethyl ether fraction of DCOE and, therefore, 
is more active at a lower concentration.  
In view of the potent activity of HC against various cancer cells, it was important 
to investigate if it had more selectivity toward cancer cells rather than normal cells. To 
this end, HC was also tested in normal colon cell line (CCD-33Co; non-mutagenic colon 
fibroblast cells) and cell viability was determined 48 hours post treatment. HC treatment 
(10 and 25μg/ml) did not show a significant cytotoxicity to the CCD-33Co cells that 
conserved a relatively slow doubling time, supporting the idea that HC is selective toward 
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cancer cells and thereby indicating the relative safety of HC as a potential 
chemotherapeutic drug. This, however, needs further testing in faster dividing colon, skin 
and breast cell lines. The use of CCD-33Co cell line as a control normal cell has been 
described previously in studies assessing the safety of Cationic Hybrid Liposomes against 
HCT116 colorectal cancer cell line (Ichihara et al., 2016) and Black Tea Theaflavins 
against Caco-2 colon cancer cell line (Lu et al., 2000).  
The effect of HC used concomitantly with Cisplatin, a well-known approved 
cytotoxic drug, showed an additive effect in various colon cancer cell lines [HT-29 and 
LoVo (p˂0.05); T-84 and Sk-Co (p˂0.01) after 24 and 48 hours of HC treatment, and 
Caco-II P˂0.05 after 24 hours of treatment]. This could offer a solution for the well 
documented side effects of Cisplatin, particularly nephrotoxicity. Twenty percent of 
patients treated with high-dose Cisplatin will suffer from severe renal dysfunction (Yao et 
al., 2007) and many novel approaches have tried to alleviate this effect. One such 
approach aimed to reduce the expression of the renal Organic Cation Transporter 2 
(OCT2), which is responsible for renal clearance of drugs, by Glycation (Thomas et al., 
2004), or by competition with Cimetidine for the transport of OCT2 (Ludwig et al., 
2004). Another approach to reduce Cisplatin-induced nephrotoxicity was to use the 
effects of antioxidant agents such as melatonin, selenium, vitamins C and E in reducing 
the effect of oxidative stress injury caused by Cisplatin to renal cells (Şener et al., 2000; 
Weijl et al., 2004). The aforementioned findings are still not common practice in 
reducing nephrotoxicity. The effect of normal saline and electrolyte replacement with 
forced diuresis on increasing renal excretion, reducing toxic agent formation and 
inducing osmotic stress reaction in response to Cisplatin renal toxicity have also been 
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investigated and the results emphasized on the role of extensive hydration in reducing 
nephrotoxicity (Dumas et al., 1990; Santoso et al., 2003). Understanding the pathogenesis 
of renal tubular damage by Cisplatin is still under investigation and whilst several novel 
approaches to limit the nephrotoxicity have been attempted, this side effect has yet to be 
overcome (Yao et al., 2007).  
7.3 The effect of HC on cell cycle distribution and apoptosis 
 
In an attempt to elucidate the mechanism of action of HC, its effect on cell cycle 
distribution using colon and epidermal cancer cell lines was investigated. Both cell types 
showed similar cell cycle patterns upon treatment with HC. At low HC concentrations 
(10µg/ml), there was a significant accumulation of the cell content in both sub-G1 and G-
1 phases which was accompanied by a significant reduction in the cell content in the S 
and G2/M phases. These alterations were more significantly enhanced with higher 
concentrations of HC (25µg/ml), where the cell content was completely assembled in the 
Sub-G1 phase, implicating complete DNA fragmentation, which is a major characteristic 
of late apoptosis (Riccardi and Nicoletti, 2006; Kajstura et al., 2007). The normal healthy 
cell cycle is broadly divided in two phases: the interphase and the mitosis. The interphase 
is sub-divided in three major sub-phases: Gap1 (G1), Synthesis (S) and Gap2 (G2), in 
addition to Gap0 (G0) or quiescent stage. G1 is usually responsible for cell growth where 
the proteins are synthesized preparing the cell for duplication, whereas the S phase is 
characterized by the duplication of the chromosomes. In the G2 phase, the cell resumes 
its growth in preparation for division, checks the duplicated chromosomes for any 
possible errors and repairs these when necessary. G0 is a cell cycle arrest phase that takes 
place when the cell does not divide. Mitosis is the eukaryotic nuclear division phase that 
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is followed by cellular division (cytokinesis) (Cooper and Hausman, 2000). The 
appearance of discrete and sharp sub-G1 peaks in analyzing cell cycle distribution 
represents a subpopulation of apoptotic cells in G0 or G0-G1 transition phase with 
invariable DNA content (Kajstura et al., 2007). Farnesiferol, a type of coumarins used as 
a folk remedy for cancer treatment (Hasanzadeh et al., 2017), and Zinc oxide 
nanoparticles (ZnO NPs) (Boroumand Moghaddam et al., 2017), a well-known powerful 
cytotoxic agents against breast cancer cells, were shown to induce Sub-G1 phase 
apoptosis, an effect similar to that observed with HC treatment. Other commonly used 
chemotherapeutic drugs such as Taxol were reported to induce apoptosis via arresting 
cells in the G2/M phase (Wang et al., 2013).   
The use of Annexin V/ PI staining of apoptotic cells is a commonly used approach 
used to study the cellular apoptotic/necrotic vs viable state of cells under various 
treatments (Rieger et al., 2011). Propidium iodide (PI) is used in conjunction with 
Annexin V to determine the condition of the cells by quantifying the cellular content 
predominantly the DNA, using the flow cytometry (Vermes et al., 2000). Propidium 
Iodide is a membrane impermeable DNA stain that cannot cross the plasma membrane of 
living cells. Consequently, it doesn’t stain viable or early apoptotic cells. In necrotic or 
late apoptotic cells, the plasma and nuclear membranes lose their integrity and 
permeability, the fact that allows PI to penetrate into the cell and the stain the nucleic 
acids (Kroemer et al., 1998). One of the earliest features of apoptosis is loss of plasma 
membrane asymmetry. This is a characteristic of all eukaryotic membranes where various 
lipid species and proteins are asymmetrically distributed in the membrane bilayer, hence 
providing it with different physiological roles (Fadeel and Xue, 2009). In apoptotic cells, 
225 
 
the phospholipid phosphatidylserine (PS) of the membrane becomes exposed to the 
external environment by translocation from the inner to the outer leaflet of the plasma 
membrane. Annexin V is conjugated to fluorescent fluorochromes for detection of 
apoptotic and dead cells. Annexin V has a high affinity for PS. It can bind to both PS and 
fluorescent fluorochromes, staining the cells undergoing apoptosis (early or late) and 
serving as a sensitive probe for flow cytometric analysis (O'Donnell et al., 2013). As a 
result, viable cells are considered Annexin V/PI negative, cells in early apoptosis are 
Annexin V positive and PI negative, cells in late apoptosis are Annexin V/PI positive and 
cells in necrosis are PI positive and Annexin V negative (Rieger et al., 2011). The effect 
of HC on various cancer cell lines (colon and epidermal) showed similar results in 
determining the apoptotic/necrotic mode of cell death. In the colon cancer cell line 
SW1116, the percent cell content exhibited a greater shift towards the necrotic area than 
toward the late apoptotic one. In the skin cancer cell line HaCaT-ras II-4, the percent cell 
content was more prominent in the late apoptotic region than in the necrotic one. This 
difference in programmed cell death (apoptotic) versus accidental cell death (necrotic) 
may be attributed to a PARP-activation mode of cell death (Goodman, 2004; Zong et al., 
2004). It is known that cancer cells rely preferentially on the glycolysis pathway for ATP 
production and Thomson and colleagues (2004) found that during glycolysis, cancer cells 
rely on cytoplasmic NAD to produce ATP. Alkylating cytotoxic agents act by activating 
PARP, thus depleting the cytosolic NAD that is directly correlated to glycolysis and 
inducing necrosis (Edinger and Thompson, 2004). This is in accordance with our work, 
where the SW1116 cell line exhibited a high percentage of cell content in the necrotic 
region. 
226 
 
The ‘genome guardian’ p53 plays a vital role in maintaining genomic stability by 
repairing any DNA damage that may result from oxidative stress (Mirza et al., 2003). In 
response to oxidative stress and DNA sustained damage, p53 can induce growth arrest by 
holding the cell cycle in the G1/S phase, leading to DNA repair or initiating apoptosis in 
case of irreparable DNA damage. During homeostasis, p53 is maintained at low protein 
levels by its negative regulator Mouse double minute 2 homolog (Mdm2). The Mdm2-
p53 interaction is disrupted by stress-induced acetylation and phosphorylation on Mdm2 
(Miyachi et al., 2009). Activated p53 triggers the transcription of the powerful CDK 
inhibitor p21, which inactivates the G1-S/CDK and K2 complexes that are responsible 
for cell transition from G1 to S phase. The inhibition of G1-S/CDK and K2 complexes 
leads to cell cycle arrest in G0/G1 phase (Koljonen et al., 2006). The results of our 
investigations into the effect of HC on this process agreed with these reports, 
demonstrating cell cycle arrest in the Sub-G1 phase and up-regulation in the activity of 
p53 and p21 in SW1116 cells. In the HaCaT cell line, the p53 gene is mutated (Boukamp 
et al., 1988) and accordingly, an abnormal decrease in the expression of p53 was 
observed. The cyclin-dependent kinase inhibitor p21, however, showed a significant up-
regulation in its activity after treatment of the HaCaT-ras II-4 cells by HC. In addition, 
the cell cycle in these cells also displayed a complete Sub-G1 arrest at high 
concentrations of HC (25μg/ml). The observed decrease in p53 and increase in p21 
implicate that cell cycle arrest and apoptosis in HaCaT-ras II-4 cells were mediated 
through the up-regulation of the expression of p21 in a p53-independent manner 
(Macleod et al., 1995; Phalke et al., 2012). Similar results were obtained while studying 
the effect of the DCOE sub-fraction F2 on HaCaT-ras II-4 cells, where the expression of 
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p21 was increased with a decrease in the expression of p53 and these were associated 
with cell content accumulation in the Sub-G1 phase at high F2 concentrations (50μg/ml) 
(Shebaby et al., 2017). These findings are in accordance with other studies where 
Curcumin (Chiu and Su, 2009) and other polyphenolic compounds (Soleas et al., 2001) or 
cytotoxic agents as cis-dichlorodiammine platinum(II) (DDP) (Damia et al., 2001) down-
regulated the expression of p53 in cancer cells harboring the mutant p53 gene.   
The extrinsic and intrinsic apoptotic pathways are responsible for programmed 
cell death through a cascade of proteins that interact together in one aim to get DNA 
fragmentation and apoptosis (Fulda and Debatin, 2006). These pathways express 
themselves through the activation of apoptotic proteins mainly the Bcl-2 family in the 
mitochondrial pathway (intrinsic) and the Caspase family with PARP proteins in the 
receptor pathway (extrinsic) (Roy and Nicholson, 2000). In the intrinsic pathway, upon 
stimulation of the membrane death receptors and activation of FADD/Caspase-8 
complex, Bid protein becomes activated and up-regulates the apoptotic protein Bax and 
down-regulates the anti-apoptotic protein Bcl-2. This, in turn, leads to the release of the 
mitochondrial Cytochrome-c, creating the Cyt-c/Apaf-1/Caspase-9 complex, which 
activates Caspase-3, initiating apoptosis either via ICAD/CAD cleavage or via PARP 
cleavage. In the extrinsic pathway, the stimulation of the membrane death receptors 
activates the FADD/Caspase-8 complex that causes direct cleavage of Caspase-3 and 
other effector Caspases, and causing apoptosis either via ICAD/CAD cleavage or via 
PARP cleavage (Fulda and Debatin, 2006). It is important, therefore, when elucidating 
the mechanism of apoptosis to measure all the markers that may help in identifying the 
cell apoptotic pathway. This was achieved in this study by examining the pro- and anti-
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apoptotic proteins involved in the apoptotic process. The levels of Bax apoptotic proteins 
were up-regulated and the Bcl-2 anti-apoptotic proteins were down-regulated in both 
HaCaT-ras II-4 and SW1116 cancer cell lines. In the HaCaT-ras II-4 cells, Cleaved or 
active Caspase-3 activity was measured in in vitro as well as in in vivo models. In all 
experiments, there was a significant increase in the expression of the cleaved Caspase-3 
activity indicating an induction of cell apoptosis. In the SW1116 cell line, the protein 
levels of Pro-Caspase-3 and PARP proteins were assessed and the results showed a 
significant decrease in the expression of Pro-Caspase-3 proteins associated with a 
significant increase in the cleaved PARP proteins expression. These findings support the 
fact that HC exerts an apoptotic effect through the intrinsic pathway. Similar results were 
obtained when using the pentane diethyl ether fraction of DCOE (60% HC) where a 
down-regulation of Pro-Caspase-3 and PARP proteins was observed (Shebaby et al., 
2015a) further supporting these findings.  
P53 has the ability to interact with both apoptotic pathways to induce apoptosis 
(Bai and Zhu, 2006; Wachter et al., 2013). In the death receptor pathway (extrinsic), p53 
can directly activate Caspase-8 that triggers the activation of the chain effector Caspases 
(-3, -6 and -7). In the mitochondrial pathway (intrinsic), upon cellular stresses (DNA 
damage, heat shock, hypoxia, or chemotherapy) p53 can activate Bcl-2 family proteins, 
causing the release of mitochondrial Cytochrome-c and the formation of apoptosome 
complex with Apaf-1 and Caspase-9 leading to apoptosis (Bai and Zhu, 2006). The 
elevated expression of the level of p53 in the SW1116 treated cells or in the DMBA/TPA 
in vivo model may implicate a p53 mode of apoptosis. 
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Similarly to Cisplatin which caused cell cycle arrest within the G1 phase in 
response to DNA damage via p53 stimulation of the cyclin dependent kinase (Cdk) 
inhibitory protein p21 (Lakin and Jackson, 1999), HC induced cell cycle arrest at G1 
phase at low dose (10mg/kg) via p21 overexpression, through p53-dependent and 
independent mechanisms. HC also induced apoptosis by up-regulating the pro-apoptotic 
protein Bax and down-regulating the anti-apoptotic protein Bcl-2, resulting in an increase 
in Bax to Bcl-2 ratio, in the same way as Cisplatin induced apoptosis by overexpressing 
Bax protein and increasing its ratio over Bcl-2 (Park et al., 2002). The mismatch repair 
(MMR) pathway, the nucleotide excision repair (NER) system and many other repairing 
mechanisms are being implicated by cancer cells in recognizing, binding and excising 
DNA defects caused by Cisplatin (Kelland, 2007). Further DNA investigations are, 
therefore, required in future work to assess the mode of DNA damage induced by HC and 
the repairing mechanisms adopted by malignant cells to escape the apoptotic effect of 
HC. Many analytical methods can be used in the future work to identify and quantitate 
DNA damage and adducts. Such highly sensitive methods include the Accelerator mass 
spectrometry (AMS) that can detect levels of 1 to 10 adducts per 1012 nucleotides, and the 
32P-Postlabeling technique that has a limit of detection of 1 adduct per 1010 nucleotides, in 
addition to many others (Himmelstein et al., 2009). 
The MAPK and PI3K signalling pathways have been implicated in cancer 
development due to genetic mutations affecting the protein cascades (Dhillon et al., 
2007). Targeting both pathways is being widely investigated to develop new anticancer 
drugs (Santarpia et al., 2012; Asati et al., 2016). Everolimus (Afinitor) is a mammalian 
target of rapamycin (mTOR) inhibitor in the PI3K/Akt/mTOR signaling pathway that has 
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recently been approved for the treatment of breast cancer in combination with 
Exemestane, a steroidal aromatase inhibitor (Jerusalem et al., 2014). It has been 
established that 50% of melanomas contain active mutations of BRAF which promote 
MAPK signalling (RAS-RAF-MEK-ERK) pathway activation and melanoma 
proliferation. Vemurafenib is a kinase inhibitor selective for BRAF V600E, the commonest 
mutant form of the BRAF kinase, was approved in 2011 as a targeted therapy for BRAF 
positive melanoma patients (Ilieva et al., 2014). In the present study, all cells (HaCaT-ras 
II-4 and SW1116) treated with HC exhibited a down-regulation of phosphorylated Erk 
and Akt proteins. Significant decreases in the ratios of p-Erk/Erk and p-Akt/Akt were 
also observed. The in vivo DMBA/TPA translated model displayed similar decreases in 
the p-Erk and p-Akt proteins, as well as in the p-Erk/Erk and p-Akt/Akt ratios. These 
findings are in accordance with previous reports where the effect of the pentane diethyl 
ether of DCOE was studied against HT-29 colon cancer cells (Shebaby et al., 2015a), and 
against HaCaT skin cancer cells (Shebaby et al., 2017). These outcomes of the 
chemically-induced cancer model are in accordance with those of the in vitro work, and 
strongly support the effect of HC in inducing apoptosis through the MAPK and PI3K 
pathways. 
 
7.4 The effect of HC on chemically-induced carcinogenesis models 
 
Although the murine carcinogenesis models are useful in inducing cancer 
development, each model owns its characteristics and limitations. It is, therefore, up to 
the researcher to choose the most suitable model for his study.     
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Chemically induced carcinogenesis models are developed by a variety of 
synthetic chemicals that are exposed to the body via ingestion, inhalation, injection, or 
cutaneous application. These models mimic the human cancer development and are 
characterized by non- or less invasiveness than other models, abundant tumor volume, 
different types of cancer, and reproducible with low cost models (Liu et al., 2015). Many 
chemical carcinogens have been shown to induce cancers in experimental animals upon 
prolonged exposure. Different organs can be affected in enhancing carcinogenesis 
according to the chemical used. N-Nitrosodiethylamine (DENA), for example, is a N-
nitroso compound (NOC) that induces liver carcinogenesis in rodents with a high analogy 
to the development of hepatocellular carcinoma in humans (Yang et al., 2004). DENA is 
metabolized in the liver to Ethyl-acetoxyethyl-nitrosamine, which leads to the production 
of ethyl-diazonium ion that ethylates cellular macromolecules causing DNA adducts  
(Thirunavukkarasu et al., 2002; Yang et al., 2004). Moreover, the synthetic compounds 
1,2-Dimethylhydrazine dihydrochloride (DMH) along with its metabolites azoxymethane 
(AOM) and methylazoxymethanol (MAM) are highly specific complete carcinogens for 
rodent colorectal carcinogenesis models (Hamiza et al., 2012). The reactive metabolite 
MAM produces in the colon methyldiazonium, which can alkylate macromolecules as 
guanine causing DNA adducts, which are often correlated with the degree of 
tumorigenesis (Cain, 1992). The 7,12-Dimethylbenzanthracene (DMBA), however, is a 
polycyclic aromatic hydrocarbon (PAH) that initiates skin carcinogenesis in mice when 
topically applied combined with the promoter 12-O-tetradecanoylphorbol-13-acetate 
(TPA) (Amornphimoltham et al., 2008). DMBA causes irreversible mutation at the 
second nucleotide of codon 61 (CAA → CTA) in the c‐Ha‐ras gene on mice skin by a 
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single topical application (Fujiki et al., 1989). DMBA also acts as a potent complete 
carcinogen in inducing breast cancer when given by gavage to rats (Ferreira et al., 2013). 
Benzo[a]pyrene (BaP) is also a powerful polycyclic aromatic hydrocarbon, which usually 
induces lung, stomach, colon and other organs carcinogenesis (Goyal et al., 2010). BaP 
with its numerous metabolizes can induce the formation of DNA adducts (Gelboin, 1980; 
Joseph and Jaiswal, 1994). All of these chemicals with many others are known to induce 
murine carcinogenesis models in a way similar to human cancer development. The 
tumors are usually multifocal, with various sizes and induced in the targeted organs. 
Some disadvantages, however, exist with these models, including the time-consuming 
progress of carcinogenesis, the assessment of the noninvasive tumor burden in the 
relatively small animals and the necessity to perform histopathology after sacrificing the 
animals to identify the tumors and their response to treatment (Liu et al., 2015). 
A syngeneic mouse model is another pattern to induce murine carcinogenesis. It 
consists of tumor tissues derived from the same genetic background as a given mouse 
strain (Murphy, 2015). As the syngeneic mice retain intact immune systems, this model is 
mainly pertinent for immunotherapy assessment, where monitoring of tumor growth or 
shrinkage as well as metastasis is possible, and murine survival rate is also inspected in 
the presence of a functional immune system. The tumors in syngeneic mouse models, 
however, tend to grow fast and tumor cells are rodents in origin, expressing the murine 
homologues of the anticipated targets (Murphy, 2015). In order to overcome this 
disadvantage, the human tumor xenograft model was generated using human cancer cells 
for transplantation into immunocompromised mice as athymic nude mice or severely 
compromised immuno-deficient (SCID) mice (Morton and Houghton, 2007; Richmond 
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and Su, 2008). Many models of human tumor xenograft have been developed such as the 
ectopic tumor xenograft model, the orthotopic tumor xenograft model, the metastatic 
cancer model and the patient-derived tumor xenograft (Jung, 2014). The ectopic tumor 
xenograft model consists of transplanting tumor cells in a different site from their original 
one. It is used to monitor tumorigenicity and tumor growth easily, and to evaluate the 
efficacy of anticancer drugs (Jung, 2014). The assessment of invasion and metastasis, 
however, is limited in this model due to the difference in microenvironments between 
that of the immunosuppressed mice and the one of human cancer. For this reason, the 
orthotopic tumor xenograft model was developed, based on the transplantation of cancer 
cells into the same origin site of the tumor (Jung, 2014). The measurement of tumor 
growth, however, is limited to the subcutaneous-arising tumors as in melanoma, while 
visceral tumors need more sophisticated imaging machinery as optical imaging, 
computerized tomography or magnetic resonance imaging for their detection (Hsu et al., 
2006; Jung, 2014). The metastatic cancer model is another human tumor xenograft 
model, which consists of transplanting tumor cells either after removal of the primary 
tumor (Banyard et al., 2013), or by directly injecting intravenously cancer cells in SCID 
or nude mice, so that they circulate like cancer stem cells and trigger metastasis (Yano et 
al., 2005). A magnetic resonance imaging or a positron emission tomography are usually 
used in detecting metastatic lesions in this model, which is favored in determining the 
appropriate anticancer therapy (Jung, 2014). Despite the advantages of xenograft models 
in determining the response rate of patients to a particular treatment, the reliable 
prediction of drug response in a clinical trial is still missed and not achieved (Jung, 
2014). To overcome this defect, a patient-derived tumor xenograft (PDTX) model was 
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developed, using cancer patient tissues for direct transplantation into 
immunocompromised mice. This model has been successfully used to screen new drugs, 
evaluate response rate and resistance to treatment despite its technical constraints, high 
cost and being time-consuming (Cook et al., 2012).   
The genetically engineered mouse model (GEMM) is considered the most 
advanced animal model of human cancer and it is used to evaluate the mechanisms of 
cancer growth and drug resistance (Frese and Tuveson, 2007). The GEM model refers to 
an animal strain with manipulated genomic alterations, including the upregulation of an 
oncogene or the downregulation of a tumor suppressor gene (Doetschman, 2011). It can 
be classified into transgenic and endogenous types. The transgenic GEMM uses mutant 
mice that exhibit oncogenes or dominant-negative tumour-suppressor genes (TSGs) in a 
non-physiological manner owing to ectopic promoter and other enhancer components. 
The endogenous GEMM, however, represents mutant mice that miss the expression of 
tumour-suppressor genes or exhibit dominant-negative TSGs or oncogenes from their 
innate promoters by using the knockout and knockin technology (Frese and Tuveson, 
2007). Many advantages have been attributed to the GEM models, including their 
usefulness in interpreting biological processes and exploring tumor cells and their 
microenvironment (Jung, 2014). The disadvantages of the GEM models, however, are the 
difficulty to reliably mimic the complexity of the human tumor, the heterogeneity in 
therapeutic response between the mice and human tumors, and the high expenses with 
time-consuming models development (Richmond and Su, 2008).  
The DMH colon carcinogenesis model was established in the present work to 
assess the effect of HC on colon cancer because it is a reproducible model that imitates 
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human cancer development and results in multifocal lesions that can be 
histopathologically assessed (Newell and Heddle, 2004; Liu et al., 2015). DMH is known 
to be extremely toxic as it is originally derived from ‘cycasin’ a natural harmful toxin 
(Visek et al., 1991). In order to evaluate the antioxidant effect of HC, DMH was 
administered at 20mg/kg body weight for eight consecutive weeks. HC showed a 
moderate antioxidant effect where significant decreases in the GST activity and to a 
lesser extent in SOD activity were observed when animals were treated with HC before 
DMH injection. Histopathological examination revealed dysplastic precancerous lesions 
in the colon of animals, indicating the need for a longer exposure time in order to achieve 
carcinogenesis. Similar results were reported in previous studies  (Santiago et al., 2007; 
Rosenberg et al., 2008).  
In order to achieve colon carcinogenesis in mice, a DMH dose of 30mg/kg b.w. 
was used for a period of 17 weeks. Eight weeks of treatment with HC post cancer 
induction resulted in a significant reduction in the tumor size at different concentrations 
(10, 25 and 50mg/kg) which was also confirmed histopathologically. At low and medium 
concentrations (10 and 25mg/kg), HC did not show any hepato-toxicity. The moderate 
liver toxicity observed with the highest dose (50mg/kg) was not consistent with the 
DMH/Silymarin experiment, where data showed a hepato-protective role for HC. Such a 
finding may be explained by the relatively low survival of animals in this group post 
DMH treatment. HC also exhibited a significant renal protective function that may be 
useful in resolving Cisplatin dose-limiting nephro-toxicity. Concomitant combinations of 
HC50 with Silymarin and HC25 with Cisplatin1.25 and Silymarin displayed significant 
reduction in tumor incidence as well as in renal interstitial inflammation. These 
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combinations may require further in vivo investigations using different animal models in 
order to support the efficacy/safety of the above combination therapies.  
The DMBA/TPA skin carcinogenesis model revealed both protective and 
therapeutic roles for HC. The protective role was assessed over a period of 20 weeks of 
concomitant treatment of HC/TPA post DMBA cancer initiation. Data revealed a 
significant reduction in papilloma yield, incidence and volume at all IP doses used in 
addition to the topical application. These results were also confirmed histopathologically 
and are consistent with previous studies on the pentane diethyl ether fraction of DCOE 
(Shebaby et al., 2017). No previous studies on the therapeutic effect of DCOE, DCOE 
fractions, or HC on skin cancer have been previously reported. Therefore, the therapeutic 
effect of HC was investigated 12 weeks post DMBA/TPA tumor promotion. Six weeks of 
HC and Cisplatin treatment significantly reduced papilloma yield and volume and 
histopathological examination showed relatively smaller carcinomatous lesions in both 
HC and Cisplatin treated groups. HC showed no liver toxicity at all doses used and the 
mean body weight of mice was stable until the end of the experiment. The Cisplatin 
group, however, displayed a significant (P˂0.05) decrease in body weight at the end of 
experiment, in addition to an increase in ALT activity. Thus, HC appears to be a potent 
and safe potential chemotherapeutic drug with a comparable effectiveness to Cisplatin 
while causing no significant side effects on liver function and body weight loss. 
The 4T1 breast cancer experiment exhibited similar results to both colon and skin 
cancer experiments. The tumor incidence and size in the mammary gland region was 
reduced in both Cisplatin and HC treated mice and the inflammation prevalence induced 
in the lungs and livers of the mice was also reduced in these mice. The colony formation 
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in the blood upon addition of 6-thioguanine and the liver enzyme activity were also 
reduced in the treated groups. However, there was a delay in the appearance of lung or 
liver metastases, and this may be attributed to the manipulation process during the 
cultivation and inoculation of the 4T1 cells, where a big number of cells can be lost 
during this operation (Pulaski and Ostrand‐Rosenberg, 2001), taking into account that 
this is a dose-dependent process (Bailey-Downs et al., 2014). Other future work may 
imply an optimum amount of inoculated 4T1 cells, or the use of the MDA-MB-231breast 
cancer cell line with immunocompromised NSG mice.    
7.5 Conclusions and Future work 
 
The present study demonstrated the anticancer activity of HC against a panel of 
skin and colon cancer cells and revealed a potential benefit from the concomitant 
treatment of HC with Cisplatin. HC was also shown to possess low toxicity to laboratory 
mice and to be an effective antitumor agent when tested using the DMH colon 
carcinogenesis and DMBA/TPA skin carcinogenesis models. Assessment of the 
mechanism of action revealed that HC exerts its effect through an induction of cell cycle 
arrest and promotion of apoptosis mainly through the intrinsic pathway and via partial 
inhibition of the MAPK/ERK and PI3K/AKT pathways. In conclusion, HC could be a 
promising potential anticancer agent that needs further clinical investigations to find its 
place in cancer treating protocols. 
Future in vivo studies are necessary to confirm the activity and safety of HC 
especially when used concomitantly with various established anticancer drugs. A more 
extensive toxicological assessment is also needed when an extended period of treatment 
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is used. The anti-metastatic effect of HC also needs further investigation using other 
metastatic animal models. Additional DNA investigations should also be performed to 
assess the mechanism of DNA damage caused by HC and the repairing mechanisms 
implemented by malignant cells to avoid HC apoptotic effect. Although in the present 
study HC was found to be an effective anticancer agent when administered weekly to 
animals, it is still very important to conduct a pharmacokinetic study in order to find the 
optimum dosing pattern. Finally, HC may be considered a novel chemotherapeutic agent 
which could be a useful molecule that can be subjected to various chemical modifications 
in order to enhance its activity against various cancer cells while preserving/improving its 
safety.   
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